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Summary	  	  
	   Over	  the	  past	  years,	  Next-­‐Generation	  Sequencing	  (NGS)	  has	  become	  an	  effective	  and	  accurate	  tool	  for	  the	  detection	  of	  potential	  causes	  and	  for	  the	  better	  understanding	  of	  human	  genetic	  diseases.	  Here,	   I	  applied	  bioinformatics	  analysis	  of	  NGS	  data	   to	  shed	  new	  light	  on	  the	  biology	  of	  two	  very	  different	  types	  of	  diseases,	  ocular	  melanomas	  and	  Mendelian	   diseases.	   For	   each	   patient,	   we	   sequenced	   either	   the	   coding	   regions	   of	   the	  genes,	   by	  means	  of	  Whole-­‐Exome	  Sequencing	   (WES),	   or	   the	   full	   genome,	   by	  means	  of	  Whole-­‐Genome	  Sequencing	   (WGS),	   this	   latter	   giving	  more	   complete	   and	  more	  diverse	  genetics	  alterations,	  compared	  to	  WES.	  	  In	  the	  first	  part,	   I	  exploit	  the	  WGS	  data	  to	  understand	  the	  genetic	  causes	  of	  two	  subtypes	  of	  ocular	  melanomas,	  Uveal	  Melanoma	  (UM)	  and	  Conjunctival	  Melanoma	  (CM),	  both	  characterized	  by	  an	  overall	  high	   rate	  of	  metastatic	   transformation	  and	  mortality.	  Via	  the	  full	  genome	  sequencing	  of	  2	  patients	  with	  CM,	  we	  highlighted	  the	  presence	  of	  a	  high	   number	   of	   somatic	   mutations	   with	   a	   majority	   of	   cytosine	   to	   tyrosine	   (C>T)	  substitutions,	   specifically	   found	   at	   the	   3’	   end	   of	   pyrimidine	   dinucleotide.	   They	   are	  classical	  features	  of	  UV	  light	  mutational	  signature.	  From	  a	  cohort	  of	  34	  patients	  with	  UM,	  we	   determined	   the	   genomic	   landscape	   of	   UM,	   which	   is	   very	   distinct	   from	   CM.	   More	  specifically,	  we	   detailed	   four	   classes	   of	   UM,	   depending	   on	   specific	   genetic	   alterations,	  corresponding	   to	   large	   copy	   number	   variants	   and	   mutations	   in	   driver	   genes	   (BAP1,	  
EIF1AX,	  and	  SF3B1),	  which	  could	  be	  useful	  to	  infer	  a	  potential	  metastatic	  development.	  	  In	   the	   second	   part,	   I	   was	   dealing	   with	   genomic	   analysis	   of	   rare	   inherited	  Mendelian	   diseases,	   more	   specifically	   with	   retinal	   degenerations	   and	   skeletal	   or	  metabolic	   disorders.	   I	   developed	   bioinformatics	   procedures	   aimed	   at	   detecting	   the	  variations	  present	  in	  the	  WES	  or	  the	  WGS	  data	  of	  patients	  of	   interest.	  Then,	  I	  set	  up	   in	  
silico	  analyses	  to	  identify	  the	  disease-­‐causing	  candidate	  DNA	  variants	  and	  to	  reduce	  the	  overall	   noise,	   which	   is	   rather	   abundant	   in	   all	   NGS-­‐based	   approaches.	   These	   tools	  allowed	   us	   to	   discover	   two	   new	   developmental	   syndromes	   (caused	   by	   HSPA9	   and	  
NANS),	   to	   characterize	   four	   genes	   causing	   retinal	   degeneration	   (CEP78	   and	  TTLL5),	   a	  skeletal	  phenotype	  (ASAH1)	  and	  a	  multisystem	  disorder	  (NBAS).	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Résumé	  	  	   Ces	   dernières	   années,	   le	  séquençage	   à	   haut	   débit	   (en	   anglais	   «	  Next-­‐Generation	  Sequencing	  »	  -­‐	  NGS)	  est	  devenu	  un	  outil	  efficace	  et	  précis	  pour	   la	  détection	  des	  causes	  potentielles	   des	   maladies	   génétiques	   humaines.	   Durant	   ma	   thèse,	   j’ai	   appliqué	   des	  analyses	   bioinformatiques	   pour	   étudier	   deux	   types	   de	   maladies	   bien	   différentes,	   les	  mélanomes	   oculaires	   et	   les	   maladies	   mendéliennes.	   Pour	   chaque	   patient,	   nous	   avons	  séquencé	   soit	   les	   régions	   codantes	   des	   gènes	   via	   la	   technique	   de	   «	  Whole	   Exome	  Sequencing	  »	   (WES),	   soit	   le	   génome	   en	   entier	   via	   du	   «	  Whole	   Genome	   Sequencing	  »	  (WGS).	  En	  comparaison	  au	  WES,	   le	  WGS	  donne	  des	   informations	  plus	  précises	  et	  plus	  complexes	  sur	  toutes	  les	  altérations	  génétiques.	  D’une	  part,	  j’ai	  cherché	  à	  comprendre	  les	  causes	  génétiques	  de	  deux	  mélanomes	  oculaires,	   le	   Mélanome	   de	   l’Uvée	   (UM)	   et	   le	   Mélanome	   de	   la	   Conjonctive	   (CM),	  caractérisés	  par	  un	  taux	  élevé	  de	  métastases	  et	  un	  faible	  pronostic	  vital.	  En	  séquençant	  le	  génome	  de	  deux	  patients	  atteints	  de	  CM,	  j’ai	  mis	  en	  avant	  la	  présence	  d’un	  très	  grand	  nombre	   de	  mutations	   somatiques	  ;	   avec	   une	  majorité	   de	   substitutions	   de	   cytosine	   en	  tyrosine	  (C>T),	  trouvées	  spécifiquement	  du	  côté	  3’	  des	  couplets	  de	  pyrimidine.	  Ce	  sont	  des	   modifications	   caractéristiques	   de	   l’action	   des	   rayons	   ultra-­‐violets.	   A	   partir	   d’une	  cohorte	  de	  34	  patients	  atteints	  d’UM,	  j’ai	  déterminé	  les	  bases	  génomiques	  de	  ce	  cancer,	  très	  différentes	  de	   celles	  de	  CM.	   J’ai	   notamment	  détaillé	   quatre	   classes	  d’UM,	   chacune	  ayant	   des	   altérations	   génétiques	   spécifiques,	   consistant	   en	   de	   larges	   variations	   du	  nombre	  de	  copies	  et	  des	  mutations	  dans	  des	  gènes	  «	  drivers	  »	  (BAP1,	  EIF1AX,	  et	  SF3B1),	  ce	  qui	  pourrait	  être	  utile	  pour	  prédire	  des	  potentiels	  développements	  métastatiques.	  D’une	   autre	   part,	   j’ai	   étudié	   des	   maladies	   mendéliennes	   rares,	   plus	  particulièrement	   les	   dégénérations	   rétiniennes	   ainsi	   que	   les	  maladies	   du	   squelette	   et	  métaboliques.	   J’ai	   développé	   des	   pipelines	   bioinformatiques	   détectant	   les	   variations	  génétiques	  présentes	  dans	   le	  WES	  ou	   le	  WGS	  de	  nos	  patients.	   J’ai	  ensuite	  mis	  en	  place	  des	  analyses	   in-­‐silico	  pour	  identifier	  les	  variantes	  pouvant	  potentiellement	  expliquer	  la	  maladie,	   tout	   en	   réduisant	   les	   faux	  positifs,	   qui	   sont	   très	   fréquents	   en	  NGS.	   Ces	   outils	  m’ont	   permis	   de	   découvrir,	   avec	   mes	   collaborateurs,	   deux	   nouveaux	   syndromes	  développementaux	   (causés	   par	   les	   gènes	   HSPA9	   et	   NANS)	   et	   de	   caractériser	   quatre	  autres	   gènes	   causant	   une	   dégénérescence	   rétinienne	   (CEP78	   et	   TTLL5),	   une	   maladie	  squelettique	  (ASAH1)	  et	  une	  maladie	  multi-­‐systémique	  (NBAS).	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Genetics	   is	   the	   study	   of	   heredity,	   conceptually	   acquiring	   its	   to-­‐date	   from	   the	  pioneering	  work	  of	  Gregor	  Mendel	  in	  the	  mid-­‐19th	  century.	   	  Developments	  in	  all	   fields	  of	  genetics	  and	  genetic	  technology	  in	  the	  first	  half	  of	  the	  20th	  century	  provided	  the	  basis	  for	  the	  later	  developments	  and	  in	  particular	  for	  the	  implementation	  of	  Next-­‐Generation	  Sequencing	  (NGS).	  The	  aim	  of	   this	   thesis	   focuses	  on	  the	  use	  of	  NGS	  technologies,	   their	  adaptation	  and	  improvement	  from	  a	  bioinformatics	  standpoint,	  in	  order	  to	  identify	  and	  better	  understand	  the	  causes	  underlying	  a	   large	  spectrum	  of	  human	  genetic	  disorders.	  In	   the	   first	   part	   of	   the	   Introduction,	   basic	   concepts	   of	   human	   genetics	   are	   presented,	  together	  with	  a	  description	  of	  the	  two	  main	  types	  of	  diseases	  studied	  in	  this	  thesis,	   i.e.	  ocular	   melanomas	   and	   Mendelian	   disorders.	   The	   second	   part	   describes	   the	   different	  NGS	  technologies.	  The	  third	  part	  focuses	  on	  the	  bioinformatics	  workflows	  or	  “pipelines”	  that	  were	  developed,	  optimized	  and	  used	  in	  order	  to	  process	  raw	  NGS-­‐derived	  data	  for	  the	  identification	  of	  disease-­‐causing	  mutations.	  	  
1.1 Human	  diseases	  with	  a	  genetic	  origin	  
DNA,	  genes	  and	  genetic	  variations	  The	   instructions	   for	   the	   normal	   development	   and	   functioning	   of	   all	   living	  organisms	  are	  contained	   in	   the	  DeoxyriboNucleic	  Acid	  (DNA).	  Composed	  of	  more	  than	  three	  billions	  of	  bases	  in	  humans,	  this	  molecule	  is	  made	  of	  a	  repetition	  of	  four	  different	  nucleotides:	  Adenine	  (A),	  Cytosine	  (C),	  Guanine	  (G)	  and	  Thymine	  (T).	  The	  human	  DNA	  is	  compacted	  in	  the	  cell	  nucleus	  into	  23	  pairs	  of	  chromosomes,	  22	  of	  which	  are	  autosomal	  and	  one	  is	  a	  pair	  of	  sex	  chromosomes,	  either	  two	  X-­‐chromosomes	  for	  females	  or	  one	  X-­‐chromosome	  and	  one	  Y-­‐chromosome	  for	  males.	  Less	  than	  2%	  of	  the	  total	  DNA	  codes	  for	  proteins,	   and	   the	  molecular	  unit	  of	  heredity	   consists	  of	   the	   so-­‐called	  genes.	  Genes	  are	  composed	  of	  coding	  parts	  (the	  exons),	  of	  non-­‐coding	  parts	  (the	  introns)	  surrounded	  by	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untranslated	   but	   transcribed	   regions	   (the	   UTRs)	   (Figure	   1).	   In	   exons,	   a	   sequence	   of	  three	   nucleotides	   corresponds	   to	   a	   codon,	   translated	   into	   one	   of	   20	   different	   amino	  acids.	   The	   boundaries	   between	   exons	   and	   introns	   are	   defined	   by	   splicing	   sites,	  which	  provide	  relevant	  signals	  to	  the	  cell	  splicing	  machinery.	  	  
	  
Figure	  1:	  DNA	  molecule,	  from	  the	  chromosome	  to	  the	  genes	  (Create	  Commons®)	  	  
Genes	  are	  small	  segments	  of	  the	  DNA	  molecule,	  composed	  of	  exons	  (the	  coding	  and	  expressed	  regions),	  and	  
introns	  (the	  non-­‐coding	  regions).	  The	  DNA	  sequence	  is	  compacted	  into	  the	  46	  chromosomes	  of	  the	  human	  
genome.	  	   The	  genetic	  differences	  between	  two	  individuals	  are	  explained	  by	  less	  than	  2%	  of	  variations	   in	   their	  DNA	  sequences.	  These	  genetic	  variations	  can	  be	  population-­‐specific	  or	  person-­‐specific.	  A	  variation	  is	  considered	  to	  be	  a	  polymorphism	  if	  its	  allelic	  frequency	  is	  more	  than	  1%	  within	  a	  population,	  and	  rare	  otherwise.	  They	  can	  have	  different	  sizes,	  such	  as	  a	  single	  base,	  but	  also	  a	  part	  of	  chromosome	  to	  an	  entire	  one.	  Single	   Nucleotide	   Variants	   (SNVs)	   are	   different	   combinations	   of	   single	   base	  substitutions,	  deletions	  or	  insertions.	  “Indels”	  represent	  the	  insertion	  or	  deletion	  of	  one	  or	  of	  a	  small	  stretch	  of	  nucleotides	  (Figure	  2.A).	  If	  a	  SNV	  impacts	  the	  coding	  region	  of	  a	  gene,	   it	   can	   modify	   a	   codon	   and	   therefore	   the	   encoded	   amino	   acid	   residue,	   and	   the	  variant	   is	  considered	   to	  be	  non-­‐synonymous.	  However,	  due	   to	   the	  degeneration	  of	   the	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genetic	   code	   (different	   codons	   encode	   the	   same	   amino	   acid),	   the	   nucleotide	   variation	  may	  give	  rise	  to	  a	  triplet	  encoding	  the	  same	  amino	  acid	  as	  the	  original	  one.	  This	  type	  of	  variant	  is	  called	  synonymous.	  Larger	  regions	  of	  the	  genome	  (generally	  larger	  than	  1000	  bases)	   that	  vary	  between	   individuals,	   leading	   to	  an	   insertion,	  duplication,	   inversion	  or	  deletion	   of	   thousands	   of	   nucleotides,	   are	   called	   structural	   variants	   (SVs)	   [1].	   Copy	  Number	  Variations	  (CNVs)	  are	  subtypes	  of	  SVs	  resulting	  from	  gain	  or	  loss	  of	  a	  copy	  of	  an	  entire	  DNA	  region	  by	  deletion	  or	  duplication	  	  (Figure	  2	  B)	  [2].	  	  	  
	  
Figure	  2:	  Types	  of	  genetic	  alterations	  in	  the	  genome,	  (A)	  small	  modifications	  (B)	  larger	  rearrangements	  [3]	  	  Both	  SNVs	  and	  SVs	  are	  frequently	  present	  in	  the	  genome	  and	  they	  constitute	  the	  basis	   of	   evolution	   and	   adaptation.	   However,	   some	   of	   these	   variations	   may	   have	   a	  negative	  effect	  on	  the	  protein	  level,	  its	  activity,	  its	  function	  and	  its	  specificity,	  which	  may	  eventually	  lead	  to	  a	  disease.	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Human	  genetic	  diseases	  The	  spectrum	  of	  human	  genetic	  diseases	  is	  very	  large.	  It	  refers	  to	  abnormalities	  in	  the	  genome	  resulting	  in	  the	  complete	  gain,	   loss	  or	  disruption	  of	  the	  integrity	  of	  one	  or	  more	  genes.	  These	  DNA	  alterations	  can	  either	  be	  inherited	  from	  the	  parents	  (germline	  mutations)	  or	  they	  can	  be	  acquired	  throughout	  life	  (somatic	  mutations)	  because	  of	  aging	  and/or	   environmental	   conditions	   (Figure	   3).	   Pathologies	   resulting	   from	   germline	  mutations,	   which	   can	   be	   transmitted	   to	   the	   following	   generations,	   are	   commonly	  referred	   to	   as	   hereditary	   diseases,	   while	   somatic	   DNA	   insults	   are	   usually	   not	  transmittable	  to	  the	  offspring	  and	  usually	  lead	  to	  malignancies.	  	  	  
	  
Figure	  3:	  Somatic	  versus	  germline	  genetic	  variations	  [4]	  
	   SNVs	  or	  SVs	  can	  potentially	  modify	  the	  normal	  production	  of	  proteins;	  by	  directly	  affecting	  the	  genes	  encoding	  them,	  through	  deleterious	  non-­‐synonymous	  variants,	  splice	  site	  variations	  or	  large	  rearrangements	  impacting	  one	  or	  more	  exons.	  Similarly,	  they	  can	  influence	   the	   normal	   function	   of	   the	   genes	   also	   by	   affecting	   non-­‐genic	   regulatory	  regions.	  The	  identification	  of	  the	  genetic	  basis	  of	  inherited	  diseases	  and	  cancer	  is	  essential	  for	   the	   understanding	   of	   the	   pathophysiological	   mechanisms	   underlying	   them.	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Furthermore,	   it	  potentially	  provides	  hints	  of	  prognosis	  and	  eventual	   treatment	  as	  well	  as	  advice	  for	  the	  family	  members.	  	  	  
1.1.1 Introduction	  to	  ocular	  melanomas	  Melanoma	   is	   a	   type	   of	   cancer	   originating	   from	   melanocytes,	   the	   cells	   producing	  melanin.	  The	  most	  common	  form	  of	  melanoma	  is	  cutaneous	  melanoma,	  originating	  from	  the	  melanocytes	  of	  the	  epidermis.	  The	  tumors	  often	  have	  similar	  appearances	  to	  moles,	  some	  may	  also	  develop	  from	  moles.	  Intense	  exposure	  to	  Ultra-­‐Violet	  (UV)	  light	  is	  a	  key	  element	   for	   the	  development	  of	   this	   cancer.	  Cutaneous	  melanoma	  has	   a	  prevalence	  of	  more	  than	  21	  new	  cases	  per	  year	  per	  100’000	  individuals	  [5],	  counting	  for	  less	  than	  5%	  of	   skin	   cancers	   but	   responsible	   for	   about	   75%	   of	   all	   death	   from	   skin	   cancers	   [6].	  Cutaneous	  melanoma	  is	  well	  curable	  with	  early	  recognition	  and	  treatment,	  but	  it	  is	  more	  challenging	  to	  treat	  it	  in	  advance	  stages,	  because	  of	  dissemination	  in	  other	  parts	  of	  the	  body.	  Melanomas	   occurring	   in	   the	   different	   layers	   of	   the	   eye	   are	   referred	   to	   as	   ocular	  melanomas.	  
	  
Figure	  4:	  Structure	  of	  the	  eye,	  the	  conjunctiva	  and	  the	  uvea	  are	  highlighted	  
Conjunc'va*
Iris%
Ciliary%body%
Choroid%
Uvea*
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Conjunctival	  Melanoma	  Conjunctival	  melanoma	   (CM)	   represents	  5%	  of	   all	   ocular	  melanomas	  and	   it	   affects	  about	   0.2	   individuals	   per	   million	   worldwide.	   The	   primary	   site	   of	   the	   tumor	   is	   the	  conjunctiva,	  a	  thin	  membrane	  that	  covers	  part	  of	  the	  sclera,	  which	  is	  directly	  exposed	  to	  light,	  as	  well	  as	  the	  inner	  surface	  of	  the	  eyelids	  (Figure	  4).	  It	  is	  a	  highly	  recurrent	  tumor	  leading	  to	  metastatic	  disease	  and	  death	  within	  10	  years	  in	  25–30%	  of	  patients	  [7].	  The	  most	  frequent	  sites	  of	  metastasis	  are	  the	  lungs,	  followed	  by	  the	  liver,	  the	  brain	  and	  the	  bones.	   Interestingly,	   CM	   incidence	   and	   morbidity	   have	   increased	   over	   the	   past	   few	  years,	  in	  particular	  in	  regions	  where	  sunlight	  is	  more	  abundant	  [8].	  CM	  usually	  initiates	  as	  a	  pigmented	  nodular	  lesion	  in	  the	  conjunctiva	  during	  the	  sixth	  or	  seventh	  decade	  of	  life.	   Recent	   molecular	   investigations	   have	   indicated	   that	   conjunctival	   and	   cutaneous	  melanomas	  may	  share	  common	  features	  [9].	  For	  instance,	  epidemiological	  studies	  have	  shown	   an	   association	   between	   decreasing	   latitude	   and	   increasing	   incidence	   of	  conjunctival	  melanoma	  [8],	  suggesting	  that	  exposure	  to	  sunlight	  has	  a	  role	  in	  its	  etiology	  [9].	  However,	  strong	  molecular	  proof	  of	  such	  correlation	  has	  not	  been	  established	  yet.	  Currently,	   the	   treatment	   includes	   the	   surgical	   removal	  of	   the	  pigmented	  node	  and	   the	  surrounding	   area	   followed	   by	   cryotherapy,	   a	   cold-­‐induced	   procedure	   decreasing	   cell	  growth	  and	  reproduction	  [10].	  	  	  	  
Uveal	  Melanoma	  Despite	  having	  a	  very	  rare	  incidence	  of	  5-­‐8	  new	  cases	  per	  million	  per	  year	  [11,	  12],	  uveal	  melanoma	   (UM)	   is	   the	  most	   common	   primary	   intraocular	   tumor	   of the adult.	   It 
develops from melanocytes in the choroid, the ciliary body, or the iris (collectively called	  the 
"uvea", one of the inner layers of the eye) (Figure	  4)	  and usually metastasizes	  through	  the	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blood	   stream	   to	   the	   liver	   [13,	   14].	   Symptoms	   include	   variable	   and	   painless	   visual	  disturbances,	   often	   presenting	   when	   the	   tumor	   has	   already	   reached	   a	   considerable	  mass.	   Survival	   and	   potential	   therapeutic	   options	   depend,	   among	   other	   things,	   on the 
presence of specific genetic	   alterations	   [15].	   While	   population	   studies	   suggest	   ethnic	  predisposition	   [16,	   17],	   environmental	   factors	   that	   are	   directly	   involved	   in	   the	  transformation	   process	   have	   not	   been	   clearly	   delineated.	   For	   instance,	   a	   possible	  association	  with	  UV	  light	  exposure	  has	  been	  suggested	  [18-­‐21],	  but	  it	  has	  recently	  been	  questioned	  based	  on	  molecular	  data	  [22].	  	  UM	   shows	   two	   distinct	   classes	   of	   progression:	   the	   first	   class	   is	   characterized	   by	   a	  high	  survival	   rate	   (95%	  after	  8	  years)	  and	  without	  metastases,	  while	   the	  second	  class	  shows	  a	  lower	  survival	  rate	  (31%	  after	  8	  years)	  and	  patients	  usually	  present	  metastases,	  mainly	   in	   liver,	   with	   high	   resistance	   to	   chemotherapy	   [23].	   Despite	   recent	  breakthroughs	  in	  understanding	  the	  molecular	  biology	  of	  this	  malignancy,	  e.g.	  mutations	  in	   driver	   genes	   (BAP1,	  SF3B1,	  EIF1AX	  [24])	   and	   specific	   CNVs	   (chr3	  monosomy	   [25]),	  UM	   prognosis	   has	   not	   increased	   over	   the	   last	   40	   years.	   After	   hepatic	   metastatic	  dissemination,	   the	   median	   overall	   survival	   is	   less	   than	   one	   year,	   and	   the	   standard	  treatments	  do	  not	  improve	  this	  outcome.	  Thus,	  it	  is	  necessary	  to	  develop	  new	  therapies	  based	  on	  our	  understanding	  of	  the	  genetic	  alterations	  of	  this	  melanoma.	  	  	  
1.1.2 Introduction	  to	  Mendelian	  diseases	  
Mendelian	  Diseases	  Based	  on	  Mendel’s	  rules,	  a	  recessive	  trait	  is	  the	  consequence	  of	  the	  action	  of	  two	  alleles	  on	  the	  two	  chromosomal	  copies	  of	  a	  gene,	  while	  a	  dominant	  trait	  only	  requires	  an	  allele	  on	  a	  single	  chromosome.	  In	  X-­‐linked	  trait,	  both	  recessive	  and	  dominant	  rules	  may	  occur.	   In	  Mendelian	  diseases,	   pathogenicity	   is	   driven	  by	  mutations	   in	   a	   single	   gene.	  A	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single	  heterozygous	  mutation	  can	  lead	  to	  a	  dominant	  disease	  due	  to	  haploinsufficiency	  or	  gain-­‐of-­‐function.	  Recessive	  disease	  requires	  disruption	  of	  both	  copies	  of	  a	  gene,	  either	  via	   the	   same	  mutation	   (homozygous	   variant),	   or	   two	  heterozygous	  mutations,	   one	   on	  each	  copy	  (compound	  heterozygous	  variants)	  (Figure	  5).	  
	  
Figure	  5:	  Possible	  configurations	  of	  pathogenic	  mutations	  for	  autosomal	  recessive	  and	  autosomal	  dominant	  
inheritance	  [26].	  	   Mutations	   can	   either	   be	   inherited	   from	   one	   parent	   or	   newly	   acquired	   in	   the	  patient.	  This	  latter	  is	  called	  a	  de	  novo	  mutation.	  Every	  individual	  usually	  carries	  45	  to	  60	  
do	   novo	  mutations	   [27]	   [28].	   It	   is	   important	   to	   note	   that,	   regardless	   of	   the	   type	   of	  mutation	  within	   single	   pedigrees,	   pathogenic	  Mendelian	   variants	   always	   co-­‐segregate	  with	   the	   disease	   in	   affected	   individuals.	   Therefore,	   all	   patients	  within	   a	   family	   should	  necessarily	   share	   the	   same	  mutation(s)	   but	   not	   necessarily	   the	   same	   innocuous	   DNA	  variants.	  	  
Prevalence	  of	  Mendelian	  disorders	  
Mendelian	   diseases	   generally	   tend	   to	   have	   relatively	   low	   prevalence	   in	   the	  population;	  nevertheless	  they	  collectively	  affect	  millions	  of	  individuals	  [29].	  Within	  this	  category,	   rare	   genetic	   disorders	   are	   estimated	   to	   range	   between	   1’000	   to	   30’000	   in	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humans,	   and	   only	   half	   of	   them	   have	   been	   elucidated	   at	   the	   genetic	   level	   [30].	   This	   is	  particularly	  true	  for	  rare	  Mendelian	  disorders	   leading	  to	  retinal	  degenerations	  such	  as	  retinitis	   pigmentosa,	   cone-­‐rod	   dystrophy,	   Leber	   congenital	   amaurosis	   and	   other	  subtypes.	  These	  diseases	  are	  genetically	  heterogeneous,	  meaning	  that	  the	  disruption	  of	  any	  of	  250	  genes	  known	  so	  far	  [31]	  gives	  rise	  to	  a	  similar	  clinical	  phenotype.	  	  
	  
Detection	  of	  disease-­‐causing	  variants	  
Following	  the	  concept	  that	  rare	  diseases	  are	  caused	  by	  rare	  mutations,	  we	  focused	  on	  DNA	  variations	   that	  have	  an	   impact	  on	  protein	   function	  and	  occur	  with	  a	  very	   low	  frequency	   in	   the	   general	   healthy	   population.	   Indeed,	   since	   heterozygous	   recessive	  mutations	   are	  not	   disease	   causing,	   they	   can	  be	  present	   in	   the	   general	   population	   [32,	  33],	   even	   at	   non-­‐negligible	   frequencies.	   This	   simple	   genetic	   concept	   has	   tremendous	  consequences	   in	  NGS-­‐based	  searching	   for	  mutations,	   as	  only	  about	  a	  dozen	  genes	  will	  harbor	  rare,	  non-­‐synonymous	  variants	  in	  homozygous	  or	  compound	  heterozygous	  state	  genome-­‐wide	   [26].	   For	   this	   reason,	   recessive	  diseases	   are	  more	  easily	  diagnosed	  with	  NGS	   techniques	  but	   it	   is	  more	   complicated	   for	   dominant	   diseases.	  Different	   strategies	  have	   been	   developed	   to	   efficiently	   identify	   the	   variants	   of	   interest.	   Some	   of	   these	  strategies	  are	  described	  further	  in	  the	  bioinformatics	  section	  of	  this	  work.	  	  
1.2 Next-­‐generation	  sequencing	  
1.2.1 Current	  usage	  of	  NGS	  	  Next-­‐generation	   sequencing	   (NGS),	   also	   called	   high-­‐throughput	   sequencing,	  consists	  of	  modern	  technological	  methods	  used	  to	  query	  megabases	  of	  DNA	  and	  RNA	  at	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once,	   through	   computer-­‐based	   alignment	   of	  millions	   of	   short	   reads.	   Compared	   to	   the	  Sanger	   sequencing	   [34],	   one	  of	   the	   first	   sequencing	   techniques,	  NGS	  allows	   faster	   and	  cheaper	  sequencing	  results.	  	  Since	   its	  beginning	   in	  2008,	  NGS	   is	  widely	  used,	  both	   in	  diagnostic	   and	   research	  laboratories.	  This	   is	   especially	   true	   for	   the	   sequencing	  of	   all	   the	   coding	   regions	  of	   the	  genome,	  by	  means	  of	  Whole	  Exome	  Sequencing	   (WES);	   and	   the	   sequencing	  of	   the	   full	  genome,	  by	  means	  of	  Whole	  Genome	  Sequencing	  (WGS).	  The	  main	  reasons	  for	  this	  are	  the	  speed	  of	  processing,	  and	  the	  lowering	  price	  of	  NGS,	  which	  is	  now	  affordable	  for	  most	  laboratories	   and	   clinical	   diagnostic,	   with	   a	   exponential	   drop	   in	   the	   cost	   of	   human	  genome	   sequencing,	   starting	   from	   billions	   of	   dollars	   to	   about	   $	   1,000	   per	   sample	  currently	  [35]).	  However,	  due	  to	  the	  generation	  of	  enormous	  amounts	  of	  raw	  data	  (from	  dozens	  to	  hundreds	  of	  Gigabytes),	  the	  analysis	  of	  any	  NGS	  data	  nowadays	  requires	  the	  usage	  of	  an	  adapted	  computational	  framework	  to	  generate	  readable	  information	  that	  is	  relevant	  for	  the	  phenotype	  studied.	  Many	  different	  NGS	  technologies	  have	  been	  developed	  over	  the	  past	  decade,	  such	  as	   the	   ones	   from	   Illumina,	   Life	   Sciences,	   Oxford	   Nanopore,	   Pacific	   Biosciences	   or	  Complete	   Genomics.	   They	   allow	   us	   to	   sequence	   the	   exome,	   the	   genome,	   the	  transcriptome	  and	  the	  epigenome	  of	  any	  individuals	  and	  from	  many	  different	  tissues.	  All	  these	  sequencing	  platforms	  have	  their	  own	  advantages	  and	  disadvantages	  [36]	  [37]	  [38]	  based	  on	  different	  parameters,	  e.g.	  throughput	  (time	  of	  sequencing	  of	  a	  given	  number	  of	  samples),	   read	   length,	   accuracy,	   robustness,	   price	   and	   applications	   available	   after	   the	  sequencing,	  etc.	  [39].	  	  For	  the	  most	  recent	  sequencing	  platforms,	  the	  time	  of	  sequencing	  is	  significantly	  reduced.	  This	  characteristic	  is	  of	  high	  importance	  for	  treatment	  of	  patients,	  especially	  in	  the	  field	  of	  neonatal	  care	  or	  aggressive	  cancers	  [40-­‐42].	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Short-­‐reads	   sequencing	   is	   a	   useful	   technology,	   which	   has	   proven	   its	  performances	   over	   the	   past	   decade.	   However,	   with	   the	   recent	   development	   of	   long-­‐reads	   sequencing	   platforms	   (e.g.	   from	   Pacific	   Biosciences),	   repetitive	   and	   complex	  regions	  of	  the	  genome	  can	  now	  be	  accessible,	  and	  essential	  for	  detecting	  more	  precisely	  indels	  of	  more	  than	  50	  base	  pairs,	  structural	  variants	  and	  genome	  phasing	  [39].	  Single	   cell	   sequencing	   aims	   at	   detecting	   the	   cellular	   heterogeneity	   present	   in	  tissues,	   and	   has	   become	   particularly	   relevant	   for	   the	   screening,	   diagnostics	   and	  treatment	  of	  heterogeneous	  cancer	  types.	  It	  is	  also	  widely	  used	  in	  non	  invasive	  prenatal	  diagnostics	  [43].	  	  
1.2.2 NGS	  technology	  used	  during	  the	  thesis	  	  
Main	  workflow	  of	  NGS	  	  DNA	  is	  extracted	  from	  a	  given	  tissue	  (e.g.	  blood)	  or	  biopsy	  after	  the	  signature	  of	  an	  informed	  consent	  by	  the	  patients	  and	  their	  geneticist,	  in	  accordance	  with	  regulations	  for	   studies	   on	   human	   subjects.	   The	   genome	   is	   then	   randomly	   fragmented	   into	   small	  pieces,	  followed	  by	  ligation	  of	  adapter	  sequences.	  After	  an	  amplification	  procedure,	  the	  short	  DNA	   fragments	   are	   then	   purified	   and	   sequenced	   into	   short	   reads	   (Figure	   6,	   left	  panel).	  Compared	  to	  single	  read	  sequencing,	  where	  only	  one	  end	  of	  the	  DNA	  fragment	  is	  sequenced,	   paired-­‐end	   sequencing	   enables	   both	   ends	   of	   the	   DNA	   fragment	   to	   be	  sequenced.	  The	  reverse	  and	  forward	  reads	  are	  constructed	  with	  a	  known	  interval,	  which	  allows	  generating	  high-­‐quality	  and	  well	  alignable	  sequence	  data.	  Moreover,	  paired-­‐end	  sequencing	  facilitates	  the	  detection	  of	  genomic	  rearrangements,	  repetitive	  sequences,	  as	  well	  as	  novel	  transcripts.	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Figure	  6:	  NGS	  methodology,	  starting	  with	  the	  sequencing	  of	  the	  DNA	  and	  followed	  by	  the	  generation	  all	  the	  
variants	  present	  in	  a	  patient,	  and	  the	  detection	  of	  the	  disease-­‐causing	  variants.	  The	  coverage	  of	  sequencing	  refers	   to	   the	  average	  number	  of	   reads	   that	  align	   to	  known	   reference	   bases.	   Based	   on	   the	   different	   coverage	   level,	   we	   can	   determine	   the	  degree	  of	  confidence	  of	  a	  reference	  nucleotide	  or	  of	  a	  variation	  in	  the	  DNA	  sequence	  of	  a	  patient.	   The	   higher	   the	   coverage,	   the	   more	   confidence	   we	   have	   in	   the	   base	   quality.	  However,	  the	  price	  of	  the	  sequencing	  also	  increases	  with	  the	  depth	  of	  coverage.	  
	  
WES	  versus	  WGS	  All	  samples	  processed	  by	  WES	  and	  mentioned	  in	  this	  work	  were	  sequenced	  on	  an	  Illumina	  HiSeq	  2000	  machine,	  generating	  100	  bp	  paired-­‐end	  reads	  with	  coverage	  of	  50x	  to	  99x,	  depending	  on	  the	  project.	  All	  the	  WGS	  samples	  were	  sequenced	  by	  the	  Complete	  Genomics	  technology	  [44],	  with	  paired-­‐end	  reads	  and	  sequencing	  depth	  between	  >50x	  to	   >80x	   of	   coverage.	   The	   technology	   used	   by	   Complete	   Genomics	   is	   slightly	   different	  from	  Illumina	  sequencing.	  It	  uses	  high-­‐density	  DNA	  nanoarrays	  that	  are	  populated	  with	  DNA	  nanoballs	  [44].	  By	  definition,	  WES	  focuses	  exclusively	  on	  the	  expressed	  regions	  of	  the	  genome.	  In	  order	   to	   sequence	   only	   these	   exonic	   regions,	   an	   extra	   capturing	   step	   is	   needed	   in	   the	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NGS	  procedure,	  using	  specific	  libraries	  of	  probes,	  which	  can	  selectively	  hybridize	  to	  the	  genomic	   regions	   of	   interest.	   Only	   these	   DNA	   fragments	   will	   then	   be	   amplified	   and	  sequenced.	  On	  the	  contrary,	  WGS	  queries	  every	  single	  base	  of	  the	  genome,	  with	  a	  better	  sensitivity	  and	  uniform	  coverage	  compared	  to	  WES	  results,	  especially	  in	  coding	  regions	  [26].	   Indeed,	   the	   absence	   of	   the	   capturing	   step,	   characteristic	   of	  WES,	   permits	   a	   less	  artificial	  representation	  of	  the	  genome,	  which	  can	  be	  used	  to	  assess	  with	  better	  quality	  intronic	  and	  intergenic	  variants,	  but	  also	  large	  insertions	  and	  deletions	  which	  might	  be	  in	   heterozygous	   state	   (Figure	   7)	   [26].	   However,	   for	   highly	   heterogeneous	   and	  contaminated	  tumors,	  the	  usage	  of	  WES	  at	  very	  deep	  coverage	  (up	  to	  10’000	  times)	  has	  proven	  to	  be	  more	  efficient	  in	  detecting	  SNVs	  than	  WGS	  [45].	  
	  
Figure	  7:	  Features	  of	  WGS	  versus	  WES	  [26]	  	  	  In	  Mendelian	  diseases,	  most	  of	  the	  disease-­‐causing	  variants	  are	  located	  within	  the	  coding	  region	  of	  genes	  [32,	  46,	  47].	  Therefore,	  WES,	  targeting	  only	  the	  coding	  part	  of	  our	  genome	  is	  a	  valid	   investigation	  tool,	  despite	   that	   the	  exome	  represents	  only	  2%	  of	   the	  entire	  genome	  and	  does	  not	  provide	  accurate	  information	  for	  “atypical”	  mutations	  (e.g.	  structural	  variations,	  copy	  number	  variations).	  Conversely,	  WGS	  is	  more	  expensive	  and	  
is also in general more uniform, since genomic DNA is
provided to the sequencer ‘‘as is’’, without undergoing
selection procedures that may artificially create an uneven
representation of the template material to be sequenced.
Unfortunately, the wealth of infor ation produced by
WGS, despite being preferable from a theoretical stand-
point, may as well represent a burden for the identification
of DNA variants meaningful to medical genetics. Such
variants typically consist of one or a few mutations that
have to be distinguished from thousands of benign DNA
changes, and their identification has often been compared
to the detection of a needle in a haystack. To follow the
same analogy, WGS provides better chances of identifying
pathological targets than WES, but at the same time it
increases the size of the haystack, to the point that innoc-
uous DNA changes may no longer be recognized as
such. The advantages of WGS procedures can therefore be
fully achieved only when analytical approaches can effi-
ciently differentiate abnormal DNA changes from the
multitude of benign variants that determine normal human
heterogeneity.
To better illustrate all of these concepts, this review will
focus on the use of WGS as a tool to detect rare DNA
variants with a high phenotypic effect, such as germline
mutations in Mendelian hereditary disorders and somatic
mutations in cancer.
The medical genome: generalities and common
procedures
The human reference genome
Because of the complexity of the human genome, NGS
reads from WGS projects cannot be efficiently assembled
via de novo procedures, but have to be mapped to a stan-
dard template sequence, the human ‘‘reference sequence’’.
This human reference genome is a pooled sequence data of
13 healthy individuals with European ancestry [2], and has
gradually evolved with the improvement of sequencing
methods. It provides a common and unambiguous system
of relationships between genomic coordinates and corre-
sponding DNA bases.
Mapping of sequence reads and identification
of variants
Following the generation of the raw DNA sequence reads
by an NGS platform, the process of obtaining the full
genome sequence of an individual (or, better, a reliable
approximation of it), consists of a two-step, computer-
based procedure. First, the short NGS reads are mapped to
the reference genome by assigning to them specific geno-
mic coordinates. This procedure is in general computer
intensive and is achieved by the use of various algorithms
(e.g., BWA [3], AGILE [4], NovoAlign [novocraft.com],
or FastHASH [5]). Then, mismatches between the refer-
ence genome and the individual genome are assessed by a
bioinformatic process referred to as ‘‘variant calling’’ (e.g.,
via software such as GATK [6] or VCMM [7]).
Both mapping and variant calling procedures can be
highly parameterized and are susceptible to producing
different outputs as a function of such parameters. There-
fore, although for a given individual there is only one
physical genome, made of DNA, at the present time we can
only obtain one or more imperfect representations of it,
made of bits and bytes. As a general rule, each step of any
genome analysis produces both false positives, i.e., variants
that are called but are not physically present in the genome,
and false negatives, i.e., variants that are not called but are
present in the physical genome. It is therefore important to
minimize errors at these initial mapping and variant calling
steps, since all of downstream analyses will be made on the
assumption that these data are a faithful representation of
the physical genome.
General filtering procedures
Since every WGS project produces on average*4,000,000
called variants [8, 9], identification of mutations relies on a
series of filtering procedures that have as goal to recognize
rare DNA changes with a pathogenic effect and discard the
multitude of variants that are unrelated to the disease
studied. Comparison with databases reporting information
from the unaffected population such as dbSNP [10], the
ESP database (evs.gs.washington.edu), the Exome Aggre-
gation Consortium (ExAC) (exac.broadinstitute.org), etc.
represents the most consistent filtering step, under the
assumptions that such public databases report (a) reliable
information and (b) include polymorphic variants having
Table 1 Features of whole genome sequencing (WGS) vs. whole
exome sequencing (WES)
Feature WGS WES
Exonic variants Yes Yes
Intronic variants Yes No
Intergenic variants Yes No
Indels Yes Yes
Copy number variations Yes Not directly/imprecise
Large insertions and deletions Yes Not directly/imprecise
Transposable elements Yes Not directly/imprecise
Detection of copy number variations, large insertion and deletions, as
well as of transposable elements are imprecise in WES since data are
available for coding regions only, and these events can originate
elsewhere
1464 B. Royer-Bertrand, C. Rivolta
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requires	   more	   complex	   analysis,	   but	   it	   virtually	   provides	   information	   on	   all	   possible	  types	  of	  pathogenic	  genetic	  events,	  such	  as	  gene	  fusions,	  duplications,	  and	  deletions,	  and	  non-­‐coding	  regions.	   In	  standard	  protocols,	  WES	   is	  usually	   the	   first	  sequencing	  method	  performed	  on	  a	  patient,	  and	  if	  negative,	  WGS	  can	  then	  be	  attempted.	  	  	  
1.3 Development	  of	  bioinformatics	  pipelines	  for	  genetic	  diseases	  
	  
Mapping	  and	  variant	  calling	  step	  The	   process	   of	   obtaining	   the	   full	   exome	   or	   genome	   sequence	   of	   an	   individual	  consists	  of	  a	  two-­‐step	  computer-­‐based	  procedure.	  First,	  the	  short	  NGS	  reads	  are	  mapped	  to	  the	  reference	  genome	  by	  assigning	  them	  specific	  genomic	  coordinates,	  corresponding	  to	  the	  amplified	  regions	  of	  the	  libraries	  used	  (Figure	  6,	  middle	  panel,	  top).	  For	  this	  step,	  we	   used	   the	   Novoalign	   software	   (Novocraft,	   2010),	   one	   of	   the	   most	   popular	   reads	  aligner	  with	  BWA	  [48],	  and	  Bowtie-­‐2	  [49].	  While	  the	  two	  last	  aligners	  are	  both	  based	  on	  backward	  search	  with	  Burrows-­‐Wheeler	  Transform,	  Novoalign	  uses	  a	  hash-­‐based	  index	  to	   search	   the	   genome	   and	   gives	   very	   good	   performance	   results	   [50].	   After	   a	   step	  removing	   the	   low-­‐quality	   sequences	   data,	  mismatches	   between	   the	   reference	   genome	  and	   the	   individual	   genome	   are	   assessed	   via	   a	   bioinformatic	   process	   referred	   to	   as	  “variant	   calling”	   (Figure	   6,	   middle	   panel,	   bottom).	   All	   the	   steps	   follow	   the	   guidelines	  provided	  by	  the	  Genome	  Analysis	  ToolKit	   (GATK)	  best	  practices	   [51],	  a	  bioinformatics	  suite	   developed	   by	   the	   Broad	   Institute,	   which	   offers	   a	   wide	   variety	   of	   tools	   with	   a	  primary	   focus	   on	   the	   discovery	   of	   variants	   and	   genotyping.	   The	   same	   protocol	   was	  applied	   to	   all	   our	   WES	   generated	   data,	   having	   the	   advantage	   of	   achieving	   data	  homogeneity,	  with	  the	  same	  technical	  errors.	  This	  simple	  practice	  enables	  the	  reduction	  of	   the	   sequencing	   “noise”	   (e.g.	   low	   quality	   calls,	   false	   positive	   variants).	   For	   WGS,	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Complete	  Genomics	  directly	  performed	  these	  bioinformatics	  steps	  and	  provided	  us	  the	  raw	  files	  and	  the	  processed	  data	  for	  all	  the	  SNVs,	  SVs	  and	  CNVs.	  	  
Annotation	  and	  filtering	  steps	  After	   the	   generation	   of	   all	   the	   variants	   present	   in	   an	   individual,	   two	   analytic	  procedures	  still	  remain	  and	  are	  highly	  important	  to	  identify	  the	  disease-­‐causing	  variants	  (Figure	   6,	   right	   panel).	   The	   first	   step	   is	   the	   annotation	   of	   all	   the	   genes	   and	   variants,	  which	   is	   then	   used	   for	   the	   second	   step	   that	   is	   the	   filtering	   of	   the	   variants	   based	   on	  specific	  criteria,	  which	  are	  relevant	  for	  the	  disease	  of	  interest.	  	  	  
	  
Figure	  8:	  NGS	  methodology	  for	  hereditary	  diseases	  and	  cancer,	  extracted	  from	  [26]	  More	   specifically,	   diverse	   bioinformatics	   analytical	   procedures	   or	   “pipelines”	  have	  been	  developed	  for	  application	  either	  in	  the	  context	  of	  cancer	  or	  Mendelian	  cases	  (Figure	  8).	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1.3.1 Bioinformatics	  for	  Cancer	  analysis	  In	   cancer,	   especially	   for	   tumors	   caused	   by	   mutations	   acquired	   during	   an	  individual’s	   lifetime,	  it	   is	  highly	   important	   to	  detect	  all	   the	  somatic	  mutations	   that	  are	  specific	   of	   the	   tumor.	   In	   term	   of	   experimental	   set-­‐up	   approach,	   both	   tumor	   DNA	   and	  normal	  DNA	  of	   the	   same	  patient	  are	   sequenced.	  The	  cancer	  genome	   is	   extracted	   from	  tissue	  biopsy	  of	   the	   tumor,	  while	   its	  normal	   counterpart	  usually	   comes	   from	  blood	  or	  biopsy	  of	  a	  normal	  tissue.	  The	  simple	  comparison	  between	  tumor	  and	  normal	  genomes	  allows	   the	   detection	   of	   somatic	   mutations	   present	   only	   in	   the	   tumor	   (Figure	   8,	   right	  part).	  In	  this	  situation,	  any	  somatic	  change	  is	  potentially	  a	  good	  candidate;	  no	  matter	  its	  frequency	   and	   type	   of	   mutation.	   However,	   a	   strong	   and	   deleterious	  mutation	   will	   be	  more	   interesting	   to	  study,	  as	  well	  as	   if	   the	  gene	   impacted	  has	  already	  been	  associated	  with	   a	   cancer	   or	   if	   it	   is	   involved	   in	   a	   relevant	   pathway	   for	   cancer	   progression	   or	  treatment.	  Chapter	  5.1	  provides	  a	  more	  detailed	  procedure	  of	  the	  analytic	  workflow	  for	  cancer.	  In	  case	  of	  heterogeneous	  tumors,	  one	  important	  criterion	  is	  the	  correct	  choice	  of	  the	  depth	  of	  sequencing,	  since	  high	  sequencing	  coverage	  may	  be	  able	  to	  detect	  variants	  present	  in	  very	  low	  percentage	  in	  the	  DNA.	  Single-­‐cell	  sequencing	  is	  also	  a	  valuable	  tool	  to	  properly	  assess	  the	  cellular	  heterogeneity	  of	  the	  tumor	  sample.	  	  
1.3.2 Bioinformatics	  in	  Mendelian	  diseases	  	  
Filtering	  procedures	  	  In	  Mendelian	  diseases,	  only	  one	  or	  two	  mutations	  in	  a	  single	  gene	  are	  responsible	  for	   the	   pathological	   phenotype.	   However,	   all	   individuals	   carry	   more	   or	   less	   frequent	  variations,	   which	   make	   them	   unique	   but	   are	   usually	   not	   disease-­‐causing.	   The	   most	  critical	  part	  of	   the	  bioinformatics	  procedures	  applied	   to	  Mendelian	  disorders	   is:	  being	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able	  to	  identify	  disease-­‐causing	  candidate	  DNA	  variants	  while	  reducing	  the	  overall	  noise,	  both	   technical	   (false	   calls)	   and	   biological	   (innocuous	   variants).	   In	   order	   to	   efficiently	  identify	  these	  candidates,	  different	  steps	  are	  have	  been	  applied	  (Figure	  9).	  	  
	  
	  
Figure	  9:	  Annotation	  and	  filtering	  steps	  for	  rare	  Mendelian	  disorders	  	  
(with	  the	  average	  number	  of	  variants	  for	  110	  WES	  samples)	  
	  The	  input	  file	  corresponds	  to	  all	  the	  variants	  detected	  in	  a	  patient’s	  WES	  or	  WGS	  data.	  It	  contains	   both	   rare	   and	   frequent	   variants;	   but	   also	   variants	   of	   different	   sequencing	  quality	  and	  different	  zygosity.	  	  
	  
Genes	  annotation	   allows	  describing	   the	   impacted	  gene,	   if	   this	  gene	   is	  often	  mutated	   in	  control	  individuals	  (and	  so	  less	  likely	  to	  be	  disease-­‐causing)	  (Table	  1,	  A-­‐B)	  and	  if	  it	  is	  a	  known	  disease	  gene	  (Table	  1,	  C).	  
Annotation	  type	   Description	   Value	   Data	  
A-­‐	  “Polymorphic”	  gene	   Number	  of	  mutation	  per	  gene	  in	  control	  population	   Low,	  medium-­‐low,	  medium,	  medium-­‐high,	  high	  
Calculated	  from	  1KG	  by	  Complete	  Genomics	  (CG)	  
	  	   Number	  of	  nonsense	  and	  frameshift	  homozygous	  changes	  (in	  more	  that	  2	  individuals)	  per	  gene	  in	  a	  control	  population	   NA,	  0,	  1,	  …	   ExAC.r0.03	  [52]	  B-­‐	  “False	  Positive”	  gene	   Annotation	  of	  the	  genes	  which	  are	  often	  mutated	  in	  WES	  data	   NA	  or	  FPGenes	   [53]	  	  C-­‐	  Link	  with	  the	  phenotype	   List	  of	  disease	  genes	   Mendelian	  disorders,	  Retinal	  Degeneration,	  Skeletal,	  Metabolic,	  Mental	  Retardation,	  …	  
OMIM	  [54],	  RetNet	  [31],	  CeGaT,	  
Table	  1:	  Description	  of	  the	  different	  annotations	  for	  the	  genes	  
Output%ﬁle%
from%
Mapping%
and%Variant%
calling%
Genes%and%
Variants%
annota7on%
%
Rare%%
(1%)%
n=%62’881% n=%1’540% n=%366%
High%quality% Inheritance%
Hom=6%
CompHet=33%
ChrX=4%
Het=356%
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Variants	  annotation:	   In	   this	   step,	  we	   add	   information	   on	   the	   variant’s	   frequency	   from	  public	   databases	   of	   healthy	   controls	   (ExAC	   [52]),	   or	   of	   in-­‐house	   control	   genetic	  databases	  (Table	  2,	  D).	  The	  effect	  on	  the	  amino	  acid	  residue	  is	  also	  considered	  (Table	  2,	  A),	   as	   well	   as	   its	   degree	   of	   deleteriousness	   (Table	   2,	   B),	   and	   the	   conservation	   of	   the	  nucleotide	   impacted	   (Table	   2,	   C).	   The	   information	   about	   known	   variants	   of	   clinical	  significance	   at	   the	   same	   position	   or	   in	   the	   surrounding	   25	   nucleotides	   is	   described	  (Table	  2,	  E).	  Splicing	  events	  are	  calculated	  for	  every	  variant	  (Table	  2,	  F)	  as	  well	  as	  their	  distance	  from	  the	  closest	  exon	  boundaries	  (Table	  2,	  G).	  	  
Annotation	  type	   Description	   Value	   Data	  
A-­‐	  Protein	  impact	   Description	  of	  the	  impact	  of	  the	  variant	  on	  the	  protein	  sequence	   Nonsense,	  Frameshift,	  Splicing	  Site,	  Missense,	  Synonymous,	  intronic	  	   annovar	  [55]	  	  B-­‐	  Amino	  Acid	  impact	   Score	  reflecting	  the	  impact	  of	  the	  change	  based	  on	  known	  pathogenic	  mutations	   Between	  0	  (poor	  impact)	  to	  1	  (high	  impact)	   In	  house	  data	  	   VEST3	  predictive	  score	  for	  the	  deleteriousness	  of	  the	  variant	   Between	  0	  (poor	  impact)	  to	  1	  (high	  impact)	   [56,	  57]	  C-­‐	  Conservation	  of	  the	  nucleotide	   PhyloP	  score	  between	  46	  mammals	   Conserved	  if	  >	  1.5	   PhyloP	  [58]	  	  D-­‐	  Frequency	  of	  the	  variant	   Frequency	  of	  the	  variant	  in	  public	  database	  or	  its	  absence	   NA	  or	  frequency	   Wellderly,	  from	  CG,	  1KG	  from	  CG,	  ExAC	  [52]	  	   Frequency	  of	  the	  variant	  in	  in-­‐house	  database	  (WES/WGS)	   NA	  or	  number	  of	  individuals	  with	  the	  same	  variant	   In	  house	  data	  E-­‐	  Clinical	  Significance	   Presence	  of	  a	  variant	  with	  reported	  clinical	  significance	   Pathogenic,	  likely	  pathogenic,	  likely	  benign,	  benign	  or	  NA	   ClinVar	  [59]	  	   Number	  of	  pathogenic	  variants	  in	  25	  nucleotides	  around	  the	  variant	   Number	  between	  0	  to	  50	   	  F-­‐	  Splice	  Site	  prediction	   Prediction	  of	  creation	  or	  disruption	  of	  a	  splice	  site	   Annotation	  if	  it	  creates	  or	  disrupts	  a	  splice	  site	   MaxEntScan	  [60]	  G-­‐	  Exon	  boundaries	   Calculation	  of	  the	  closest	  exon	  boundary	  from	  the	  variant	   Number	  of	  nucleotides	  from	  the	  exon	  boundary	   RefGene	  
Table	  2:	  Description	  of	  the	  different	  annotations	  for	  the	  variants	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After	   this	   intensive	   annotation	   step,	   it	   is	   now	  possible	   to	   filter	   the	   candidate	   variants	  based	   on	   the	   most	   relevant	   and	   biological	   information	   we	   can	   gather	   from	   the	  phenotype.	  	  
Rare	  (1%):	  By	  definition,	  we	  are	  focusing	  on	  rare	  genetic	  alterations,	  which	  could	  cause	  a	   rare	   disease.	  We	   usually	   set	   up	   the	   threshold	   of	   rarity	   of	   at	  most	   1%	   of	   the	   allelic	  frequency,	  which	   takes	   into	  account	  healthy	  carrier	  of	   single	  heterozygous	  pathogenic	  mutations.	  We	  also	  filter	  the	  variants	  present	  in	  our	  in-­‐house	  databases	  of	  hundreds	  of	  WES	   data	   of	   affected	   and	   unaffected	   individuals,	   for	   various	   diseases.	   Moreover,	   we	  remove	  all	  the	  rare	  variants	  that	  can	  be	  found	  in	  homozygous	  state	  in	  healthy	  carriers.	  	  	  
High	   quality:	   We	   only	   consider	   variants	   with	   a	   high	   sequencing	   quality,	   based	   on	   a	  minimal	  number	  of	  15	  reads,	  a	  percentage	  of	  alternative	  reads	  of	  at	  least	  15%	  compared	  to	  the	  reference	  reads	  and	  a	  genotype	  quality	  of	  50	  or	  more	  (out	  of	  99,	  being	  the	  best	  quality).	  Below	  these	  values,	  it	  is	  difficult	  to	  assess	  the	  real	  presence	  of	  the	  variant	  and	  its	  quality.	  During	  this	  step,	  most	  of	  the	  non-­‐exonic	  variants	  are	  discarded,	  as	  they	  are	  outside	   of	   the	   range	   of	   WES.	   However,	   intronic	   variants	   of	   good	   quality	   in	   the	  surrounding	  exon	  boundaries	  may	  be	  kept,	  especially	  if	  they	  create	  new	  splicing	  events.	  
	  
Inheritance	  pattern:	  Depending	  on	  the	  transmission	  mode	  of	  the	  disease,	  the	  variants	  are	  separated	   in	   4	   files:	   homozygous	   variants	   for	   autosomal	   recessive	   diseases	   as	  well	   as	  compound	   heterozygous	   variants,	   heterozygous	   variants	   for	   autosomal	   dominant	  diseases	  and	  variants	  on	  the	  X-­‐chromosome	  for	  X-­‐linked	  diseases.	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Strategies	  to	  identify	  disease	  genes	  
Each	  disease	  and	  each	  patient	  is	  different.	  However,	  common	  strategies	  have	  been	  developed	   based	   on	   i)	   the	   inheritance	   pattern	   of	   the	   disease,	   ii)	   a	   clear	   clinical	  description	  of	  the	  phenotype,	  iii)	  the	  availability	  of	  family	  members	  and	  information,	  iv)	  the	  availability	  of	  genetic	  information	  from	  other	  patients	  with	  the	  same	  disorder.	  In	  the	  end,	  depending	  on	   the	   context,	   up	   to	  6	  different	   strategies	   can	  be	  applied	   (Figure	  10)	  [61].	   	  
	  
Figure	  10:	  Strategies	  to	  identify	  disease-­‐causing	  genes	  in	  NGS	  studies,	  extracted	  from	  [61].	  Affected	  
individuals	  have	  filled	  symbols;	  carriers	  are	  represented	  with	  a	  dot.	  Dashed	  rectangles	  contain	  the	  
individuals	  that	  were	  sequenced.	  Circles	  below	  each	  pedigree	  represent	  the	  strategy	  used	  to	  identify	  the	  
disease	  genes.	  	  
Linkage-­‐based	   strategy,	   which	   compares	   the	   rare	   variants	   found	   in	   all	   the	   affected	  individuals	  versus	  healthy	  members	  of	  the	  same	  family.	  
Homozygous-­‐base	  strategy,	  which	  focuses	  on	  homozygous	  variants	   inherited	  from	  both	  parents,	  in	  case	  of	  rare	  inherited	  recessive	  disease	  and	  suspected	  consanguinity.	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Double-­‐hit-­‐based	  strategy,	  which	  analyses	  rare	  homozygous	  or	  compound	  heterozygous	  variants	   present	   in	   a	   patient	   without	   other	   family	   member	   available	   and	   when	   the	  disorder	  is	  suspected	  to	  be	  inherited	  in	  a	  recessive	  manner.	  
Overlap-­‐based	  strategy,	  which	  searches	  for	  a	  single	  gene	  with	  different	  rare	  variants	   in	  multiple	  patients.	  
De	  novo-­‐based	  strategy,	  which	   analyses	   both	   the	   patient	   and	   their	   parents	   in	   order	   to	  find	  a	  variant	  that	  has	  newly	  arisen	  in	  the	  patient	  only.	  It	  is	  also	  called	  a	  Trio	  analysis.	  
Candidate-­‐based	  strategy,	  which	  corresponds	  to	  the	  strategy	  for	  single	  affected	  patients	  with	   a	   suspected	   dominant	   inherited	   disorder.	   In	   this	   case,	   a	   prioritization	   of	   the	  mutations	  is	  made	  based	  on	  different	  features,	  such	  as	  the	  impact	  of	  the	  variant	  on	  the	  protein	  function,	  the	  conservation	  of	  the	  modified	  amino	  acid	  and	  other.	  	  
	  	   During	   my	   Ph.D.	   work,	   all	   of	   these	   strategies	   have	   been	   applied	   on	   different	  patients.	   The	   overlap-­‐based	   strategy	   was	   used	   in	   a	   large	   cohort	   of	   patients	   with	  recessive	   form	   of	   Cone-­‐Rod	   Dystrophy	   and	   results	   are	   presented	   in	   Appendix	   6.4	  However,	   in	   the	  majority	   of	   cases,	   the	   inheritance	  pattern	  was	  unclear	   and	   additional	  patients	   or	   family	  members	  were	   not	   sequenced,	   for	   cost	   effective	   reasons.	   Thus,	   the	  candidate-­‐base	  strategy	  was	  intensively	  used.	  In	  order	  to	  confirm	  the	  pathogenicity	  of	  a	  variant,	  co-­‐segregation	  of	  a	  variant	  within	  the	  affected	  family	  members	  (when	  available)	  was	  checked.	  Note	  that	  Chapter	  5.1	  provides	  a	  more	  detailed	  procedure	  of	  the	  analytic	  workflow	  for	  Mendelian	  disorders.	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1.4 Aim	  of	  this	  thesis	  	   The	  aim	  of	  this	  Ph.D.	  work	  was	  to	  develop	  novel	  bioinformatics	  techniques	  specific	  to	  large	  scale	  sequencing	  sets	  in	  order	  to	  efficiently	  identify	  the	  genetic	  insults	  with	  high	  phenotypic	  effects,	   such	  as	  germline	  mutations	   in	  Mendelian	  hereditary	  disorders	  and	  somatic	  mutations	  in	  rare	  ocular	  cancers.	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2 Results	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This	  chapter	  gives	  a	  summary	  of	  the	  main	  results	  of	  the	  projects	  in	  which	  I	  took	  part	  during	  my	  doctoral	  work.	  Moreover,	  it	  contains	  the	  experimental	  follow-­‐up	  carried	  out	  in	   the	   lab.	   A	  more	   detailed	   explanation	   of	  my	   personal	   contribution	   for	   each	   study	   is	  described	  at	  the	  beginning	  of	  each	  subchapter.	  	  
2.1 Overview	  of	  NGS	  analysis	  of	  human	  diseases	  	  In	  the	  first	  part	  of	  my	  thesis,	  the	  applications	  of	  NGS	  technologies	  are	  reviewed	  to	  better	  understand	  the	  genetic	  alterations	   leading	  to	  human	  diseases.	  More	  specifically,	  we	   discuss	   the	   different	   existing	  methods	   for	  Mendelian	   disorders	   gene	   discovery	   on	  one	  side,	  and	  for	  the	  identification	  of	  causative	  somatic	  mutations	  in	  cancer	  on	  the	  other	  side.	  An	  emphasis	  is	  given	  on	  the	  benefits	  and	  disadvantages	  of	  using	  WGS	  compared	  to	  WES.	  Moreover,	  we	  detail	  the	  general	  pipelines	  used	  to	  study	  both	  Mendelian	  diseases	  and	   cancer.	   In	   this	   work,	   I	   reviewed	   the	   literature	   and	   wrote	   the	   manuscript.	   (See	  chapter	  5.1,	  [26])	  	  
2.2 Ocular	  Melanomas	  	  In	   this	   chapter,	   a	   focus	   is	  provided	  on	   the	   study	  of	   two	  different	   types	  of	   ocular	  melanomas:	  the	  conjunctival	  melanoma	  (CM)	  and	  the	  uveal	  melanoma	  (UM)	  by	  means	  of	  WGS.	  Our	  findings	  on	  CM	  highlight	  the	  presence	  of	  a	  high	  number	  of	  somatic	  mutations	  (more	  than	  90,000	  single	  nucleotide	  substitutions)	  and	  a	  majority	  of	  cytosine	  to	  thymine	  (C>T)	   substitutions,	   specifically	   found	   at	   the	   3’	   end	   of	   pyrimidine	   dinucleotides.	   They	  are	   classical	   features	   of	   the	   presence	   of	   typical	   UV	   light	   mutation	   signature,	   a	  characteristic	   of	   cutaneous	   melanomas.	   In	   this	   project,	   I	   did	   all	   the	   bioinformatics	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analysis	  and	  statistics,	  and	  I	  participated	  in	  the	  writing	  of	  the	  manuscript.	  (See	  chapter	  5.2.1,	  [62])	  Uveal	  Melanoma	  is	  the	  most	  common	  form	  of	  ocular	  melanoma	  and,	  unlike	  CM,	  it	  is	   genetically	   different	   from	   cutaneous	   melanoma.	   Whole-­‐genome	   sequencing	   of	   34	  primary	   and	   metastatic	   UM	   patients	   allowed	   us	   to	   further	   characterize	   the	   genetic	  landscape	   proper	   to	   this	   type	   of	   cancer.	   In	   particular,	   we	   were	   able	   to	   classify	   the	  patients	   according	   to	   particular	   genetic	   events,	   such	   as	   Copy-­‐Number	   Variations	   and	  mutations	   in	  cancer	  driver	  genes.	  We	   identified	  and	  designated	  four	  distinct	  classes	  of	  UM,	  with	  large	  genomic	  alterations	  and	  mutations	  in	  BAP1	  associated	  to	  classes	  A	  and	  B,	  usually	  linked	  with	  a	  bad	  prognosis	  and	  metastatic	  capabilities.	  On	  the	  other	  hand,	  C	  and	  D	   classes	   harbor	   minor	   alterations	   and	   single	   mutations	   in	   SF3B1	   or	   EIF1AX.	  Interestingly,	  when	  looking	  at	  the	  CNV	  levels	  of	  the	  long	  arm	  of	  chromosome	  8,	  we	  were	  able	   to	  correlate	  high	  amplification	   level	   (ploidy	  of	  5	  or	  more)	  with	  metastatic	  UM	  (p-­‐value=8.6x10-­‐4),	  while	   single-­‐copy	   gain	   (ploidy	   of	   3)	  was	  more	   likely	   to	   be	   associated	  with	  class	  D	  and	  EIF1AX	  mutations	   (p-­‐value=4.7x10-­‐3),	  previously	  characterized	   in	   the	  literature	  as	  patients	  with	  late	  metastatic	  potential.	  For	  this	  project,	  I	  took	  care	  of	  all	  the	  bioinformatics	   set-­‐up,	   analysis	   and	   creation	   of	   figures	   and	   tables	   and	   wrote	   the	  manuscript.	  (See	  chapter	  5.2.2)	  	  
2.3 Rare	  inherited	  Mendelian	  disorders	  	  The	  bioinformatic	  procedures	  developed	  in	  the	  course	  of	  my	  Ph.D.	  were	  applied	  to	  many	  types	  of	  rare	  inherited	  Mendelian	  disorders,	  ranging	  from	  retinal	  degenerations	  to	  skeletal	  and	  metabolic	  disorders.	  In	  this	  chapter,	  I	  detailed	  my	  major	  novel	  findings	  for	  a	  specific	  Mendelian	  disease.	  The	  appendix	  (Chapter	  6)	  contained	  other	  projects	  for	  which	  the	  bioinformatics	  procedures	  were	  applied	  and	  allowed	  us	  to	  make	  new	  discoveries.	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   We	   were	   able	   to	   detect	   the	  mitochondrial	   chaperone	  HSPA9	   as	   the	   cause	   of	   a	  novel	   disorder,	   called	   EVEN-­‐PLUS	   syndrome	   [MIM	   #616854]	   (Epiphyseal,	   Vertebral,	  Ear,	  Nose,	  PLUS	  associated	  findings).	  Interestingly,	  HSPA9	  protein	  interacts	  with	  LONP1,	  another	  mitochondrial	  protein	  leading	  to	  a	  similar	  syndrome	  (CODAS	  [MIM	  #600373])	  [63,	   64].	   This	   interaction	   delineates	   a	   family	   of	   “mitochondrial	   chaperonopathies”,	  bringing	   first	   evidence	   of	   an	   unexplored	   role	   of	   mitochondrial	   chaperones	   in	   human	  embryonic	   morphogenesis.	   For	   this	   study,	   I	   analyzed	   the	  WES	   results	   and	   found	   the	  disease-­‐causing	   gene	   in	   the	   three	   patients.	   I	  worked	   on	   the	   figures	   of	   the	   paper.	   (See	  chapter	  5.3.1,	  [65])	  	   Nine	   patients	   with	   infantile-­‐onset	   severe	   developmental	   delay	   and	   skeletal	  dysplasia	   were	   sequenced	   and	   we	   identified	   biallelic	   mutations	   in	   NANS,	   the	   gene	  encoding	   the	   synthase	   for	   N-­‐acetylneuraminic	   acid	   (sialic	   acid).	   Further	   functional	  experiments	   performed	   with	   collaborators	   showed	   that	   NANS-­‐mediated	   synthesis	   of	  sialic	  acid	  is	  required	  for	  early	  brain	  development	  and	  skeletal	  growth.	  In	  this	  project,	  I	  analyzed	  the	  WES	  results	  of	  the	  patients,	  and	  generated	  the	  figures	  related	  to	  these	   in-­‐
silico	  findings.	  (See	  Appendix	  6.1,	  [66])	  In	  a	   family	  presenting	  with	  severe	  peripheral	  osteolysis,	  (a	  disease	  showing	  adult-­‐onset	  progressive	  shortening	  of	  fingers	  and	  toes	  with	  redundancy	  of	  the	  overlying	  skin),	  we	   found,	   in	   all	   affected	  members,	   compound	   heterozygous	  mutations	   in	  ASAH1,	   the	  gene	   coding	   for	   acid	   ceramidase.	   This	   allowed	   us	   to	   confirm	   the	   diagnosis	   of	   Farber	  disease	  [MIM	  #228000]	   in	  what	  appear	  to	  be	  the	  oldest	  affected	  individuals	  known	  so	  far	   for	   this	   disease.	   Here,	   I	   generated	   the	  WES	   results	   and	   analyzed	   the	   data,	   which	  allowed	  us	  to	  identify	  the	  disease-­‐causing	  gene.	  I	  produced	  the	  figures	  related	  to	  these	  
in-­‐silico	  findings.	  (See	  Appendix	  6.2,	  [67])	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We	   reported	   two	   unrelated	   patients	   with	   a	   very	   similar	   multisystemic	   disease	  involving	   the	   liver,	   vision,	   immune	   system,	   connective	   tissues,	   and	   bones,	   caused	   by	  recessive	  variants	  in	  the	  neuroblastoma	  amplified	  sequence	  (NBAS)	  gene.	  Although	  this	  gene	   has	   already	   been	   associated	   with	   human	   diseases	   of	   acute	   liver	   failure	   [MIM	  #616483]	  [68]	  and	  short	  stature	  and	  optic	  atrophy	  [MIM	  #614800]	  [69],	  we	  observed	  a	  wider	   phenotypic	   spectrum	   of	   NBAS	   deficiency	   than	   previously	   describes,	   including	  skeletal,	   hepatic,	  metabolic,	   and	   immunologic	   aspects.	   In	   this	   project,	   I	   generated	   the	  WES	  results	  and	  contributed	  to	   the	   identification	  of	   the	  NBAS	  gene.	   I	  made	  the	   figures	  related	  to	  these	  in-­‐silico	  findings.	  (See	  Appendix	  6.3,	  [70])	  	  With	   the	  help	   of	   the	   bioinformatics	   pipeline,	  we	  discovered	   three	   individuals	  with	  cone-­‐rod	  degeneration,	   a	   specific	   form	  of	   retinal	  degeneration	  affecting	   central	   vision,	  with	   bi-­‐allelic	   variants	   in	   the	   centrosomal	   gene	   CEP78.	   The	   patients	   also	   developed	  hearing	   loss	   or	   hearing	   deficit	   with	   age.	   Our	   data	   revealed	   a	   previously	   undescribed	  clinical	  syndrome	  of	  a	  ciliary	  nature	  characterized	  by	  blindness	  and	  deafness	  but	  clearly	  distinct	  from	  Usher	  syndrome	  [MIM	  #276900],	  a	  condition	  for	  which	  visual	  impairment	  is	   due	   to	   retinitis	   pigmentosa,	   another	   type	  of	   retinal	   degeneration.	   For	   this	   project,	   I	  applied	   the	  WES	   pipeline	   I	   developed	   and	   helped	   in	  merging	   the	  WES	   results	   for	   the	  different	  patients	  of	  the	  cohort,	  which	  eventually	  led	  to	  the	  finding	  of	  this	  new	  gene	  in	  two	  different	  families.	  (See	  Appendix	  6.4,	  [71])	  
TTLL5,	   a	   gene	   recently	  associated	  with	  Cone-­‐Rod	  dystrophy	   [72],	  has	  been	   further	  characterized	   in	   our	   study	   of	   8	   patients	   suffering	   from	   a	   recessive	   form	   of	   cone-­‐dominated	   retinopathy.	  We	  were	   able	   to	   link	   loss-­‐of-­‐function	  mutations	   in	  male	  with	  reduced	   sperm	   motility	   and	   infertility,	   delineating	   a	   novel,	   allele-­‐specific	   syndrome	  causing	  defects	   in	   two	  unrelated	   functions,	   reproduction	  and	  vision.	  For	   this	  project,	   I	  contributed	   to	   the	   development	   of	   the	   bioinformatics	   pipeline,	   which	   allowed	   the	  identification	  of	  the	  disease-­‐causing	  gene.	  (See	  Appendix	  6.5,	  [73])	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Optimization	  of	  bioinformatics	  procedures	  In	   this	   work,	   NGS	   technology	   has	   been	   used	   as	   the	   basis	   to	   decipher	   the	   genetic	  causes	  of	  various	  human	  diseases.	  Several	  bioinformatical	  procedures	  and	  filtering	  steps	  were	  developed	  and	  adapted	  to	  analyze	  different	  data	  sets.	  These	  procedures	  allowed	  us	  to	  identify	  the	  disease	  causing	  variants	  from	  thousand	  of	  benign	  genetic	  alterations	  and	  have	  been,	  of	  course,	  gradually	  optimized	  over	  the	  years.	  To	  date,	  five	  major	  versions	  of	  these	  steps	  have	  been	  developed	  and	  used,	  with	  a	  specific	  focus	  given	  on	  the	  genes,	  the	  variants	   and	   the	   different	   strategies	   to	   efficiently	   analyze	   the	   data.	   One	   of	   the	   most	  important	   features	  of	   these	  procedures	  has	  been	  the	   integration	  of	  annotated	  variants	  from	  thousand	  of	   individuals,	  such	  as	  the	  ones	  belonging	  to	  ExAC	  [52]	  or	   from	  our	   in-­‐house	  database.	  Access	  to	  the	  frequency	  of	  variants	  has	  greatly	  modified	  our	  decision	  on	  selecting	  rare	  changes	  from	  frequent	  ones.	  Interestingly,	  some	  variants,	  reported	  to	  be	  disease	   causing	   in	   studies	   before	   the	   NGS	   revolution,	   have	   proven	   to	   be	   wrongly	  annotated	   [52].	   These	   improvements	   of	   the	   different	   pipelines	   allowed	  me	   to	   provide	  more	   comprehensive	   lists	   of	   candidates’	   variants,	   including	   novel	   disease	   genes	   and	  novel	   mutations	   presented	   in	   this	   thesis.	   Moreover,	   five	   additional	   new	   candidate	  disease	   genes	   responsible	   for	   dominant	   and	   recessive	   skeletal	   disorders	   have	   been	  discovered	  and	  are	  currently	  being	  tested	  and/or	  are	  in	  the	  process	  of	  being	  submitted	  for	  publication.	  The	  pipelines	  described	  in	  this	  work	  will	  continuously	  be	  optimized	  to	  efficiently	  integrate	  all	  new	  information	  from	  NGS	  processes,	  which	  are	  being	  improved	  every	  day.	  Originally	  made	  for	  retinal	  dystrophies	  investigation,	  the	  pipelines	  were	  then	  adjusted	  for	  the	  diagnostic	  of	  skeletal	  and	  metabolic	  disorders.	  They	  are	  currently	  being	  applied	  for	  the	  analysis	  of	  intellectual	  disabilities	  and	  epilepsies,	  with	  promising	  results.	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Differential	  approaches	  to	  cancer	  and	  Mendelian	  disorders	  	  Experimental	   strategies	   and	  NGS-­‐based	   approaches	   applied	   on	   ocular	  melanomas	  are	  very	  different	  that	  those	  used	  for	  rare	  Mendelian	  disorders.	  First	  of	  all,	  detection	  of	  cancer	  variants	  requires	  the	  acquisition	  of	  both	  normal	  and	  tumor	  DNAs,	  but	  this	  latter	  could	   be	   difficult	   to	   extract.	   Indeed,	   for	   ocular	   melanomas,	   only	   patients	   with	   eye	  enucleation	  and	  without	  any	  chemotherapy	  were	   considered.	   Since	   they	  are	  very	   rare	  cancers,	   only	   few	   samples	   were	   available	   for	   the	   study.	   Moreover,	   this	   double	  sequencing	  considerably	  increases	  the	  price	  of	  any	  study.	  Secondly,	  sequencing	  data	  are	  treated	   differently	   for	   these	   two	   types	   of	   diseases.	  While	   it	   is	   essential	   for	  Mendelian	  disorders	   to	   have	   a	   large	   list	   of	   variants	   present	   in	   healthy	   individuals,	   all	   somatic	  variants	  are	  potentially	  interesting	  in	  cancer	  and	  do	  not	  require	  a	  list	  of	  variations	  in	  the	  general	   population.	   However,	   the	   process	   of	   obtaining	   high	   quality	   somatic	   variants	  might	  be	  challenging,	  especially	  in	  highly	  heterogeneous	  cancers.	  This	  is	  an	  advantage	  of	  ocular	  melanomas,	  as	  they	  are	  usually	  very	  homogeneous.	  One	  important	  point	  in	  some	  types	   of	   cancer	   is	   the	   presence	   of	   predisposition	   factors,	   which	   are	   present	   in	   the	  germline	   genome	   (i.e.	  BRCA1	   in	   breast	   and	   ovarian	   cancers).	   This	  means	   that	   cancers	  with	   such	   hereditable	   conditions	   should	   also	   be	   studied	   similarly	   to	   Mendelian	  disorders,	  otherwise	  important	  information	  may	  be	  missed.	  Finally,	  the	  pathogenicity	  of	  a	   variant	   in	   a	   gene	   for	   a	   given	   disease	   can	   be	   assessed	   by	   various	   experiments,	   the	  functional	   testing	   being	   the	   most	   informative	   one.	   However,	   a	   good	   hint	   of	   probable	  pathogenicity	   is	   given	   in	   Mendelian	   diseases	   when	   the	   candidate	   variant	   segregates	  perfectly	  within	  the	  family.	  Such	  confirmation	  could	  not	  be	  undertaken	  for	  cancer.	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Disease	  gene	  identification	  by	  NGS:	  positive	  effects	  and	  limits	  NGS	  technologies	  have	  revolutionized	  the	  field	  of	  medical	  genetics.	  They	  allow	  us	  to	  find	  disease-­‐causing	  variants	  in	  a	  much	  quicker,	  cheaper,	  and	  more	  efficient	  way	  than	  ever.	  Every	  month,	  new	  genes	  are	  being	   identified	  as	   the	  genetic	   causes	  of	  existing	  or	  novel	   syndromes,	   or	   new	   therapeutic	   approaches	   in	   cancer.	   NGS	   is	   accelerating	   at	   an	  unprecedented	   scale	   the	   understanding	   of	   genes,	   pathways	   and	   family	   of	   diseases.	   In	  Mendelian	  diseases,	  it	  is	  very	  efficient	  for	  recessive	  families,	  as	  rare	  bi-­‐allelic	  mutations	  are	   in	   the	   end	  only	   about	   a	   dozen	   in	   the	  human	  genome.	   It	   is	   even	  more	  powerful	   in	  consanguineous	   families,	   as	   regions	   of	   interest	   can	   be	   inferred	   easily	   from	  many	  NGS	  methods.	  However,	  it	  is	  more	  difficult	  to	  solve	  dominant	  cases	  because	  patients	  harbor	  much	   more	   rare	   variants	   in	   heterozygous	   state	   and	   many	   of	   them	   are	   harmless	   but	  difficult	  to	  discard.	  	  	  
Likelihood	  of	  a	  gene	  to	  be	  associated	  with	  a	  dominant	  condition	  In	  order	  to	  reduce	  the	  number	  of	  candidate	  heterozygous	  variants	  to	  consider	  in	  patients	  with	   a	   dominant	   disease,	   we	   are	   developing	   a	   predicting	   tool	   estimating	   the	  likelihood	  of	  a	  gene	  to	  be	  associated	  with	  a	  dominant	  disease.	  Our	  method	  is	  based	  on	  the	  hypothesis	  that	  genes	  responsible	  for	  rare	  autosomal	  inherited	  diseases	  should	  have	  specific	   characteristics	   such	   as,	   i)	   low	   number	   of	   rare	   variants	   in	   the	   general	   healthy	  population	   ii)	   strong	   selection	   and	   therefore	   conservation	   across	   species,	   iii)	   function	  and	   expression	   pattern	   leading	   to	   possible	   haploinsufficiency	   or	   gain-­‐of-­‐function	  mutations.	   We	   selected	   many	   gene	   features	   and	   characteristics	   (OMIM	   [54],	   BioMart	  [74],	  ExAC	   [52])	  and	  used	   linear	  discriminant	  analysis	  on	  a	   training	  set	  of	  493	  known	  dominant	  and	  recessive	  disease	  genes	  in	  order	  to	  generate	  the	  best	  model,	  which	  could	  separate	  efficiently	  the	  two	  categories	  of	  genes.	  In	  the	  end,	  from	  more	  than	  200	  features	  
	  	   41	  
selected,	  we	   retained	   8	   features,	   corresponding	   to	   the	  missenses	   load	   and	   donor	   site	  load	  per	  gene,	   the	  embryonic	  gene	  expression,	   the	  gene’s	  conservation,	   the	  number	  of	  paralogs	  and	  Gene	  Ontology	  terms.	  Our	  predictive	  tool	  is	  being	  further	  tested	  to	  validate	  the	  results	  on	  known	  genes	  and	  it	  will	  then	  be	  applied	  to	  unsolved	  dominant	  cases.	  	  	  
Benefits	  of	  NGS	  results	  NGS	  allows	  a	  better	  characterization	  of	  human	  diseases	  and	  treatable	  actions	  may	  be	   undertaken	   according	   to	   the	   patient’s	   specific	   genetic	   alterations.	   One	   very	   good	  example	   is	  gene	  therapy	  for	  patients	  with	  retinal	  degenerations.	  The	   idea	   is	   to	  replace	  the	  non-­‐functioning	  gene	  with	  a	  fully	  functional	  gene	  by	  the	  injection	  of	  a	  harmless	  virus	  in	  the	  retina,	  which	  delivers	  a	  correct	  version	  of	  the	  gene	  into	  the	  retinal	  cells.	  Although	  these	  treatments	  are	  limited	  for	  the	  moment	  to	  clinical	  trials	  and	  are	  only	  available	  for	  few	  genes,	  new	  therapies	  are	  continuously	  being	  developed	  for	  more	  and	  more	  patients	  and	  types	  of	  diseases.	   In	  cancer,	  via	  the	  use	  of	  NGS,	  personalized	  treatments	  are	  being	  undertaken	  according	  to	  the	  genetic	  landscape	  of	  the	  patients	  	  
NGS	  bias	  We	  are	  often	  biased	   in	  NGS	  analyses	  as	  we	  mainly	   focus	  on	   the	  exome,	   a	   small	  region	   of	   the	   genome,	   which	   is	   easier	   to	   understand	   and	   which	   has	   been	   deeply	  investigated	  over	   the	  past	  years.	  WES	  allows	  us	   to	   focus	  only	  on	   these	  coding	   regions	  and	  also	  has	   limits	   caused	  by	   the	  particular	   sequencing	  protocols	   involving	   the	  use	  of	  defined	  libraries	  and	  amplification	  of	  DNA	  fragments.	  WGS	  gives	  the	  possibility	  to	  access	  every	  single	  base	  of	  the	  genome,	  but	  there	  is	  still	  no	  valid	  strategy	  to	  detect	  and	  assess	  the	  pathogenicity	  of	  singular	  mutations	   in	   the	  98%	  of	   the	  genome	  constituted	  by	  non-­‐coding	  sequences.	  The	  impact	  of	  specific	  mutations	  could	  also	  be	  determined	  via	  the	  use	  of	  other	  NGS	  data,	   such	  as	   the	   transcriptomics.	   In	   cancer	   research,	  epigenetic	   changes	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detected	  with	  RNA-­‐seq	  have	  shown	  to	  be	  important	  in	  the	  development	  of	  some	  cancers	  [75,	   76],	   and	   our	   WGS	   study	   on	   Uveal	   Melanoma	   suggested	   that	   epigenetic	   changes	  might	  also	  have	  a	   role	   in	   the	  development	  of	   this	   cancer,	   especially	   for	   the	  metastatic	  forms.	   Further	   experiments	   including	   RNA-­‐seq	   analysis	   on	   some	   of	   our	  WGS	   patients	  will	  be	  undertaken	  to	  understand	  better	  the	  progression	  of	  this	  melanoma.	  	  
Ethics	  in	  NGS	  Although	   NGS	   is	   now	   routinely	   used	   in	   many	   laboratories,	   the	   privacy	   of	   the	  patients,	  their	  rights,	  and	  the	  safety	  of	  their	  genomic	  data	  are	  continuously	  questioned.	  Before	  sequencing	  someone’s	  DNA,	  an	  informed	  consent	  needs	  to	  be	  signed	  according	  to	  the	   regulations	   of	   the	   country	   where	   it	   will	   be	   done.	   This	   document	   explains	   the	  different	  NGS	  methods,	  which	  one	  will	  be	  used,	  and	  the	  expected	  analyses	  the	  patient’s	  DNA	   will	   be	   subject	   to	   as	   well	   as	   the	   related	   outcome.	   More	   specifically,	   secondary	  findings,	   i.e.	   discovery	   of	   variants	   leading	   to	   a	   specific	   disease,	   which	   is	   not	   the	   one	  prescribed	  by	  the	  geneticist,	  are	  under	  very	  particular	  regulation	  [77].	  The	  patient	  has	  the	   right	   to	   refuse	   knowing	   such	   findings,	   even	   if	   the	   pathogenic	   but	   actionable	  mutations	  (e.g.	  known	  pathogenic	  mutations	  in	  BRCA1)	  should	  be	  communicated	  to	  the	  clinical	   doctor.	   In	   order	   to	   secure	   as	   much	   as	   possible	   the	   genetic	   data,	   all	   patient’s	  personal	  information	  is	  directly	  anonymized	  before	  being	  sent	  for	  sequencing.	  One	  easy	  way	  to	  reduce	  the	   incidental	   findings	   in	  NGS	  clinical	  diagnostic	   is	   the	  usage	  of	   in-­‐silico	  panels,	  which	  focused	  only	  on	  a	   list	  of	  genes	  already	  associated	  with	  the	  phenotype	  of	  the	   patients.	   Finally,	   all	   genetic	   data	   of	   any	   patient	   has	   to	   be	   securely	   stored,	   under	  strong	   firewall	   protection,	   and	   usually	   in	   an	   internal	   server	   with	   limited	   access	   to	  outside.	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Conclusion	  Human	  genetic	  diseases	  are	  numerous	  and	  many	  of	  them	  are	  not	  yet	  elucidated	  at	  their	  genetic	  level.	  Knowledge	  of	  the	  molecular	  defects	  leading	  to	  these	  disorders	  could	  offer	  many	  benefits	  to	  the	  patients,	  their	  family,	  but	  also	  to	  the	  society.	  Indeed,	  patients	  who	   are	   accurately	   diagnosed	   could	   receive	   appropriate	   treatment,	   if	   available.	  Furthermore,	   the	   progression	   of	   their	   disease	   could	   be	   predicted	   and	  monitored,	   and	  assessment	   of	   risk	   of	   inheritance	   to	   the	   offspring	  may	   help	   them	   in	   central	   decision-­‐making	  processes	  (e.g.	  prenatal	  diagnostics,	  preventive	  screening).	  	  NGS	  has	  been	   central	   to	   the	   rapid	   evolution	  of	   current	   human	  molecular	   genetics	  and	  bioinformatics	  analyses	  have	  certainly	  lead	  the	  way	  of	  this	  important	  and	  hopefully	  continuous	   process.	   In	   less	   than	  10	   years,	   the	   usage	   of	  NGS	   technology	   has	   become	   a	  routine	   in	   many	   laboratories	   and	   clinical	   facilities,	   allowing	   the	   identification	   of	  hundreds	  of	  new	  genes	   for	  novel	  or	  existing	  syndromes	  and	  a	  better	  understanding	  of	  the	  genetic	  landscape	  of	  cancers.	  Nowadays,	  genomic	  medicine	  can	  be	  considered	  as	  personalized,	  as	  each	  patient	  can	  be	  examined	  individually	  with	  the	  sequencing	  of	  its	  genome	  or	  exome.	  Appropriate	  and	  sometimes	   unique	   treatments	   may	   be	   given	   to	   patients	   with	   very	   rare	   disorders,	   or	  specific	  subtypes	  of	  cancers.	  The	  personalized	  genetic	  information	  can	  also	  be	  used	  for	  more	  common	  conditions	  such	  as	  asthma	  or	  hypertension.	  The	  price	  of	  sequencing	  is	  continuously	  decreasing	  while	  the	  accuracy	  is	  increasing,	  and	   we	   can	   imagine	   that,	   in	   the	   next	   future,	   NGS	   will	   be	   undertaken	   to	   many	   more	  patients	  and	  will	  replace	  current	  procedures,	  which	  might	  be	  too	  costly	  and	  with	  similar	  or	  less	  accurate	  results	  (e.g.	  CGH	  array,	  Sanger	  sequencing).	  The	  number	  of	  biobanks	  of	  genetic	  information	  is	  exponentially	  increasing.	  As	  a	  result,	  not	  only	  Mendelian	  diseases	  may	  be	  easily	   solved,	  but	  also	  complex	  genetic	  disorders	  may	  be	  better	   characterized,	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leading	  to	  a	  better	  care	  for	  a	  larger	  number	  of	  subjects.	  In	  order	  to	  achieve	  so,	  constant	  technological	   development	   of	   NGS	   technology,	   and	   in	   particular	   of	   in	   silico	   analytical	  tools	  would	  play	  a	  fundamental	  role	  for	  tomorrow’s	  medicine.	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Abstract The past decade has seen the emergence of
next-generation sequencing (NGS) technologies, which
have revolutionized the field of human molecular genetics.
With NGS, significant portions of the human genome can
now be assessed by direct sequence analysis, highlighting
normal and pathological variants of our DNA. Recent
advances have also allowed the sequencing of complete
genomes, by a method referred to as whole genome
sequencing (WGS). In this work, we review the use of
WGS in medical genetics, with specific emphasis on the
benefits and the disadvantages of this technique for
detecting genomic alterations leading to Mendelian human
diseases and to cancer.
Keywords Exome ! Hereditary disease ! Mutation !
Polymorphism
Introduction
Identification of pathogenic DNA variants causing diseases
is one of the main aims of medical genetic investigations.
In the past, when direct DNA sequencing possibilities were
limited, this goal was achieved only in cases for which the
region of the genome harboring a given mutation could be
reduced to a manageable size by other procedures, such as
family-based linkage or haplotype analyses. In the absence
of large pedigrees or of other favorable factors that could
help this localization process, disease-causing variants
could remain undetected for years. The recent
commercialization of next-generation sequencing (NGS)
platforms has introduced a substantial methodological shift
in mutation detection procedures. Specifically, it has
allowed the querying of megabases of DNA at once,
through computer-based alignment of millions of short
sequence reads [1]. Parallel sequencing of panels of can-
didate disease genes and whole exome sequencing (WES),
investigating all of our protein-coding DNA (*2 % of the
human genome), have now become routine procedures in
most laboratories.
As the NGS technique develops, the price per sequenced
base decreases, to the point that sequencing entire indi-
vidual genomes is not a prohibitive effort any more.
Compared to WES, the use of whole genome sequencing
(WGS) in human genetics, and especially in medical
genetics, is still in its infancy. The reasons for this delay are
mainly two: WGS involves higher costs compared to WES
and requires more complex analyses at the computational
level. Unlike WES, however, WGS allows the identifica-
tion of complex DNA variants that are not limited to the
coding sequences of the genome and the detection of non-
conventional events involving large stretches of DNA
(Table 1). Moreover, WGS displays an increased sensi-
tivity with respect to WES in relationship to coding
sequences as well, as it analyzes contiguous DNA and
allows better sequencing and mapping approaches. More
specifically, since it is not limited by constraints originat-
ing from discontinuous DNA templates (captured exons),
WGS can take advantage of information deriving from a
‘‘regional’’ context. For instance, WGS can identify gene
fusions, duplications of exons, and other genetic defects
that would likely be missed in the absence of information
from surrounding, non-coding DNA, which is seldom tar-
geted by pre-WES purification procedures. Coverage
(number of times a given nucleotide is sequenced) in WGS
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is also in general more uniform, since genomic DNA is
provided to the sequencer ‘‘as is’’, without undergoing
selection procedures that may artificially create an uneven
representation of the template material to be sequenced.
Unfortunately, the wealth of information produced by
WGS, despite being preferable from a theoretical stand-
point, may as well represent a burden for the identification
of DNA variants meaningful to medical genetics. Such
variants typically consist of one or a few mutations that
have to be distinguished from thousands of benign DNA
changes, and their identification has often been compared
to the detection of a needle in a haystack. To follow the
same analogy, WGS provides better chances of identifying
pathological targets than WES, but at the same time it
increases the size of the haystack, to the point that innoc-
uous DNA changes may no longer be recognized as
such. The advantages of WGS procedures can therefore be
fully achieved only when analytical approaches can effi-
ciently differentiate abnormal DNA changes from the
multitude of benign variants that determine normal human
heterogeneity.
To better illustrate all of these concepts, this review will
focus on the use of WGS as a tool to detect rare DNA
variants with a high phenotypic effect, such as germline
mutations in Mendelian hereditary disorders and somatic
mutations in cancer.
The medical genome: generalities and common
procedures
The human reference genome
Because of the complexity of the human genome, NGS
reads from WGS projects cannot be efficiently assembled
via de novo procedures, but have to be mapped to a stan-
dard template sequence, the human ‘‘reference sequence’’.
This human reference genome is a pooled sequence data of
13 healthy individuals with European ancestry [2], and has
gradually evolved with the improvement of sequencing
methods. It provides a common and unambiguous system
of relationships between genomic coordinates and corre-
sponding DNA bases.
Mapping of sequence reads and identification
of variants
Following the generation of the raw DNA sequence reads
by an NGS platform, the process of obtaining the full
genome sequence of an individual (or, better, a reliable
approximation of it), consists of a two-step, computer-
based procedure. First, the short NGS reads are mapped to
the reference genome by assigning to them specific geno-
mic coordinates. This procedure is in general computer
intensive and is achieved by the use of various algorithms
(e.g., BWA [3], AGILE [4], NovoAlign [novocraft.com],
or FastHASH [5]). Then, mismatches between the refer-
ence genome and the individual genome are assessed by a
bioinformatic process referred to as ‘‘variant calling’’ (e.g.,
via software such as GATK [6] or VCMM [7]).
Both mapping and variant calling procedures can be
highly parameterized and are susceptible to producing
different outputs as a function of such parameters. There-
fore, although for a given individual there is only one
physical genome, made of DNA, at the present time we can
only obtain one or more imperfect representations of it,
made of bits and bytes. As a general rule, each step of any
genome analysis produces both false positives, i.e., variants
that are called but are not physically present in the genome,
and false negatives, i.e., variants that are not called but are
present in the physical genome. It is therefore important to
minimize errors at these initial mapping and variant calling
steps, since all of downstream analyses will be made on the
assumption that these data are a faithful representation of
the physical genome.
General filtering procedures
Since every WGS project produces on average*4,000,000
called variants [8, 9], identification of mutations relies on a
series of filtering procedures that have as goal to recognize
rare DNA changes with a pathogenic effect and discard the
multitude of variants that are unrelated to the disease
studied. Comparison with databases reporting information
from the unaffected population such as dbSNP [10], the
ESP database (evs.gs.washington.edu), the Exome Aggre-
gation Consortium (ExAC) (exac.broadinstitute.org), etc.
represents the most consistent filtering step, under the
assumptions that such public databases report (a) reliable
information and (b) include polymorphic variants having
Table 1 Features of whole genome sequencing (WGS) vs. whole
exome sequencing (WES)
Feature WGS WES
Exonic variants Yes Yes
Intronic variants Yes No
Intergenic variants Yes No
Indels Yes Yes
Copy number variations Yes Not directly/imprecise
Large insertions and deletions Yes Not directly/imprecise
Transposable elements Yes Not directly/imprecise
Detection of copy number variations, large insertion and deletions, as
well as of transposable elements are imprecise in WES since data are
available for coding regions only, and these events can originate
elsewhere
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no direct relationship with genetic diseases. However,
these databases have limitations such as the presence of
very rare and pathogenic mutations [11] and artifacts [12].
The frequency of the detected variants in the general
population could be taken into consideration during filter-
ing procedures, since alleles from some (mostly recessive)
diseases may very well be present in the general, unaf-
fected population [13, 14]. Furthermore, most of these
entries contain information about genotype and allele fre-
quency in different human populations, allowing as well
other important analyses. In addition to comparisons with
data providing information on biological variability, fil-
tering from technical errors should also be put in place.
NGS platforms as well as mapping and variant calling
pipelines tend to produce technical noise (false positives)
that is luckily rather constant and sequence specific.
Comparison with a small set of control samples sequenced
by the same NGS platform and processed by the same
informatics pipeline would help to remove errors from the
genomes.
Since a considerable amount of variants still survive
general filtering, it may be useful to incorporate in the
analysis a predictive tool that scores the impact of coding
DNA changes on the corresponding protein sequence and,
possibly, function. There are currently many software
packages that can perform these tasks and compute whe-
ther a given variant potentially affects protein formation,
expression, and/or interaction with other proteins. Among
those that are used most often, we can cite SIFT [15],
PROVEAN [16], PolyPhen-2 [17], and GERP?? [18].
Since prediction tools are not always concordant and their
output based on different parameters, most studies use a
combination of two or more tools to infer the putative
pathogenicity of the variants [19–21]. However, it is
important to stress that all these packages provide infor-
mation of predictive nature, and that filtering procedures
based on them will have in the end only a relative value.
Databases of disease-associated variants
Many public databases reporting the direct relationship
between DNA changes and specific traits exist and are
publicly available. Some of them contain information on
variants that underlie or are associated with diseases, such
as the Human Gene Mutation Database [13] or the Online
Mendelian Inheritance in Man database (OMIM) [22]. For
structural variations, the Database of Chromosomal
Imbalance and Phenotype in Humans Using Ensembl
Resources (DECIPHER) [23] lists copy number variations
present in the control and affected populations. For cancer
studies, the Catalogue of Somatic Mutations in Cancer
(COSMIC) [24] stores bona fide somatic mutations related
to human cancers. Some other databases collect the results
from pharmacogenetic studies to contribute to the devel-
opment of individualized treatments (PharmGKB [25],
Pharmaco-miR [26]). All these databases have increased
substantially in size in recent years, due to NGS and larger
and larger genetic studies. If integrated in WGS endeavors,
they can be of great help in highlighting genetic variants
associated with pathological traits.
Germline mutations
WGS in hereditary diseases
Pathogenicmutationswith a high phenotypic effect can either
be inherited from a person’s parents (germline mutations) or
be acquired throughout life (somatic mutations). Pathologies
resulting from germline mutations, which can be transmitted
to the following generations, are commonly referred to as
hereditary diseases, while somatic DNA injuries are usually
not transmittable to the offspring and lead in general to
tumors. Both germline and somatic mutations can be effi-
ciently identified byWGS; however, technical and analytical
approaches to detect these pathogenic variants are rather
different (Fig. 1). A review of the recent literature shows that
hereditary complex disorders, for which a combination of
common variants in different genes and environmental fac-
tors contribute to the pathology, are still mostly investigated
via non-NGS techniques. Conversely, WGS is beginning to
be systematically used as a tool to understand the causes of
Mendelian inherited diseases, resulting from germline
mutations in one gene (e.g., [20, 27, 28]).
The initial approach for the detection of Mendelian
mutations by WGS is virtually the same as that used for
WES-based studies. It consists of focusing first on the
coding region of genes, more specifically on variants
leading to a change in the amino acid sequence of future
proteins. However, the real power of WGS emerges when
events involving non-coding regions are investigated.
Compared to other techniques, WGS allows us to specifi-
cally extract information from parts of the genome that are
usually neglected, and at a base-pair resolution. Recent
WGS studies have indeed shown that a number of unsolved
cases from Mendelian disease can be explained by muta-
tions in non-coding regions and, at various degrees,
involving coding parts of disease genes (e.g., [8, 29]).
Similar examples include the direct identification of gene
disruption by the insertion of mobile elements, which are
already known to play a significant role in the molecular
etiology of hereditary diseases [30], but that are difficult to
identify by other NGS techniques than WGS (own
unpublished results).
It is important to note that, regardless of the type of
mutation, in all Mendelian disorders and within single
Whole genome sequencing and disease 1465
123
	  	   56	   	  
pedigrees, pathogenic variants always co-segregate with
the disease in affected individuals. Therefore, all patients
within a family should necessarily share the same muta-
tion(s) but not necessarily the same innocuous DNA
variants. This elementary concept of human genetics is one
of the most powerful elements of investigation in NGS
studies, including WGS, since it allows us to discard
benign variants that cannot be immediately recognized as
such. One of the first WGS projects that exploited this
paradigm is the one performed by Roach et al., who, fol-
lowing the comparison of individual WGS output from two
healthy parents and two affected children, could reduce the
number of candidates genes, genomewide, from thousands
to only four [31].
For monogenic disorders with no genetic heterogeneity,
a similar strategy could be extended from a single pedigree
to a group of unrelated patients. In these cases, merging
genomic data from different patients and different pedi-
grees represents a much more powerful approach, because
unrelated affected individuals would all tend to have rare
variants (mutations) only in the disease gene [27]. Con-
versely, in Mendelian disorders displaying genetic
heterogeneity, this approach may lead to false positive
results, highlighting as pathogenic benign variants that may
be coincidentally shared by a group of patients, and
therefore it should not be used.
Identification of recessive, dominant, or X-linked
mutations
Since heterozygous recessive mutations do not cause dis-
ease, they can be present, even at non-negligible
frequencies, in the general population [13, 14]. Patients
would conversely be either homozygotes for a mutation or
compound heterozygotes for two different mutations in the
same gene (Fig. 2). This simple genetic concept has tre-
mendous consequences in WGS-based searching for
mutations, as only about a dozen genes will harbor rare,
Fig. 1 Schematic workflow for the detection of potentially patho-
genic DNA variants in hereditary diseases and in cancer. In hereditary
diseases, the information from several genomes from a control cohort
(white individuals) is assembled to produce a ‘‘metagenome’’ that
includes all possible variants (both small events and copy number
variations, or CNVs) that are allegedly not causing disease in the
general population (blue bars and boxes). Potentially pathogenic
variants are then deduced by comparing the WGS information from a
patient (black individual) with that of the metagenome. In cancer,
there is no need to query a control cohort, since the control
information is provided by the genome of normal cells from the same
patient. Regardless of their frequency in the general population, all
these variants are then subtracted from the pool of DNA changes
obtained from the tumor genome, making the detection process of
pathogenic variants a more efficient and straightforward procedure
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non-synonymous variants in the homozygous or compound
heterozygous state genomewide. Other methods could be
used to identify pathogenic variants, such as the elevated
granularity of WGS data, which allows precise haplotype
phasing in trios or quartets, to the point that meiotic
recombination events in the parents of an index case could
be detected. In other words, it is possible to identify all the
regions of the genome identical by descent in affected
individuals of a kindred, which by definition should harbor
both the mutation transmitted from the father and from the
mother [31, 32]. An extension of the same concept is
autozygosity mapping, which reaches its highest possible
precision when WGS information is used. This technique
scores stretches of homozygous alleles (usually SNPs) in
consanguineous families segregating a recessive disease to
detect the single homozygous recessive mutation originat-
ing from a heterogeneous mutation in a common ancestor.
Since alleles are transmitted from one generation to the
other in large genomic ‘‘blocks’’ by meiotic recombination,
the genomic region surrounding this homozygous mutation
would also be completely homozygous for benign variants,
which would act as a beacon for the presence of pathogenic
recessive mutations [33].
In contrast, in autosomal dominant conditions, only one
variant in a specific disease gene gives rise to the path-
ological phenotype. Compared to recessive cases, it is
more difficult to infer pathogenicity of a given DNA
variant since, in absence of other information, in principle
all of the rare DNA changes detected genomewide can be
the mutation causing disease (Fig. 2). Filtering steps as
well as the careful use of clinical and public databases
and pedigree-based co-segregation analyses become
therefore essential. In case the condition is known to
display no genetic heterogeneity, then the most powerful
tool to infer pathogenicity becomes data merging across
different unrelated patients, for the reasons described
above.
Recent literature has shown that a substantial proportion
of seemingly dominant cases may also result from the
presence of de novo mutations [34–37]. In such cases, trio
analyses would be the best strategy to choose, since
appearance of de novo mutations would be easily scored by
subtracting the list of genomic variants of the patient from
those of their parents, without in principle the need to filter
data from common variation databases.
Finally, procedures for X-linked cases would be sub-
stantially the same as those for dominant ones, with the
exception that the genomic region to be considered would
be limited only to the X chromosome.
Somatic mutations
WGS in cancer
As mentioned, DNA errors can also be acquired somati-
cally through life. Because of age, environment, diet, etc.,
these mutations are usually not transmitted to the offspring
but can accumulate and lead to disease. This is the case of
most cancers, where somatic defects lead to a dysregulated
cell growth and eventually to tumor and metastasis.
Detection of pathogenic somatic variants via WGS
procedures is a much simpler effort, compared to that
involving germline mutations in hereditary diseases.
Indeed, the cancer genome of a given patient can be
directly compared with that from tumor-free tissues from
the same individual (usually blood leukocytes). This pro-
cess eliminates the need for constructing an imprecise
reference ‘‘metagenome’’ resulting from cohorts of unre-
lated patients. In this context, the fact that a given
individual’s germline genome carries polymorphic vari-
ants, rare DNA changes, or even large structural variations
with respect to control genomes is completely irrelevant,
since the mutations that count are those present in the
cancer genome only (Fig. 1). In other words, the germline
genome represents a baseline dataset used as a subtracting
factor to obtain an unbiased count of all the acquired
somatic mutations. Ley et al. were among the first to apply
this method on an acute myeloid leukemia, identifying in
the end two known mutations for cancer progression and
eight novel mutations that could be used for possible tar-
geted therapy [38].
Cancer appearance, progression, relapse
Since cancer is an evolving disorder, WGS can be used to
score tumor progression, relapse, and remission by ana-
lyzing its genomic content at different time points.
Fig. 2 Possible configurations of pathogenic mutations for autosomal
recessive and autosomal dominant conditions. Structural events are
usually better or exclusively detected via WGS procedures and
therefore genotypes b, d, e, and g may be easily missed by other
sequencing techniques
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Concerning tumor progression, a study by Ding et al. [39]
investigated basal-like breast cancer via four parallel WGS
procedures: on the peripheral blood of the patient to obtain
a baseline genome, on the primary tumor to detect the
somatic mutations, on a brain metastasis to understand
metastatic transformation, and on the genome of a human-
to-mouse primary tumor xenograph to understand the
mechanisms of tumor changes following transplantation.
Tumor evolution in the context of therapeutic treatments
can also be studied by WGS, as shown by a report on
clonal evolution in acute myeloid leukemia cells, a cancer
characterized by frequent relapses following chemotherapy
treatment [40]. In this work, the authors noted two distinct
patterns of tumor genome evolution: in the first one, the
primary tumor clone gained mutations that made it to
evolve into the relapse clone and therefore survive treat-
ment; in the second one, chemotherapy applied a selective
pressure enabling a specific sub-clone of the initial tumor
to expand, and again survive treatment.
Tumorigenic pathways
Although every cancer has a unique landscape of somatic
events, in some instances mutations tend to affect common
genes, highlighting dysregulation of shared, important path-
ways for tumor progression. Analyses aimed at identifying
such pathways can be done by considering multiple cases of
the same tumor, to increase the signal represented by driver
mutations (DNA changes providing selective advantage to a
cancer cell clone) and minimize the noise deriving from
passenger mutations (DNA changes that do not contribute to
cancer etiology but accumulate in rapidly expanding clones).
In a way, such analyses are very similar to those outlined
above for hereditary diseases, for which multiplication of the
patients’ or controls’ genomes to be analyzed helps to elim-
inateDNAchangeswhich are not relevant to the disease. This
approach has been applied to a relatively large number of
different tumors, for a total of*150 genomes analyzed [41–
49]. In addition to providingnew insights intomutation-based
differential prognosis, tumor molecular classification, pro-
gression mechanisms, etc., comparative WGS on multiple
tumor samples helps identifying tumor signatures and
mutational spectra across different types of cancer [50] or
within the same tumor type, such as smoker and non-smoker
lung cancer genomes [43].
Conclusions
From a genetic standpoint, there is nothing more exhaus-
tive than the full sequence of a genome. It is therefore easy
to predict that, when costs associated with WGS substan-
tially decrease and better analytical tools are available, this
procedure will become the technique of choice for most
medical genetics investigations. WGS can in fact detect
features of the human genome, such as copy number
variations and intronic mutations, that other techniques
cannot or struggle to identify, and that are becoming
increasingly relevant to human genetic pathology. Fur-
thermore, it is conceivable that many different genetic
tests, which are currently performed as individual analyses
(array CGH, sequence-specific mutation detection, gene
panel screening, etc.) could be soon replaced by a single
WGS run, which in fact can provide all of this information
at once.
However, for WGS to become a popular tool in research
and a routine test for DNA diagnosis, a few improvements
still have to be made. From a clinical standpoint, diagnosis
of the disease has to be very accurate, especially in terms of
inheritance, because all downstream analyses would depend
on it. Also, since a person’s whole genome is unveiled, the
risk of incidental findings is very high, revealing the need
for integrating ethical policies adapted to this specific test.
On the technical side, sequencing errors and noise have to
be better estimated and eliminated, since false positive
findings or long processing times are not compatible with
diagnostic needs. This could be done by optimizing the
reference genome, databases of common variants, predic-
tion software, and also pre-WGS experimental design (e.g.,
by including specific information of a patient’s family). In a
more distant future, complex diseases will probably also be
approached by WGS, to fully exploit the wealth of infor-
mation that this technique produces in the context of
variants that are not pathogenic per se, but that can cause
disease via additive or multiplicative effects.
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UV light signature in conjunctival melanoma; not only
skin should be protected from solar radiation
Journal of Human Genetics (2016) 61, 361–362; doi:10.1038/jhg.2015.152; published online 10 December 2015
Conjunctival melanoma represents 5% of
ocular melanomas. It is a highly recurrent
tumor leading to metastatic disease and death
at 10 years in 25–30% of patients.1 Recent
molecular investigations have indicated that
conjunctival and cutaneous melanomas may
share common features.2 For instance,
epidemiological studies have shown an
association between decreasing latitude
and increasing incidence of conjunctival
melanoma,3 suggesting that exposure to
sunlight has a role in its etiology.4 However,
strong molecular proof of such correlation
has not been established. We hereby report
the results of a genome-wide sequencing
effort of two conjunctival melanomas
documenting a strong ultraviolet (UV)
mutation signature.
We performed high-coverage whole-
genome sequencing (average read depth= 80x,
with 97.1% of the genome covered at least
40x) of two untreated perilimbic conjunctival
melanomas occurring in two Caucasian
women, aged 57 years (patient A) and 65
years (patient B) (Figures 1a and b). Somatic
mutations were ascertained by comparing the
DNA sequence of each tumor with their
respective germline matches (blood leukocyte
DNA). We identiﬁed a very high somatic
mutation load composed of more than 96 000
mutations in each tumor, resulting in an
average genome-wide mutational rate of 30
somatic mutations per million DNA bases.
On average, we detected 802 mutations in the
coding regions of genes. The ratio of
non-synonymous to synonymous variants
was 1.59:1, showing a prominence of passen-
ger mutations. Non-synonymous mutations
were composed mainly of missense (90%),
followed by nonsense changes (7%).
Moreover, detailed analysis of the mutation
spectrum uncovered a majority of cytosine to
thymine (C4T) transitions, occurring in 88
(patient A) and 83% (patient B) of the single-
nucleotide substitutions in these tumors
(Figure 1c). In addition, 80 and 100% of
these C4T changes, respectively, occurred at
the 3′ end of pyrimidine dinucleotides and
CC4TT changes represented 470% of all
tandem substitutions, showing the presence
of a typical UV mutational signature.5
Altogether, our molecular ﬁndings support
the occurrence of UV-induced DNA damage
in conjunctival melanoma indicating a link
between solar radiation and development of
this tumor. Awareness should therefore be
raised in the general population about the
beneﬁts of wearing UV-shielding eyeglasses,
in addition to skin sunscreens, when exposed
to sunlight.
Figure 1 (a) A partially pigmented melanoma is seen in the inferior perilimbic area with extension onto the cornea. The isolated inferior and temporal
pigmented areas were primary acquired melanosis (patient A). (b) A pigmented melanoma can be observed in the superior perilimbic area (patient B). (c)
Mutation spectrum of the two conjunctival melanomas (A: patient A, B: patient B), showing a clear ultraviolet-induced DNA damage signature. No somatic
mutations were detected in the melanoma-related genes BRAF and NRAS.
Journal of Human Genetics (2016) 61, 361–362
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Comprehensive Genetic Landscape of Uveal Melanoma
by Whole-Genome Sequencing
Beryl Royer-Bertrand,1,2 Matteo Torsello,3 Donata Rimoldi,4 Ikram El Zaoui,1 Katarina Cisarova,1
Rosanna Pescini-Gobert,1 Franck Raynaud,5,6 Leonidas Zografos,7 Ann Schalenbourg,7 Daniel Speiser,4
Michael Nicolas,7 Laureen Vallat,7 Robert Klein,8 Serge Leyvraz,9 Giovanni Ciriello,5,6 Nicolo` Riggi,3
Alexandre P. Moulin,7,10 and Carlo Rivolta1,10,*
Uveal melanoma (UM) is a rare intraocular tumor that, similar to cutaneous melanoma, originates from melanocytes. To gain insights
into its genetics, we performed whole-genome sequencing at very deep coverage of tumor-control pairs in 33 samples (24 primary and 9
metastases). Genome-wide, the number of coding mutations was rather low (only 17 variants per tumor on average; range 7–28), thus
radically different from cutaneous melanoma, where hundreds of exonic DNA insults are usually detected. Furthermore, no UV light-
induced mutational signature was identified. Recurrent coding mutations were found in the known UM drivers GNAQ, GNA11,
BAP1, EIF1AX, and SF3B1. Other genes, i.e., TP53BP1, CSMD1, TTC28, DLK2, and KTN1, were also found to harbor somatic mutations
in more than one individual, possibly indicating a previously undescribed association with UM pathogenesis. De novo assembly of un-
matched reads from non-coding DNA revealed peculiar copy-number variations defining specific UM subtypes, which in turn could be
associated with metastatic transformation. Mutational-driven comparison with other tumor types showed that UM is very similar to
pediatric tumors, characterized by very few somatic insults and, possibly, important epigenetic changes. Through the analysis of
whole-genome sequencing data, our findings shed new light on the molecular genetics of uveal melanoma, delineating it as an atypical
tumor of the adult for which somatic events other than mutations in exonic DNA shape its genetic landscape and define its metastatic
potential.
Despite having the very rare incidence of 5–8 new cases per
million per year,1,2 uveal melanoma (UM [MIM: 155720])
is the most common primary intraocular tumor of the
adult. It develops from melanocytes in the choroid, the
ciliary body, or the iris (collectively called the ‘‘uvea,’’
one of the inner layers of the eye) and usually metastasizes
through the blood stream to the liver.3,4 Symptoms
include variable and painless visual disturbances, often
presenting when the tumor has already reached a consider-
able mass. Survival and potential therapeutic options
depend, among other things, on the presence of specific
genetic alterations.5 Although population studies suggest
ethnic predisposition,6,7 environmental factors that are
directly involved in the transformation process have not
been clearly delineated. For instance, a possible association
with UV light exposure has been suggested,8–11 but ques-
tioned recently by molecular data.12 Research on UM
molecular genetics has been performed mostly by investi-
gating coding mutations or copy-number variations
detectable by direct sequencing of target genes, karyotype,
array-CGH, MLPA, or SNP-array analyses.13–17 As a result,
mutations at codon 209 of the paralogous oncogenes
GNAQ (MIM: 600998) and GNA11 (MIM: 139313)18,19
and in the tumor suppressor BAP1 (MIM: 603089)20 have
been identified in the majority of UMs, whereas insults
in EIF1AX (MIM: 300186) and SF3B1 (MIM: 605590) or
other genes seem to be less frequent, accounting for
at most 20% of cases.12,21–26 Moreover, copy gains and
losses are common events in this tumor, typically
involving chromosome 3 monosomy, 6p gain, and 8q
gain.14,17 After whole-genome sequencing of a series of
tumor-control pairs, we present here an analytically unbi-
ased and comprehensive assessment of the genetic land-
scape of UM.
We screened 33 UM samples (24 primary tumors and 9
unrelated metastases; Table S1) and corresponding normal
tissue pairs by deep-coverage whole-genome sequencing
(WGS), using the processing platform by Complete Geno-
mics.27 Written informed consent was obtained from all
individuals enrolled in this study, and approval for human
subject research was obtained from the Institutional Re-
view Boards of all participating Institutions. Sequence
reads were mapped to the human reference genome, as-
sembly GRch37, and somatic variants in tumors were
called by comparison with the matched normal genomes,
as previously described.28 All samples were surgically
collected from eye enucleations or resected from liver
metastases, allowing very clear post-surgery macroscopic
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isolation of tumor tissue from the surrounding environ-
ment. None of the 33 affected individuals received any
treatment prior to primary tumor removal. Average
coverage was 1123 (range 102–118) for both tumor and
control samples (>96% of the genome was covered 403
or more times), with minimal inter-individual variations
(not shown). Mutation calls were performed genome-
wide and included single-nucleotide variants (SNVs),
copy-number variations (CNVs), as well as structural varia-
tions (SVs) such as chromosomal rearrangements. CNVs
and SVs were assessed by comparing sequence coverage
and especially de novo assembly of reads defining novel
genetic junctions.28 Data were extracted from MasterVar
files and other relevant matrices by ad hoc Perl, bash,
and R scripts, available upon request. Overall, we detected
37,321 SNVs (average per sample 1,166; range 576–2,131),
1,584 SVs (average per sample 50; range 13–182), and a
number of CNVs corresponding to an average of 13.6%
of the genome (range 0.03%–33.9%) (Table S2).
Unsupervised hierarchical clustering of our samples
on CNVs revealed four major subgroups associated with
mutational and metastatic status, branched two by two
(Figure1).ClassesAandB (firstbranch) involvedsamplescar-
rying chromosome 3 monosomy (by Fisher test, p value ¼
4.4 3 10"6), chr 8q gain (p value ¼ 2.8 3 10"9), and in
some instances chr 8p loss (p value ¼ 3.0 3 10"2). In
addition, class B tumors also had loss of chr 6q (p value ¼
1.0 3 10"3). Conversely, classes C and D represented more
distinct subtypes with relatively few chromosomal rear-
rangements; class C tumor had no major aneuploidies,
whereas class D reported gains of the distal part of chr 8q
(p value ¼ 2.0 3 10"3). Seven samples presenting chr 1q
gain were scattered across all classes, whereas loss of chr 1p
was typical of class A tumors (p value ¼ 5.03 10"3).
Samples with monosomy of chr 3 were also associated
(77% of cases) with somatic mutations in the tumor sup-
pressor BAP1, lying on chr 3p21.1, in accordance with
Knudson’s two-hit model of tumorigenesis.29 Indeed,
BAP1 SNVs included all kinds of somatic events, but
mostly mutations leading to premature stop codons and
therefore to functional protein knockout (Figure S1, Table
S3). Hallmark driver mutations in the GNAQ and GNA11
paralogs, encoding the components of the alpha subunit
of the Gq protein heterotrimer, were present in 100% of
the samples examined. They occurred in a perfectly mutu-
ally exclusive pattern and involved only four specific mis-
senses—c.626A>T (p.Gln209Leu) (GenBank: NM_002072.
3; 11 samples) and c.626A>C (p.Gln209Pro) (GenBank:
NM_002072.3; 8 samples) in GNAQ, and c.626A>T
(p.Gln209Leu) (GenBank: NM_002067.2; 13 samples)
and c.626A>C (p.Gln209Pro) (GenBank: NM_002067.2;
1 sample) in GNA11—affecting the same functional amino
acid residue and conferring oncogenic potential to this
G protein.18,19 Six tumors (18%) had missense mutations
in SF3B1 (Splicing Factor 3B, subunit 1), affecting codon
625 (5 cases) and codon 626 (1 case) (Figure S1, Table
S3), a previously described hotspot region.21 Finally, 7
other tumors had mutations impacting the first codons
of EIF1AX (Eukaryotic Translation Initiation Factor 1A,
X-Linked) (Figure S1, Table S3).22 Mutations in SF3B1 and
EIF1AX seemed to occur in a mutually exclusive pattern
and to be enriched with classes C and D (p value ¼ 1.6 3
10"4), with SF3B1 preferentially mutated in class D. Except
for one sample, BAP1 mutations were never observed in
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Figure 1. Unsupervised Hierarchical Clustering and Global Genetic Landscape of All Tumors Analyzed in This Study
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cated in the legend provided at the top. SNVs in genes found to carry mutations in six or more individuals are shown on the left, with
mutation classes provided within gray or blue boxes. Clustering identifies four classes—A, B, C, and D (see text)—indicated within the
dendrogram.
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case subjects carrying mutations in SF3B1 or EIF1AX
(p value ¼ 1.4 3 10"5), in agreement with findings from
previous literature.23,30 Also, consistent with the fact that
all of the tumors analyzed harbored variants affecting
either GNAQ or GNA11 Gln209, no somatic SNVs were
observed in PLCB4 or CYSLTR2, two genes that have
been found to be mutated in a mutually exclusive pattern
with respect to GNAQ or GNA11 variants.25,26
Five genes (TP53BP1 [MIM: 605230], CSMD1 [MIM:
608397], TTC28 [MIM: 615098], DLK2, and KTN1 [MIM:
600381]) harbored somatic missense or truncating muta-
tions in at least two samples, across all tumor classes (Table
S3). TP53BP1 is a partner of the tumor suppressor protein
p53, known to play a crucial role in maintaining genomic
integrity as a mediator and effector of homologous recom-
bination in response to double-strand breaks. This protein
acts as a molecular scaffold that recruits responsive pro-
teins, in order to repair damaged chromatin,31 and its
depletion has been associated with increased cell prolifera-
tion.32 CSMD1 (Cub and Sushi Multiple Domains-1) is a
candidate tumor suppressor gene, the hyper-expression
of which increases survival in mice with xenografted
tumors.33 Loss of CSMD1 was detected in a large set of
cancers, including head and neck, lung, breast, and skin
primary tumors,34 and associated with high tumor grade
in invasive ductal breast carcinoma.35 TTC28 (Tetratrico-
peptide Repeat Domain 28) is a ubiquitous protein, associ-
ated with diverse biological functions. Of note, TCC28
plays a critical role in the progress of mitosis and cytoki-
nesis during mammalian cell cycle and its dysfunction
was described as a potential component of tumorigenesis
and tumor progression.36,37 DLK2 (Delta-Like 2 homolog)
is a transmembrane epidermal growth factor-like protein.
It is highly homologous to DLK1, a protein that was found
to be present at high levels in gliomas and involved
in cell proliferation.38 Similar to DLK1, DLK2 can bind
to NOTCH1,39 modulating the oncogenic potential of
cultured melanoma cells.40 Finally, KTN1 (Kinectin 1) is a
protein of the endoplasmic reticulum membrane that in-
teracts with kinesins.41,42 Its role in cancer may be linked
to dysregulation of cytoskeletal activity and mitosis. Two
of these five genes were previously found to be mutated
in UM: a missense in TTC28 was detected in 1 out 35 sam-
ples from aWES screen,22 and the cBioPortal repository re-
ports amissensemutation in KTN1 in one out of 80 tumors
profiled by TCGA.43,44
Taken together, our clustering analysis indicates that
initial events involveGNAQ orGNA11mutations, followed
by a major branching determined by the functional loss of
BAP1 and copy gains of chr 8q versus cases with a relatively
normal chromosomal ploidy. These latter samples have
conversely mutations in EIF1AX or in SF3B1 (classes A and
B versus C and D, respectively). In tumors with BAP1
mutations, the long arm of chr 6 could eventually be
lost, differentiating class B from class A. In tumors that
are negative for BAP1 mutations, part of chr 8q could un-
dergo amplification, differentiating class D from class C
(Figure 2).
Aggregate analyses on genetic data showed no signifi-
cant differences between primary UM (PUM) and metasta-
tic UM (MUM) samples, in terms of number of somatic
coding SNVs, non-coding SNVs, CNVs, and SVs, indicating
that the extent of genomic instability was here not associ-
ated with metastatic potential (Figures 3B–3E). Although
singularly none of the main somatic drivers (chr 3, 6q,
and 8q aneuploidies, as well as SNVs in BAP1, GNAQ,
GNA11, SF3B1, EIF1AX) were computed as being statisti-
cally different, enrichment in PUMs versus MUMs showed
very clear association trends (Figure 3A).
Remarkably, when considering specific levels of 8q
amplification detectable by algorithms querying non-
coding WGS data for CNVs and aneuploidies, we found a
very clear association between metastatic potential and
8q ploidy of five copies or more (p value ¼ 8.6 3 10"4,
Figure 3A). In addition, single-copy amplification of 8q
(ploidy ¼ 3) was indeed associated with primary tumors
(p value ¼ 4.7 3 10"3, Figure 3A). Similarly, when muta-
tional sets defining tumor sub-classes were considered, a
significant association between sub-class B and metastases
was identified (Figure 1, p value ¼ 2.0 3 10"2).
With respect to metastatic samples, the aneuploidies
identified correlated well with those of 66 liver metastases
from UM investigated previously, detecting chr 3 mono-
somy (73%), 8q gain (89%), 6q loss (64%), 1p loss (47%),
8p loss (45%), 1q gain (35%), and 16q loss (32%).14 Simi-
larly, the identified SNVs matched those on another study
on five liver metastases.45 Finally, the identification of a
SF3B1 mutation in one metastatic sample from our series
is also in line with late-onset metastasis occurring in indi-
viduals with SF3B1 mutations.23
Mutations targeting BAP1 are one of the genetic land-
marks of UM20 and were found here to be associated
with classes A and B (p value ¼ 1.2 3 10"4), classes that
GNAQ or GNA11
EIF1AX or SF3B1BAP13 del & 8q gain
A CB
6q del 8q gain
D
Figure 2. Inferred Somatic Events Defining Tumor Classes, as
Identified by Clustering
Colors are the same as those shown in Figure 1. All steps deter-
mining branching are statistically significant.
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are in fact defined mostly by the presence of chr 3 mono-
somy. To test for functional inactivation of the BAP1 pro-
tein, we assessed its nuclear staining in histological sec-
tions of all tumors (Figure 4). Of the 33 samples (60%),
20 displayed loss of nuclear localization (Figure 4). Of
these, 17 (85%) presented chr 3 monosomy and a coding
SNV (a truncating SNV in 14 cases and a missense or an
in-frame deletion in 3 cases), accounting for loss of hetero-
zygosity and protein delocalization.
The number of somatic SNVs involving coding and
non-coding regions was strikingly low (Figure S2). Glob-
ally, the average load of coding mutations was 0.24/Mb
(range 0.08–0.42/Mb, Table S4), one of the lowest de-
tected so far in tumors. Comparison with other cancer
types revealed that UM mutational load for coding
regions was closer to that of pediatric tumors such as
rhabdoid tumors, medulloblastoma (MIM: 155255), neu-
roblastoma, etc.,46 rather than that of adult cancers
(Figure S3). Pediatric tumors typically develop over a
shorter period than most adult malignancies, frequently
harbor few driver mutations, and may thereby have fewer
sources of heterogeneity, facilitating the assessment of
both the genetic and epigenetic determinants underlying
their pathogenesis. Our data seem to suggest that, simi-
larly to pediatric tumors, UM development may rely
more on epigenetic drivers of transformation and tumor
progression, rather than the classical accumulation of
genetic events observed in the vast majority of adult
malignancies.
The number of non-coding SNVs was also relatively low
(736 per tumor on average, range 371–1,347) and mostly
proportional to the number of coding SNVs (17 per tumor
on average, range 7–28) (Figure S2), confirming that,
compared to both cutaneous and conjunctival mela-
nomas, which also originate from melanocytes, UM fol-
lows a different oncogenic pathway, characterized by
significantly fewer mutations.47,48 In addition, we failed
to identify any statistically relevant non-coding SNVs for
tumor-specific sites that were present in four samples or
more, suggesting the absence of common regulatory vari-
ants in the landscape of these tumors, at least in our
cohort.
Another difference between UM and cutaneous and
conjunctival melanomas involved its mutational spectrum
(Figure 5). Analysis of all coding and non-coding somatic
single-nucleotide substitutions (SNSs) from our series
showed the clear absence of an UV-induced mutation
signature. This particular spectrum results from sunlight-
driven formation of pyrimidine dimers on the DNA49
and is found in both cutaneous and conjunctival mela-
nomas (Figure 6A).47,48 Direct analysis of genes known
to be involved in cutaneous melanoma, such as BRAF
(MIM: 164757), NRAS (MIM: 164790), and NF1 (MIM:
162200) revealed no somatic mutations in UM, supporting
again the notion that uveal and cutaneous melanomas
have a different molecular etiology.50,51 Conversely, the
UM mutational spectrum was remarkably similar across
all PUMs and MUMs and resembled that of apparently un-
related tumors, such as clear cell renal carcinoma, thyroid
tumor, and glioblastoma (Figure 6). Notably, despite a
different cellular origin, UM shares with these tumors
recurrent genetic modifications; BAP1 mutations and chr
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Figure 3. Genetic Features in Primary and Metastatic Tumors
(A) Overview of all major somatic events with respect to PUMs and MUMs. Each circle indicates a specific genetic event; its center
corresponds to the percentage of samples carrying this feature in PUMs versus MUMs, whereas its diameter indicates the total number
of such samples. Asterisks indicate statistical significance. The gray area depicts the surface of the plot for which there is an enrichment in
MUMs.
(B–E) Boxplots of different types of genetic alterations, at the genome-wide scale.
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3 monosomy are frequently seen in clear cell renal carci-
noma,52 while hotspot mutations in the first codons of
EIF1AX are recurrent in papillary thyroid carcinoma.53
Analysis of all specific SNS types along with composition
of the flanking bases allowed us to determine specific
mutational signatures for UM, according to the classifica-
tion of Alexandrov et al.54 Our samples appeared to be en-
riched for signatures 12 or 16 (55% of the score), signature
1B (25%), and signature 6 (20%) (Figure 5B). Signature 1B
corresponds to a rather ubiquitous pattern in cancer, re-
sulting from the spontaneous deamination of 5-methyl-
cytosine, which in turn is thought to correlate with the
process of aging.54,55 Conversely, signatures 12/16 and 6
are associated with defects in nucleotide excision repair
and DNA mismatch repair, respectively.
A more global approach, considering the intersection
between the SNVs detected in our series and the most
frequently mutated genes in cancer (TCGA PANCAN
list),56 also revealed a minimal overlap, limited to BAP1
and SF3B1 (Figure S4).
A non-negligible number of structural variants (SVs)
such as deletions, duplications, inversions, or inter- and
intra-chromosomal rearrangements were also observed
(Figure S5). Only a few of these events were recurrent, indi-
cating the absence ofmajor commondrivers constituted by
genetic events involving large parts of the genome. Among
these, however, therewere three inter-chromosomal events
thatwerepresent in at least two individuals (Figure7). Three
samples (PUM20, PUM18, and PUM5) had a translocation
involving chr 6 and chr 8 disrupting UBE2W (MIM:
614277) andMYO6 (MIM:600970) for the twofirst samples,
respectively. The third event occurred in intergenic regions.
Translocations between chr 13 and chr 17 (no genes
involved) were also present in MUM9 and PUM5 and be-
tween chr 3 and chr 12 in PUM17 (no genes involved)
and in PUM5 (disrupting KDM2B [MIM: 609078]) (Table
S5). Although these translocations impacted roughly the
same genomic areas, highlighting possible hotspot regions
in UM genome, they neither targeted the same genes nor
defined a specific tumor sub-category. Of note, one individ-
ual (PUM5) appeared to harbor a higher number of inter-
chromosomal events and SVs than the average value of
the other cases (Figure S5). Notably, this individual was
also anoutlier of our clustering analysis (Figure 1).However,
neither the medical history nor tumor pathology revealed
any uncommon feature, compared to the rest of the cohort.
Amplification of chr 8q is a well-known and important
feature of UM.17,57,58 Levels of chr 8q amplification seem
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to define prognostic status and metastatic potential in UM
and differentiate class C fromD (Figures 1 and 2). However,
the molecular bases for this phenomenon are not known.
One possible explanation is that the amplification is
driven by the MYC oncogene (MIM: 190080), which lies
in this region.59 By comparing the pattern of chr 8q ampli-
fication in our samples, we determined the minimal region
of overlap, involving a 2.3 Mb fragment toward its telo-
meric site (chr 8: 126,404,000–128,682,000).
Surprisingly, this region was very close to MYC
(chr 8: 128,748,314–128,753,680) but did not include
it. Conversely, it harbored six other genes (POU5F1B
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Figure 5. Mutational Signature of Our Samples, for SNSs, Genome-wide
(A) Main graph: comparison of mutational load of the UM samples studied with respect to two melanomas of the conjunctiva (CM),
sequenced and processed according to the same methods.48 The number of mutations is radically different in UM versus CM. Inset:
mutational spectrum of each UM sample, in percentage, showing a relatively homogeneous pattern.
(B) Results of the analysis of mutational events according to the methods and the classification proposed by Alexandrov et al.54,55 Three
main signatures are detected in our samples, evocative of Alexandrov’s signatures 12/16, 1B, and 6. The different peaks indicate specific
genetic contexts of the altered nucleotide and are ordered according to the original article.54
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[MIM:615739], FAM84B [MIM: 609483], TRIB1 [MIM:
609461], LOC100130231/LINC00861, LOC100507056/
CCAT1, and LOC727677/CASC8). The most interesting of
them was POU5F1B (POU Class 5 Homeobox 1B), a pseu-
dogene of the POU5F1/OCT4 family, recently shown to
be involved in prostatic and gastric cancer.60,61 Real-time
quantitative PCR experiments showed that only POU5F1B,
TRIB1, LINC00861, and CCAT1 were expressed in our
UM samples, but no statistically significant correlation be-
tween their expression levels and 8q amplification or tu-
mor class could be detected. The same held true for the
MYC transcript, suggesting that none of these genes play
a key role in UM pathogenesis (Figures S6 and S7).
By using a WGS-based, untargeted approach to investi-
gate the genetic components of UM, we had the unique
opportunity of assessing its genomic landscape as a whole,
from single-nucleotide variants to interchromosomal rear-
rangements, providing the basis for future functional
studies that go beyond the scope of our analysis. The global
picture emerging from our work indicates that, genetically,
UM is a relatively atypical tumor, mostly in virtue of the
paucity of somatic events that characterize it. Driver
mutations are very few and are confined to a relatively
low number of genes, such as BAP1, GNAQ, and GNA11.
Other genes, including those that were identified in this
study, may have a role in tumorigenesis, but they are none-
theless present in a small fraction of the samples studied.
Conversely, larger events such as extended copy-number
and structural variations seem to shape UM’s genome in
a much more relevant way, possibly determining tumor
progression and fate. Taken together, our results point
to a critical role for non-canonical mechanisms of cellular
transformation in UM development, where chromo-
somal rearrangements and non-coding SNVs potentially
affecting distal regulatory elements may collaborate in
the establishment of a permissive oncogenic landscape.
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5.3 Rare	  inherited	  Mendelian	  disorders	  	  
5.3.1 HSPA9	   	  	  	  	  	  	  	  	  	  	  Mutations	  in	  the	  heat-­‐shock	  protein	  A9	  (HSPA9)	  gene	  cause	  the	  EVEN-­‐PLUS	  syndrome	  of	  congenital	  malformations	  and	  skeletal	  dysplasia	  	  	  	  	  	  	  	  	  	  	  
Own	  contribution:	  Analyzed	  the	  WES	  of	  the	  three	  patients	  and	  identified	  the	  new	  disease-­‐causing	  gene.	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Mutations in the heat-shock 
ͿȋͿ) gene cause 
the EVEN-PLUS syndrome of 
congenital malformations and 
skeletal dysplasia
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We and others have reported mutations in ͷ, a gene coding for a mitochondrial chaperone 
ǡȋ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ǡ
hypoplasia, and other malformations, and for which we propose the name of EVEN-PLUS syndrome 
for epiphyseal, vǡear, nose, plusƤǤǡ
no mutation in ͷǢǡͿ, the gene that 
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EVEN-PLUS delineate a family of “mitochondrial chaperonopathies” and point to an unexplored role 
Ǥ
Recently, we and others reported on the identification of mutations in LONP1 as the cause of the human 
genetic disorder, CODAS (cerebral, ocular, dental, auricular and skeletal) syndrome (MIM 600373)1,2. 
LONP1 codes for a phylogenetically conserved protein of the mitochondrial matrix that has both 
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chaperone and protease activity. Subsequently, we have identified patients with a condition that shares 
the skeletal features of the CODAS syndrome but includes a distinct craniofacial dysmorphism and car-
diac and intestinal malformations.
A review of the literature suggests that one sporadic patient reported as having CODAS3, two sibs 
reported as having an EVE (epiphyseal-vertebral-ear) syndrome4, and a further sporadic patient reported 
as having caudal regression with anal atresia and spondylo-epiphyseal dysplasia5 may have had the disor-
der we describe here, for which we propose the name of EVEN-PLUS syndrome for epiphyseal, vertebral, 
ear, nose, plus associated findings.
We report here the identification of recessive mutations in the HSPA9 gene in our three patients 
with this syndrome. The HSPA9 gene codes for a mitochondrial chaperone that has been implicated 
in different physiologic processes, and thus has been known under several different names (heat-shock 
70 kda protein 9 (HSPA9, HSPA9B), mortalin and mortalin 2 (MOT/MOT2), 75 KDa glucose-regulated 
protein (GRP75), among others)6–8. Notably, the HSPA9 protein participates in, and is necessary for, the 
proteolytic activity of LONP19–12.
Clinical Reports
ͷǤ This girl was the first child of a non-consanguineous couple of Korean origin. Upon specific 
questioning, there was no history of Parkinson disease in parents or grandparents. She was born at term 
(39 weeks) with a length of 38 cm and a weight of 2.2 kg. Her face showed midface hypoplasia with mark-
edly hypoplastic nasal bones, giving her a flat nose with nares that were triangular in shape (Fig. 1). She 
had arched eyebrows and synophrys. Her external ears were markedly small and poorly formed (Fig. 1), 
while the ear canal was present. She was noted to have anal atresia that was subsequently surgically cor-
rected. An atrioseptal defect (ASD) was present at birth but repeat ultrasound at age 20 months showed 
that it had closed spontaneously. At age 16 months, her developmental quotient was approximately 80; a 
cerebral MRI was normal, an abdominal ultrasound examination did not show abnormalities of kidneys 
or urinary tract, an ophthalmologic examination was normal (specifically, no cataracts were observed), 
and a CGH array study gave normal results. Skeletal radiographs obtained at age 16 months at 4 yrs 
showed lateral vertebral clefts, dysplasia of the proximal femurs and acetabula, “bifid” distal femurs and 
marked epiphyseal dysplasia at her knees (Fig.  2). These skeletal changes were considered typical of 
CODAS syndrome. However, no variants in the LONP1 gene were found.
͸Ǥ This girl was born to a consanguineous couple of Chilean origin; the parents are uncle once 
removed and niece. Family history was negative for Parkinson disease. Short long bones were noted pre-
natally. She was born at 38 weeks’ gestation with a length of 39 cm (markedly below the 3rd percentile), a 
Figure 1. Photographs of patients 1 (A,B), 2 (C,D) and 3 (E,F). Common features include hypoplasia of 
the midface and of the nasal bones giving a flat nose, triangular nares, arched eyebrows with synophrys, 
and hypoplastic-dysplastic external ears. Panel G and H show the flat nose with triangular nares in patients 
3 and 2, respectively, with a single central incisor in patient 3; and panel I shows the lesion of congenital 
aplasia cutis on the vertex of patient 3.
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weight of 2.8 kg, and a head circumference of 33,5 cm (slightly below the 10th percentile). Her karyotype 
was normal in blood cells. When seen in the genetics clinic at age 5 years, her weight was 12,5 kg, and 
she had severe short stature (markedly below the 3rd percentile for Chilean children) with a height of 
80 cm; her head circumference 47,8 cm (below the 3rd percentile). She had severe bilateral microtia with 
apparently normal external ear duct, arched eyebrows with mild synophris, and a very flat nose with 
nares that were triangular in shape (Fig. 1). Her cranial fontanels were still open, she had two lateral hair 
whorls and a small area of aplasia cutis on her cranium. Her limbs looked short. An echocardiography 
showed a small ASD. Cerebral, abdominal and renal ultrasound scans gave normal results. Her language 
development was appropriate and she attended kindergarten. Radiographic findings at birth included 
dysplasia of the femoral heads and of the acetabulum as well as “bifid” distal femurs (Fig. 2). At age 5 
yrs, the proximal femoral epiphyses were not ossified, the femoral heads appeared to be dislocated, and 
the epiphyses at the knee were dysplastic.
 ͹Ǥ This girl is the younger sister of patient 2. Oligohydramnios and short long bones were 
noted prenatally. Born after 38 weeks of gestation, she was very short at birth, while weight and head 
circumference were at the lower limit of normal (weight, 2.7 kg; length, 39 cm; and head circumference, 
34,5 cm); clinically, she appeared to have short limbs. She also had rectal atresia without fistula that 
required a surgical colostomy. She had a normal female karyotype in blood cells. At age 8 months, 
developmental delay was diagnosed. An echocardiography done at age 2 years 6 months showed per-
sistent foramen ovale and aneurysmatic septum. When she was seen in the genetics clinics at age 3 
years 6 months, her weight was 12 kg and her height 79 cm (both below the 3rd percentile). She had 
brachycephaly, severe bilateral microtia (Fig. 1) with apparently normal ear canal, aplasia cutis on the 
skull vertex, a very flat nose with triangular nares, arched eyebrows with mild synophrys, high palate, 
hypodontia (Fig. 1), short neck, and imperforate anus. She was developmentally delayed and attended 
a specialized Teleton institution. Imaging studies showed right vesico-ureteral reflux with right kidney 
nephropathy. A brain CT showed dysgenesis of the corpus callosum. Skeletal-radiographic findings are 
shown in Fig. 2. Radiographic findings were similar to those seen in her sister and included vertebral 
coronal clefts (Fig. 2) and agenesis of the coccyx.
Figure 2. Skeletal-radiographic features. Panels A and B: patient 2 at birth (A) and at age 5 years (B) 
showing underossified pubic bones; bilateral dysplasia of the femoral heads at birth resulting in hip 
dislocation at age 5 yrs; and a “bifid” appearance of the distal femur with epiphyseal delay at birth, with 
dysplastic epiphyses that are “socketed” in the bifid femur at age 5 yrs; and small, laterally dislocated patellae. 
Panels C, D and E: Patient 1 at birth (C) with dysplastic femoral heads and at age 4 years (D,E) showing 
the bifid distal femur and the markedly dysplastic distal femoral epiphyses. The proximal tibial epiphyses 
are too small but less severely affected. Panels F and G: lateral lumbar spine of patient 3 at age 3 yrs (F) 
and of patient 1 at age 4 yrs (G) showing remnants of coronal clefts of the vertebral bodies. The clefts are 
prominent at birth and gradually disappear as ossification progresses.
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Results
  Ƥ Ǧ    Ϳ gene in individuals 
 ǦǤ The sequential analysis of the variants identified in the exomic 
sequence of the patients is presented in table S1. Variants were filtered for non-synonymy, for rarity, and 
for quality. Subsequently, genes were scored for the presence of either two variants at heterozygosity, or 
one or more variants at homozygosity, in the affected sibs as well as in the sporadic patient. There was 
only one gene that fit all criteria, namely, HSPA9. Patient 1 was found to be heterozygous for variants 
c.383A > G (p.Y128C) and c.882_883delAG (p.V296*). Patients 2 and 3 were found to be homozygous 
for variant c.376C > T (p.R126W). Both R126 and Y128 are extremely conserved (supplementary Figure S1). 
Results of prediction software PolyPhen-213 and Provean14 suggested damaging results on protein struc-
ture (Fig. 3). The V296* truncation mutation abolishes more than half of the protein, including all of 
the substrate binding domain (Fig. 3); however, the premature termination codon is likely to promote 
nonsense-mediated decay. All mutations were confirmed by direct bidirectional Sanger sequencing of 
a second batch of genomic DNA; heterozygosity was confirmed in the unaffected parents. All three 
mutations were present at extremely low frequency in the ExAC browser (exac.broadinstitute.org/gene/
ENSG00000113013) and were absent from the Exome Variant Server (http://evs.gs.washington.edu/EVS/) 
(Fig. 3). These frequencies are compatible with recessive inheritance of a rare disorder. Interestingly, the 
R126W mutation had been observed at heterozygosity in one individual out of three cohorts comprising 
over 1500 adult patients with Parkinson disease, and databases are since annotated with a possible role 
of this mutation in Parkinson disease15,16 (but see discussion below).
͹ͿơǤ Mapping 
of the mutated amino acids on the available HSPA9 nucleotide binding domain structure (NBD)17 
revealed that both R126W and Y128C are located next to each other on the surface of the protein, at 
some distance from the ATP/ADP binding site (Fig. 4A). Moreover, in our model the two mutations lie 
on a loop close to the predicted interface between the NBD and the substrate binding domain (SBD, 
Fig. 4B).
Discussion
 ǦǤ The identification of LONP1 mutations in the 
CODAS syndrome allowed for the recognition of its wide phenotypic spectrum1,2. Subsequently, gene-based 
phenotypic sorting allowed us to identify a CODAS-related phenotype that is not associated with LONP1 
mutations. This syndrome shares the skeletal features of the CODAS syndrome (vertebral and epiphyseal 
changes as shown in Fig. 2) but is further characterized by prenatal-onset short stature, a distinct cranio-
facial phenotype with microtia, a flat facial profile with flat nose and triangular nares, cardiac malforma-
tions, and other findings such as anal atresia, hypodontia, aplasia cutis, and others (see Fig. 1 and Table 1). 
Examples of this syndrome seem to have been previously reported: in 1990, Kozlowski et al. described a 
six-year-old boy, with « caudal regression and spondylo-epiphyseal dysplasia »5. The flat nose, dysplastic 
ears, and the combination of rectal and bladder incontinence with sacral agenesis observed in that boy are 
Figure 3. Scheme of the HSPA9 protein showing the localization of the mutations observed. The HSPA9 
(mortalin) protein has a short mitochondrial import sequence and two main domains, the nucleotide 
(ATP/ADP) binding domain and the substrate binding domain (Dores-Silva et al., 2015). The two amino 
acid substitution affect the nucleotide binding domain; the truncation mutation predicts the loss of part 
of the nucleotide binding domain and all of the substrate binding domain (unless the mRNA undergoes 
nonsense-mediated decay; see Results). The lower part shows a summary of the pathogenicity prediction 
software (PolyPhen-2, http://genetics.bwh.harvard.edu/pph2/) and PROVEAN, http://provean.jcvi.org/index.
php) as well as the allelic frequencies in the ExAC project (exac.broadinstitute.org/gene/ENSG00000113013).
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reminiscent those in our patients; the radiographic changes, namely, vertebral clefts, severe epiphyseal dys-
plasia, “bifid” appearance of the distal femur, and coccygeal agenesis, are virtually identical (see Fig. 2). In 
2009, Marlin et al. reported on a boy diagnosed as having CODAS3; however, while the facial features in the 
CODAS syndrome are non-specific, the craniofacial features and the skeletal findings of that patient closely 
match those observed in our patients. Finally, Amiel and coworkers had reported, in 1994, two sisters who 
had epiphyseal and vertebral dysplasia in combination with dysplastic external ears; they discussed CODAS 
as a possible diagnosis but concluded that those sisters probably represented a separate disorder for which 
they coined the name of EVE (epiphyses, vertebrae, ear) syndrome4. Although no DNA could be obtained 
from these individuals to test for the presence of HSPA9 mutations, the clinical resemblance and similar-
ity of radiographic features strongly suggest that these four patients had the same disorder as the one we 
Figure 4. Localization of the mutations observed on the HSPA9 protein structure. (A) Mapping of the 
R126W and Y128C mutation of the crystal structure of the NBD (light blue). Both mutations lie on the 
surface of the protein, opposite to the nucleotide binding site. R126W is shown in red, Y128C in yellow. 
(B) Localization of the mutations in relation to the NBD/SBD interface (NBD and SBD shown in light green 
and purple respectively) in a model of the full length protein. Only a portion of the SBD is shown for clarity. 
Both mutations are located on a single loop near the interface, as shown in detail in the inset.
Pat. 1 Pat. 2 Pat. 3
birth measurements
length 38 cm, weight 
2.2 kg (at week 39); both 
values markedly below the 
normal range
length 39 cm, weight 2.8 kg (at week 
38); length markedly below the normal 
range
length 39 cm, weight 2750 g (at 
week 38); length markedly below 
the normal range
nose
hypoplastic nose with 
vertical groove on tip 
(bifid tip) and triangular 
nares
hypoplastic nose with vertical groove 
on tip (bifid tip) and triangular nares
hypoplastic nose with vertical 
groove on tip (bifid tip) and 
triangular nares
ears absent external ears (anotia), open ear duct severe microtia with absent upper helix
absent external ears with open ear 
duct; possible hypoacusis
eyes synophrys; no cataract synophrys; no cataract synophrys; no cataract
teeth single upper central incisor, absence of some lateral incisors
skin atopic dermatitis, sparse hair
two lateral hair whorls and area of 
aplasia cutis on the skull vertex
area of aplasia cutis on the skull 
vertex
heart ASD (spontaneously closed at age 20 mos) ASD (ostium secundum)
patent foramen ovale and 
aneurysmatic septum
gastrointestinal anal atresia normal abdominal ultrasonography anal atresia
kidney/urogenital No abnormalities on ultrasound
1 UTI at 1 year but normal renal 
ultrasonography
vesicoureteral reflux, hypoplastic 
right kidney
brain normal MRI at age 5 mos normal cerebral ultrasonography agenesis of the corpus callosum with separated frontal horns
psychomotor development Borderline-normal Normal evaluation at kindergarten level, including language Moderate developmental delay
HSPA9 mutations p.Y128C/p.V296* pR126W/p.R126W pR126W/p.R126W
Table 1.  Synopsis of clinical features in the three individuals with EVEN-PLUS syndrome and HSPA9 
mutations.
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describe here. Thus, we propose to retain the name suggested by Amiel and coworkers and to change it to 
“EVEN-PLUS syndrome” (for epiphyses, vertebrae, ears and nose, plus associated findings), reflecting the 
main clinical findings of the syndrome. While the skeletal findings in EVEN-PLUS are shared with CODAS, 
the facial features and the presence of associated malformations are distinct to the EVEN-PLUS syndrome.
ͿǦǤ Several 
lines of evidence support the causative role of the HSPA9 mutations in the pathogenesis of this complex 
malformation syndrome. The genetic evidence consists in the rarity or absence of the variants in our 
in-house population (to exclude systemic technical errors) and in publicly available databases (ExAC, 
EVS); their presence at compound heterozygosity in patient 1 (non-consanguineous parents) as well as in 
homozygosity in patients 2 and 3 (consanguineous parents); the phylogenetic conservation of the affected 
residues (supplementary Figure 1); as well as the consequences at the protein level both for the premature 
stop codon mutation predicting the loss of more than half of the protein, and for the amino acid substi-
tutions predicted in silico to be damaging (Fig. 3). The R126W and Y128C mutations are located on the 
NDB but are unlikely to directly affect this activity, due to their distance from the active site. However, 
the proximity of the mutation sites to the predicted NBD/SBD interface could result in the disruption 
of this interaction, thereby affecting the function of the protein. Interestingly, our 3D model of HSPA9/
mortalin is consistent with a recent in solution analysis of the HSPA9 structure6, which places the NBD/
SBD interface in similar orientation as the one predicted in our own molecular model. It seems therefore 
likely that the R126W and Y128C mutations result in similar consequences as the ones expected from the 
V296* mutation, which, if the mRNA escapes nonsense-mediated decay, abolishes the NBD/SBD inter-
face and the whole substrate binding domain. Finally, albeit in another context, the R126W substitution 
has been shown to have adverse effects on HSPA9 protein function (see below).
ͿȀǡȋȌǫ The product of the HSPA9 gene, a 70 kDa 
heat-shock protein, has been extensively studied in the past 25 years and yielded precious insights on 
mitochondrial protein import and folding6–8,10. It is associated principally with the mitochondrial matrix 
but can be found in the cytoplasm as well as in the nucleus. Its main role is that of a chaperone that 
participates in the import of proteins from the cytosol to the mitochondrial matrix as well as their fold-
ing18,19. As a heat-shock protein with ATPase activity, it prevents the accumulation of unfolded, dysfunc-
tional proteins20. Because of its different localizations and multiple binding partners, the HSPA9 protein 
has been known under several different names (mHSP70, mortalin, mot-2, GRP75) and has been asso-
ciated with a large number of different processes ranging senescence to immortalization, oncogenesis, 
neurodegeneration, protection from oxidative stress, hematopoiesis, and even viral replication, among 
others6,7. Some of these studies, done in different contexts, have produced results that are relevant to our 
results. In 2005, Craven et al. studied a zebrafish mutant, crimsonless, ascertained for ineffective hemato-
poiesis. They identified a single amino acid substitution, G492E, in the HSPA9b gene (the zebrafish 
homologue of human HSPA9) as responsible for this phenotype. A morpholino knock-down model of 
HSPA9b effectively reproduced the crimsonless phenotype21. Although the study was focused on hemato-
poiesis, it was noted that the head and eyes appeared stunted as early as 38 hpf21; moreover, after 48 hpf 
all development appeared to halt, including further maturation of the musculature, fins, and internal 
organs, and the animals died around 72 hpf21, indicating that HSPA9b knockdown had more widespread 
effects on embryonic development. Other investigators have investigated a possible role of HSPA9 in the 
pathogenesis of Parkinson disease, based on the physical and functional relationship of HSPA9 (often 
referred to as mortalin in that literature) with parkins. In two studies on the possible role of genetic 
variations in HSPA9 in the pathogenesis of Parkinson disease, the R126W mutation has been identified 
at heterozygosity in 1 of 330 Spanish patients16, and subsequently in 0 (none) of two cohorts of 286 and 
1008 German patients15. In spite of the questionable statistical significance of this observation, expression 
studies using wild type and mutated HSPA9 were done, showing that the R126W mutation does impact 
the function of the HSPA9 protein measured by its effects on mitochondrial morphology, mitochondrial 
membrane potential, the production of reactive oxygen species15,22 and the cell sensitivity to exogenous 
oxidative stress22. These expression studies confirm that the R126W mutation is not a neutral polymor-
phism but does impair HSPA9 function, in accordance with in silico predictions and 3D mapping data.
ͷ    Ϳ   Ǧ -
ǲǳǤ The concept 
of families of phenotypes coming from genes in the same pathway, or related by a common function 
(such as the cohesinopathies, or the cholesterol biosynthesis defects, or the mucopolysaccharidoses) is 
well established. While the identification of mutations in a mitochondrial matrix protease (LONP1) in 
patients with the CODAS syndrome was unexpected1,2, the identification of mutations in a related gene 
(HSPA9) in EVEN-PLUS syndrome confirms the previous studies and suggests a common pathogenesis 
of the two syndromes. In fact, the functional relationship between HSPA9 and LONP1 in the mitochon-
drial chaperone-protease network9,10,23 and the phenotypic overlap between CODAS and EVEN-PLUS 
syndromes delineate a new family of disorders – the “mitochondrial chaperonopathies”.
	  	   82	   	  
www.nature.com/scientificreports/
7Scientific RepoRtsȁͻǣͷͽͷͻͺȁǣͷͶǤͷͶ͹;Ȁͷͽͷͻͺ
 Ǧ 
ơǤ In spite of the numerous stud-
ies on HSPA9 function, and of the studies of Strauss et al. on LONP1 mutations found in the CODAS 
syndrome1, the pathogenesis of the developmental defects associated with LONP1 and HSPA9 mutations 
remain unexplained. The phenotype of the CODAS syndrome, and even more so that of EVEN-PLUS, 
do not resemble those of other multisystem mitochondrial diseases; there is no indication of the “energy 
failure” process that is central to the pathogenesis of prototypical mitochondrial disorders such as the 
Pearson, Kerns-Sayre, MELAS, MERFF, or Alpers syndromes (reviewed by Andreux et al., 201324). 
Recessive mutations in a different mitochondrial chaperone-protease, CLPP, have been identified as one 
cause of the Perrault syndrome of ovarian failure and hearing loss, a condition that more closely resem-
bles the classic mitochondriopathies25. Many of the clinical features of EVEN-PLUS syndrome (micro-
tia, small nose, abnormal hair patterns, anal atresia, sacral agenesis) are the consequence of disturbed 
embryonic morphogenesis. But how can HSPA9 malfunction result in dysmorphogenesis? Heat-shock 
genes are widely expressed in vertebrate development even in absence of stress factors, suggesting a 
role in development26. Specifically, HSPA9 is known to interact with FGF127 as well as with Smad2, 
decreasing TGF-b signal transduction and affecting epithelial-mesenchymal transition28. Studies of the 
possible roles of HSPA9 in embryonic development may give an explanation for the defects observed in 
the EVEN-PLUS syndrome.
Awareness about the EVEN-PLUS syndrome and availability of molecular diagnosis will allow to rec-
ognize further cases, to increase our knowledge on the phenotypic spectrum associated with mutations 
in HSPA9, and to learn about the long-term outcome of affected individuals. The wealth on publications 
on the multiple roles of HSPA9/mortalin/mHSP70 notwithstanding, only these clinical observations may 
give us in vivo indications on the essential and non-essential roles of HSPA9 in prenatal development as 
well as over the entire human life-span.
Methods
The study was done in accordance with regulations for studies on human subjects of the hospitals in 
Lausanne, Seoul, and Rancagua. In addition, approvals from the IRB of the Seoul National Hospital, and 
of the Ethics Commission of the Lausanne University Hospital, were obtained. Peripheral blood was 
obtained with informed consent from the patients and their parents and genomic DNA was extracted 
by routine methods. Fragmented genomic DNA was purified with AMPure XP beads and the quality 
of the fragmented DNA was assessed with an Agilent Bioanalyzer. Preparation of the exome enriched, 
barcoded sequencing libraries was perfomed using Agilent SureSelect Human All Exon v4 kit. The final 
libraries were quantified with a Qubit Fluorometer (Life Technologies) and the correct size distribution 
was validated with an Agilent Bioanalyzer. Libraries were sequenced on Illumina HiSeq 2000, generating 
100 bp paired-end reads. Raw reads were aligned onto the hg19 reference genome with Novoalign (http://
www.novocraft.com) and the data cleanup and variant calling were performed according to GATK Best 
Practices recommendations29. Variant filtering was made with Annovar30 and with own perl and bash 
scripts (available on request). Variants identified by this procedure were verified by direct PCR ampli-
fication of target exons from genomic DNA and bidirectional Sanger sequencing. A molecular model 
for the full-length human HSPA9 protein was generated with I-TASSER31. Figures were generated in the 
PyMOL Molecular Graphics System, Version 1.7.4 (Schrödinger, LLC ).
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Intellectual developmental disorders (IDDs) affect 2–2.5% of children 
and adults worldwide1. The developmental origin of IDDs is reflected in 
their definition as “substantial impairments of intellectual function and 
social or adaptive functioning present from early childhood” (ref. 2). 
Recent advances have shown that, in many cases, the etiology of these 
disorders is genetic, most frequently involving de novo mutations3,4. 
Along with a better understanding of the surrounding condition 
and prognosis, insights into the molecular basis of neurocognitive 
impairment allow for the development and application of targeted 
therapeutic strategies5. Although less frequent than IDDs, genetic 
disorders affecting skeletal development and growth (commonly 
called ‘skeletal dysplasias’) are a group of over 500 distinct disorders6. 
NANS-mediated synthesis of sialic acid is required for 
brain and skeletal development
Clara D M van Karnebeek1,2,28, Luisa Bonafé3,28, Xiao-Yan Wen4,5,28, Maja Tarailo-Graovac2,6, Sara Balzano7, 
Beryl Royer-Bertrand3,7, Angel Ashikov8, Livia Garavelli9, Isabella Mammi10, Licia Turolla11, Catherine Breen12,  
Dian Donnai12, Valerie Cormier13, Delphine Heron13, Gen Nishimura14, Shinichi Uchikawa15, Belinda Campos-Xavier3,  
Antonio Rossi16, Thierry Hennet17, Koroboshka Brand-Arzamendi4,5, Jacob Rozmus1, Keith Harshman18,  
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We identified biallelic mutations in NANS, the gene encoding the synthase for N-acetylneuraminic acid (NeuNAc; sialic acid), in 
nine individuals with infantile-onset severe developmental delay and skeletal dysplasia. Patient body fluids showed an elevation 
in N-acetyl-D-mannosamine levels, and patient-derived fibroblasts had reduced NANS activity and were unable to incorporate 
sialic acid precursors into sialylated glycoproteins. Knockdown of nansa in zebrafish embryos resulted in abnormal skeletal 
development, and exogenously added sialic acid partially rescued the skeletal phenotype. Thus, NANS-mediated synthesis of sialic 
acid is required for early brain development and skeletal growth. Normal sialylation of plasma proteins was observed in spite of 
NANS deficiency. Exploration of endogenous synthesis, nutritional absorption, and rescue pathways for sialic acid in different 
tissues and developmental phases is warranted to design therapeutic strategies to counteract NANS deficiency and to shed light 
on sialic acid metabolism and its implications for human nutrition. 
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Studying their molecular basis has provided valuable insights into 
the many factors necessary for skeletal development, ranging from 
minerals and structural molecules to enzymes and to signaling mol-
ecules and transcription factors6,7. We report here a genetic disorder 
presenting as a combination of severe IDD with skeletal dysplasia and 
short stature. Our data show that the pathogenic basis of this disorder 
is an inborn error of metabolism that affects the endogenous synthesis 
of NeuNAc. Exploration of the biochemical and molecular features 
of this disorder provides new information on the role of sialic acid in 
the development of brain and bone.
RESULTS
Clinical and radiographic phenotypes of NANS deficiency
Clinical patient reports are presented in extenso in the Supplementary 
Note. Nine patients from six families were studied; patients 1, 2, and 5 
have previously been described8,9. The main clinical features of the dis-
order included a prenatal history that was unremarkable in all patients 
except for one (patient 8), in whom prenatal hydrocephalus was diag-
nosed. No specific signs and symptoms were present at birth, except 
for disproportionately short limbs that were observed in three patients 
(patients 3, 8, and 9). In the first months of life, all patients showed 
muscle hypotonia, and the achievement of early developmental mile-
stones such as sitting and walking was delayed. Subsequently, global 
developmental delay, including cognitive impairment, was the major 
medical concern. All adult patients showed moderate-to-severe IDD; 
only one patient acquired speech, and none was living independently. 
Seizures were a prominent and early feature in one patient but were 
infrequent in some and absent in others. Social competences were rela-
tively preserved. Body measurements at birth were normal or slightly 
lower than normal, but growth velocity decreased during the first or 
second year of life, and short stature with shortening of both the trunk 
and limbs was present in all adult patients. Facial features included a 
prominent forehead, mild synophrys, a sunken nasal bridge, a promi-
nent bulbous nasal tip, and full lips (Fig. 1). No endocrine anomalies 
were noted, and adult patients had gone through pubertal develop-
ment. Neuroimaging was available for six patients: patient 8 showed 
prenatal-onset hydrocephalus, whereas patient 9 showed perisylvian 
polymicrogyria, small basal ganglia, and reduced white matter mass 
(Supplementary Fig. 1); the other four patients showed moderate 
cerebral atrophy with nonspecific changes in white matter. Distinct 
features that permitted these individuals to be distinguished from 
among the large group of persons with severe IDD included the facial 
dysmorphisms and the skeletal dysplasia with short stature, premature 
carpal ossification, platyspondyly, longitudinal metaphyseal striations, 
and small epiphyses (see Fig. 1 for details). For more radiographic 
details, see also the previous clinical reports for patients 1 and 2 
(ref. 8) and for patient 5 (corresponding to patient 1 in ref. 9).
Identification of NANS mutations and functional analysis
Exome sequencing was performed on genomic DNA from patients 
1–4. After passage through the filtering pipeline (Online Methods 
and Supplementary Table 1), only one gene, NANS, showed biallelic 
variants in all four patients (Table 1). A small indel just 5` to exon 
4, c.449–10_449–5delGATTACinsATGG, was seen in a heterozygous 
state in all four patients (reference transcript ENST00000210444, NCBI 
reference sequence NM_018946.3). In addition to this shared mutation, 
patients 1 and 2 (who are sisters) had a single-nucleotide insertion 
predicted to result in a frameshift with early truncation (c.389_390insT, 
p.Lys131Glnfs*8), whereas patients 3 and 4 (who are brother and sis-
ter) had a mutation of a canonical splice donor site (c.448+1G>A). 
Computational haplotype reconstruction using exome data identified 
a specific haplotype encompassing a region of 1.38 Mb on chromosome 
9 (from 100,388,119 (rs10817858) to 101,767,385 (rs41305481) bp) in 
the four individuals carrying the intronic indel, indicative of a com-
mon origin for this variant. Sanger sequencing was used to confirm 
the mutations and to verify segregation with disease in all families. 
To test for the pathogenicity of the identified variants, NANS cDNA 
was retrotranscribed from fibroblast or lymphoblastoid cell RNA from 
patients 1, 3, and 4, as well as from the parents of patients 3 and 4, 
incubated with or without cycloheximide, PCR amplified, and ana-
lyzed by capillary electrophoresis (Supplementary Fig. 2). The c.449–
10_449–5delGATTACinsATGG indel (patients 1–4) resulted in very 
low levels of mRNA, with the presence of wild-type mRNA as well 
as an isoform lacking both exons 3 and 4 (in frame); in the presence 
of cycloheximide, this allele seemed to produce additional abnormal 
isoforms, which apparently were subject to nonsense-mediated RNA 
decay (NMD). The c.448+1G>A variant (patients 3 and 4) produced 
two splicing isoforms, one lacking both exons 3 and 4 (similar to the 
previous mutation) and expressed at levels comparable to the wild-type 
allele and an out-of-frame isoform lacking exon 3 and part of exon 4 
that was detected at very low levels. The exonic insertion c.389_390insT 
(patients 1 and 2) triggered NMD, as demonstrated by sequencing 
RT–PCR clones obtained from cells with or without cycloheximide 
treatment. Thus, all three mutations resulted either in unstable or non-
functional NANS mRNA or in reduced levels of wild-type transcripts. 
We then screened patients 5–8 by selective PCR amplification of NANS 
exons from genomic DNA and direct bidirectional Sanger sequenc-
ing of the amplicons and found biallelic mutations in all the patients, 
including four missense mutations and one triplet insertion leading to 
the duplication of one amino acid (Fig. 2 and Table 1).
Investigation of patient 9, the youngest patient in our series, fol-
lowed a different course; this patient was enrolled into the TIDEX 
study, which combines genomics and metabolomics screening10. 
Metabolomic screening had identified an unusual metabolite, 
N-acetyl-d-mannosamine (ManNAc), in the plasma and urine of this 
child. Among the variants identified by exome sequencing in this 
patient, two missense mutations in NANS stood out as ManNAc-6-
phosphate is the substrate of the NANS enzyme and malfunction of 
this enzyme could account for the accumulation of ManNAc in body 
fluids. The NANS variants identified in patient 9 were confirmed via 
Sanger sequencing and were shown to segregate correctly in the fam-
ily. Of note, the exome results for patients 1–5 were examined for pos-
sible pathogenic mutations in the GNE gene, but none were observed. 
After this stage, the data from patients 1–8 and those from patient 9 
were combined for all subsequent studies.
Mapping of mutations on the three-dimensional protein 
model of NANS
The NANS protein was modeled as a homodimer on the basis of the 
Neisseria meningitidis homolog, as well as recent results supporting 
dimer formation for the human protein11. Of the predicted amino acid 
changes (Table 1), four mapped in or near the active site: p.Lys131Gln, 
p.Gly133Val, p.Tyr188His, and p.Pro189Leu. It is likely that any of 
these would affect the catalytic activity of the enzyme, by changing 
the ability of the protein to bind substrate (Lys131 and Tyr188 are 
also predicted to make hydrogen bonds with substrates11; Fig. 2), by 
changing the pocket shape (p.Gly133Val), or by affecting functional 
residues in the active site (Pro189 is located right next to Tyr188). 
The p.His29Asn and p.Arg237Cys substitutions are localized at the 
dimer interface and likely affect protein folding, stability, and/or dimer 
formation. Although close to the dimer interface, the Ile327 residue 
that is duplicated is not involved in protein contacts in our model, the 
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duplication could be affecting folding instead. 
Finally, p.Arg151His is located on the sur-
face of the protein and away from the dimer 
interface and substrate-binding site, possi-
bly interfering with folding or with a critical 
protein interaction.
NANS mutations lead to accumulation of  
N-acetylmannosamine in vivo
Next-generation metabolic screening (Online Methods) was first 
applied to the cerebrospinal fluid (CSF) of patient 9 (Fig. 3 and 
Supplementary Table 2) and then to the plasma of patients 1–4 and 9 
(data not shown), leading to the identification of an unusual com-
pound, ManNAc, in all five patients. Quantitative nuclear magnetic 
resonance (NMR) spectroscopy was then used to determine the con-
centration of ManNAc in available urine samples from patients. In 
patients 1–4 and 8 (all adults at the time of study), the urine con-
centration of ManNAc ranged from 41 to 98 Mmol/mmol creatinine 
(reference values, <10 Mmol/mmol creatinine), whereas the excretion 
of ManNAc was highest (295 Mmol/mmol creatinine) in patient 9 (age 
3 years). NMR spectroscopy was applied to homogenates of cultured 
fibroblasts to explore the intracellular sialic acid synthesis pathway. In 
fibroblasts from two unrelated patients (patients 3 and 9), this analysis 
showed increased intracellular levels of ManNAc-6-phosphate rather 
than free ManNAc in comparison to control cells. NANS can act as a 
NeuNAc phosphate synthase (MIM 605202; Enzyme Commission (EC) 
database 2.5.1.57). This may account for the accumulation of ManNAc 
in body fluids and ManNAc-6-phosphate within cells in patients. 
The free NeuNAc concentration in patient-derived fibroblasts was 
normal (Supplementary Table 2). Finally, we evaluated whether 
deficient NANS activity would lead to systemic deficiency for sialic 
acid. The concentration of free NeuNAc was evaluated in the urine 
of five patients from four families (relative to creatinine excretion) 
as well as in the CSF of patient 9. In all patients, normal values were 
found (Supplementary Table 3), suggesting that there was no sys-
temic depletion of free neuraminic acid. Analysis of plasma transfer-
rin and apolipoprotein C-III isoforms, to evaluate the biosynthesis of 
N- and O-linked glycans, respectively, has been carried out repeatedly 
on several of the patients in the clinical setting, with these analyses 
giving normal results (Supplementary Table 4). This evidence further 
contributes to the notion that peripheral sialylation is not significantly 
affected, despite NANS deficiency.
NANS mutations impair enzyme activity
In two preliminary experiments, we explored the sialylation of pro-
teins and lipids at the cell surface of patient-derived and control 
fibroblasts using FITC-labeled Sambucus nigra lectin (which spe-
cifically binds to terminal galactose-bound sialic acid residues) and 
FACS analysis to determine the cellular content of CMP-NeuNAc 
a e g i k
b d f h j l
qponm
r s t u
cFigure 1 Morphological and skeletal features  
of NANS-deficient patients. (a,b) Patient 9 at 
age 6 months (a) and at age 3 years (b).  
(c,d) Patient 8 at age 28 years. (e,f) Patient 4 
at age 24 years. (g,h) Patient 3 at age 28 years. 
(i,j) Patient 2 at age 38 years. (k,l) Patient 1 at 
age 40 years. For patient 9, only the phenotype 
of short limbs is apparent at age 6 months; 
facial dysmorphism with prominent forehead, 
saddle nose, full lips, and coarsening of traits 
is apparent at age 3 years. All adult patients 
have short stature (height between 130 and 
150 cm). All photographs were obtained and 
published with consent. (m–o) Lateral spine 
films showing coronal clefts at birth (patient 8)  
(m) and severe vertebral body dysplasia at 
age 3 years (patient 9) (n); in adulthood, 
the vertebral bodies have a normal shape 
(patient 2) (o). (p,q) At the knees, there are 
metaphyseal striations and small epiphyses 
(epimetaphyseal dysplasia) at age 9 years 
(patient 8) (p); in adulthood, epiphyses remain 
small, whereas metaphyseal striations have 
disappeared (patient 2) (q). (r,s) Advanced 
carpal ossification at age 21 months (patient 9) 
(r) and metaphyseal striations (distal  
radius) with epiphyseal dysplasia at age  
9 years (patient 8) (s). (t,u) Short femoral necks 
and small, irregular capital femoral epiphyses 
(epimetaphyseal dysplasia) at age 3 years,  
7 months (patient 9) (t); in the adult (patient 3), 
short femoral neck and small epiphyses are 
present, but bone and cartilage structure 
appear normal (u). Compare the radiographic 
images of patients 1 and 2 and patient 5, as 
reported earlier8,9.
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and total NeuNAc before and after the addition of 10 mM ManNAc12. 
No differences between patient-derived and control fibroblasts were 
seen, possibly because the concentration of ManNAc used was sub-
stantially higher than what is found physiologically. We then devel-
oped a method to measure NANS enzyme activity in cell lysates 
by incubating lysates with ManNAc-6-phosphate and phosphoe-
nolpyruvate (PEP) and quantifying newly formed NeuNAc by mass 
spectrometry (Fig. 3d). In comparison with fibroblasts from five 
healthy controls (613 o 150 nmol NeuNAc/mg protein, mean o s.d.), 
the three available patient-derived fibroblast lines showed reduced 
production of NeuNAc (163 o 111 nmol NeuNAc/mg protein, mean 
o s.d.) after 24 h of incubation. Fibroblasts from the heterozygous 
father of patients 3 and 4 showed intermediate NANS activity (403 
nmol NeuNAc/mg protein). Although residual activity in this assay 
was high, these results are in agreement with an autosomal recessive 
defect in NANS.
Incorporation of N-acetyl-D-mannose into sialoglycoproteins 
is impaired
We then applied metabolic labeling of sialic acids using propargy-
loxycarbonyl (Poc)-derivatized analogs of ManNAc and NeuNAc 
(ManNPoc and NeuNPoc, respectively)13, in a recently developed 
technique that had been useful in confirming deficient sialic acid 
incorporation in cells deficient for the Golgi transporter of CMP–sialic 
acid14. NeuNPoc, which enters the metabolic pathway downstream of 
the enzymatic step catalyzed by NANS, was incorporated efficiently 
into glycoproteins in all cell lines analyzed, whereas ManNPoc, which 
enters the pathway upstream of the NANS-catalyzed step (Fig. 4), 
was incorporated in fibroblasts from a control and a heterozygote 
for a NANS mutation but not in fibroblasts from patients 3, 8, and 9 
(Fig. 3e). These data confirm the functional impairment of NANS 
activity in the metabolic pathway of sialic acid biosynthesis and pro-
tein sialylation. NANS deficiency should therefore be included on the 
list of congenital disorders of glycosylation (CDGs). Notably, these 
data suggest that exogenous NeuNAc might be used to bypass the 
enzymatic block.
nansa knockdown perturbs zebrafish skeletal development
There are two zebrafish orthologs for the human NANS gene, the 
nansa and nansb genes (see the Online Methods for details). nansa 
is expressed during early embryonic development, including during 
the stages with 50% epiboly in the axis, 1–13 somites at the notochord 
and polster, and 14–19 somites at the hatching gland. Thereafter, 
nansa is strongly expressed in the head, immature eye, myotome, 
optic tectum, and pharyngeal arch skeleton15. The expression pat-
tern of nansb is unknown. We designed morpholino oligonucleotides 
(MOs) that block splicing to knock down both the nansa and nansb 
genes16 (Online Methods). Microinjection of nansa MO into newly 
fertilized zebrafish eggs resulted in embryos with a small head, peri-
cardial edema, and developmental anomalies of the skeleton, high-
lighted by Alcian blue staining, at 6 days post-fertilization (d.p.f.) 
(Fig. 5a,b). Interestingly, nansa morphants showed a complex pheno-
type in the area of the head, including hypoplastic or absent Meckel’s 
cartilage, a lack of basihyal, shortened and abnormal ethmoid plate, 
trabecula, parachordal and palatoquadrate, and absence of the cera-
tobranchial structures (Fig. 5b)17. nansb morphants did not show 
an overt abnormal phenotype even at higher concentrations of the 
MOs (data not shown).
Partial rescue of skeletal development by exogenous NeuNAc
Given the position of Nansa (and NANS in human) in the synthetic 
pathway of NeuNAc, we tested whether the addition of sialic acid 
in zebrafish embryo water would rescue the head and skeleton 
Table 1 Overview of the NANS mutations observed in the nine patients
Genomic DNA posi-
tion on chr. 9 (bp) cDNA changea Exon Protein change Present in databasesb PolyPhen score Provean score
Observed in 
patient(s)
100,819,175 c.85C>A 1 p.His29Asn No Probably damaging Deleterious Pt. 8
100,839,236 c.389_390insT 3 p.Lys131GlnfsTer8 Wellderly (0.0008) NA NA Pts. 1 and 2
100,839,249 c.398G>T 3 p.Gly133Val No Probably damaging Deleterious Pts. 6 and 7
100,839,300 c.448+1G>A 3 Aberrant splicing of exons 3 and 
4 as seen in mRNA studies
ExAC (0.00002633) NA NA Pts. 3 and 4
100,840,462 c.449–10_449– 
5delGATTACinsATGGc
4 Aberrant splicing of exons 3 and 
4 as seen in mRNA studies
ExAC (0.00004947) NA NA Pts. 1 and 2  
Pts. 3 and 4
100,840,478 c.452G>A 4 p.Arg151His Wellderly (0.0008) Probably damaging Neutral Pt. 5 (homozygous)
100,840,588 c.562T>C 4 p.Tyr188His No Probably damaging Deleterious Pt. 9
100,840,592 c.566C>T 4 p.Pro189Leu No Probably damaging Deleterious Pt. 8
100,843,203 c.709C>T p.Arg237Cys No Probably damaging Deleterious Pt. 9
100,845,238 c.981insATC 6 p.Ile327dup No Probably damaging Deleterious Pts. 6 and 7
NA, not applicable.aBased on transcript ENST00000210444 (CCDS6733), NCBI reference sequence NM_018946.3. bThe databases considered included the ExAC database (accessed 
November 2015) and the Wellderly database (accessed January 2016) (see URLs). cThis mutation was flagged as the following two distinct events, both in our pipeline and in the ExAC browser: 
(i) an intronic insertion, chr. 9: g.100840462C>CTGA (http://exac.broadinstitute.org/variant/9-100840462-C-CTGA), and (ii) an intronic deletion, chr. 9: g.100840465GATTAC>G (http://exac.
broadinstitute.org/variant/9-100840465-GATTAC-G). This is due to the fact that both our pipeline and the ExAC pipeline used GATK variant calling software (see URLs). In ExAC data, the ‘two’ 
mutational events have been seen in the same number of individuals of European origin. Sanger sequencing in our samples confirms that the variant is a single mutational event.
TIM barrel
 domain
AFPL 
domain
His29
Arg237
Arg151
Arg151
Lys131
Lys131
Pro189
Tyr188
Ile327ins
Gly133
TIM barrel
domain
TIM barrel
domain
AFPL domain
ManNAc-6-P
PEP
PEP
a b
c
Figure 2 Three-dimensional model of the NANS protein and mapping of 
amino acid residues affected by mutations. (a) Model of the human NANS 
protein, showing one monomer in gray and one monomer in blue. Mutated 
residues are color-coded according to patient, with each allele mapped on a 
separate monomer. Lys131 and Arg151 are shown on both monomers. (b,c) 
Detailed views of the location of the alterations. PEP, phosphoenolpyruvate; 
TIM, triose phosphate isomerase.
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developmental phenotypes of nansa morphants. Addition of sialic 
acid at a concentration of 200 MM resulted in partial rescue of the skel-
etal phenotype, as measured by the reappearance and development 
of Meckel’s cartilage structure; this structure was correctly formed in 
9% of embryos under baseline nansa knockdown conditions but in 
61% of embryos when sialic acid was added to the water (Fig. 5c,d). 
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eFigure 3 Evidence of impaired NANS activity ex vivo and in cell culture.  (a–c) 500-MHz one-dimensional 1H NMR spectra of body fluids and model  
compounds (the horizontal axis shows the chemical shift; the vertical axis  
reflects the relative intensity of a metabolite). (a) CSF from patient 9 contains  
ManNAc at a concentration of 180 MM (reference, <5 MM). “AManNAc C1H”  
represents resonance from the proton on carbon atom number 1 in the alpha  
anomeric form of N-acetylmannosamine; “AManNAc CH3” represents resonance  
from protons in the methyl group in the N-acetyl part of N-acetylmannosamine).  
Resonances of alpha and beta forms of N-acetylmannosamine are shown in the  
insets. (b) Top to bottom, resonances of the alpha and beta forms of ManNAc  
for the inset-relevant part of the CSF spectrum in a in comparison to the spectra for  
ManNAc, GalNAc (N-acetylgalactosamine), and GlcNAc (N-acetylglucosamine). (c) Top to bottom, spectra obtained from the fibroblasts of a control and patient 
8 and the spectrum for a model compound, ManNAc-6-phosphate. (d) NANS enzyme activity in fibroblast lysates. Fibroblast lysates were from five controls 
(Ctr.), the heterozygous father of patients 3 and 4 (Father), and patients 4, 8, and 9. For details on the enzyme assay, see the Online Methods. (e) Metabolic 
labeling of sialylated proteins. Fibroblasts from a control, the heterozygous father of patients 3 and 4, and patients 4, 8, and 9 (Table 1) were incubated with 
peracetylated propargyloxycarbonyl analogs of ManNAc and NeuNAc—ManNPoc and NeuNPoc, respectively (see Fig. 4 for the entry point of these molecules 
in the sialic acid biosynthetic pathway). Cell proteins were detected by immunoblotting using streptavidin-HRP (top) or antibody against GAPDH (bottom) as an 
internal control. In cells from the control and the heterozygous father, both ManNPoc and NeuNPoc result in strong labeling of proteins. In patient-derived cells, 
ManNPoc (which enters the synthetic pathway upstream of NANS) is unable to label proteins, whereas NeuNPoc (which enters the pathway downstream of the 
NANS enzyme) is incorporated efficiently. These findings confirm a metabolic block between ManNAc and NeuNAc, consistent with impaired NANS activity.
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Figure 4 Simplified scheme of N-acetylneuraminic 
acid metabolism in human. Biosynthesis of NeuNAc 
is achieved largely in the cytoplasm, except for the 
CMP–sialic acid synthase (CMAS) reaction, which 
takes place in the nucleus (the nuclear envelope 
and its possible transporters are omitted here for 
simplicity). The synthesis of ManNAc is carried 
out in two steps by the bifunctional enzyme GNE/
ManNAc 6-kinase. NeuNAc synthase (NANS) is 
highlighted in red. CMP–sialic acid is transferred 
by a specific transporter, SLC35A1, into the medial 
and trans-Golgi apparatus, where it is used as a 
substrate for the sialylation of proteins and lipids 
by various sialyltransferases. When sialylated 
glycoproteins and lipids are degraded in the 
lysosome, the free sialic acid released by sialidases 
can diffuse out of the lysosome through the 
lysosomal sialic acid transporter (SLC17A5).  
Free NeuNAc (as well as non-human sialic acid, 
NeuNGc) can be taken up by pinocytosis and 
released into the cytoplasm by the SLC17A5 
transporter. Free sialic acid can then reenter the 
biosynthesis pathway (indicated as ‘salvage’ in  
the scheme). The relative importance of biosynthesis 
and salvage in different cell types and tissues  
is largely unknown. The metabolic scheme also shows the entry points of the two synthetic analogs used in this study, ManPoc and NeuNPoc, with the  
first being upstream and the second downstream of the step catalyzed by NANS.
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Interestingly, the rescue effect of sialic acid was dependent on the tim-
ing of its addition; rescue was observed when sialic acid was added to 
the embryo water right after MO injection but not when it was added 
24 hours post-fertilization (h.p.f.), suggesting that sialic acid has a 
critical role in early embryonic development, potentially in cartilage 
and skeleton cell lineage specification or growth.
DISCUSSION
We present evidence that biallelic deleterious mutations in NANS 
are associated with severe IDD and skeletal dysplasia. First, we iden-
tified ten different NANS variants in nine patients from six unre-
lated families, segregating according to a recessive disease model. 
Second, the NANS mutations impaired the activity of the NeuNAc 
synthase enzyme, as evidenced by reduced enzyme activity and by 
the specific block of ManNAc analog incorporation in cultured cells. 
Third, dysfunction of NANS in vivo was confirmed by the accumu-
lation of substrates of the missing enzyme, ManNAc in body fluids 
and ManNAc-6-phosphate in cultured cells. Finally, inactivation 
of the enzyme activity in zebrafish embryos resulted in a complex 
phenotype including abnormal development of skeletal structures. 
The conclusion that NANS mutations are the cause of the clinical 
phenotype is strengthened by the fact that it was reached by two inde-
pendent approaches. Patients 1–8 were ascertained because of their 
phenotype of intellectual disability and specific skeletal dysplasia, 
and the genomic approach led to identification of NANS mutations 
and to their validation through RNA studies. Patient 9 was subjected 
to metabolomic screening first to elucidate the cause of severe IDD 
and dysmorphisms, leading to the identification of ManNAc in body 
fluids, and this biochemical phenotype allowed us to prioritize NANS 
mutations as the most likely to be pathogenic among the variants 
found subsequently through exome sequencing. Although most of our 
patients were ascertained retrospectively and the clinical assessment 
is heterogeneous, there are indications of different degrees of clini-
cal severity. The study of additional patients is needed to determine 
the clinical spectrum of NANS deficiency and to establish possible 
genotype–phenotype correlations.
The brain contains the highest concentration of total sialic acid 
among human organs18. Sialic acid is present on glycoproteins and 
glycolipids such as the gangliosides, which are particularly abundant 
in nervous tissue, and NANS is highly expressed in the human brain 
(Supplementary Fig. 3). Genetic deficiency of either the sialyltrans-
ferase ST3GAL3 (MIM 604402) or ST3GAL5 (MIM 609056), two 
enzymes that use CMP-NeuNAc to add terminal sialic acid residues 
to the glycosidic antennae of glycoproteins and glycolipids, leads to 
infantile epilepsy and/or developmental arrest, suggesting that appro-
priately sialylated glycoproteins and/or glycolipids are necessary for 
higher brain functions19–22. Mutations affecting the CMP-NeuNAc 
transporter SLC35A1 (MIM 605634; see Fig. 4) result in developmen-
tal disability with ataxia and bleeding diathesis23. The observation of 
IDD in NANS-deficient patients and the brain dysplasia observed in 
two of them underline the relationship between sialylation and neu-
rological functions and suggest that the requirements for sialic acid 
in the developing brain must be met at least partially by endogenous 
synthesis of sialic acid through the NANS pathway.
The short stature and skeletal dysplasia in NANS-deficient indi-
viduals also indicate that NANS-mediated sialic acid synthesis has 
a pivotal role in skeletal development, specifically in growth plate 
cartilage. The skeletal anomalies seen in the zebrafish knockdown 
model support this notion. The avascular nature of cartilage may 
make it dependent on endogenous synthesis. Several of the key players 
in cartilage and bone growth and development, such as chondroitin 
sulfate proteoglycans24, bone sialoprotein25, and osteopontin26, are 
heavily sialylated and are candidates for further studies.
Tests detecting hyposialylated transferrin and apolipoprotein C-
III yielded normal results in our NANS-deficient patients, and there 
was no clinical or laboratory evidence of hyposialylation of plasma 
proteins or clotting factors, suggesting that sialylation of plasma pro-
teins is not greatly affected. How sialylation is achieved with impaired 
NANS activity is unclear. Several lines of explanation can be consid-
ered. First, the mutations in our patients may allow for some residual 
activity; none of our patients had a combination of two bona fide null 
alleles. Second, endogenous NeuNAc synthesis may be rate limiting 
in certain tissues and at certain times, where and when synthetic 
requirements are maximal (such as in the brain, during periods of 
rapid growth before birth and in the first 2 years of life27–29, or in 
cartilage during infancy and childhood) but not in other tissues where 
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Figure 5 Abnormal skeletal development in 
zebrafish with morpholino-mediated knockdown 
of nansa is partially rescued by exogenous 
sialic acid. (a,b) nansa-e3i3 morphants 
(4 ng/nl) display a small head, pericardial 
edema, and abnormal cartilage and skeleton 
development, including hypoplastic or absent 
Meckel’s cartilage (m) and lack of basihyal 
(bh) together with shortened and abnormal 
ethmoid plate (ep), trabecula (tr), parachordal 
(pch), palatoquadrate (pq), and ceratobranchial 
(cb) structures (dorsal and ventral views). ch, 
ceratohyal cartilage. Scale bars, 500 Mm  
in a and 200 Mm in b. (c) 200 MM sialic 
acid partially rescues the abnormal skeletal 
phenotype, as assessed by Meckel’s cartilage 
measurement: P1, complete Meckel’s cartilage; 
P2, incomplete Meckel’s cartilage; P3, absent 
Meckel’s cartilage. Scale bar, 200 Mm.  
(d) The graph  shows the proportion of fish with 
a Meckel’s cartilage phenotype of P1, P2, or P3 
with or without exogenously added sialic acid. For each experimental condition, approximately 10–12 embryos were analyzed (exact numbers are shown 
in the figure); experiments were carried out in triplicate. Error bars, s.d. from triplicate experiments. For nansa morphants, the difference between 
embryos with and without 200 MM sialic acid is statistically significant: *P = 0.05 for P1 embryos, **P = 0.01 for P3 embryos (two-tailed t test). 
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synthetic requirements for sialic acid may be lower. Such a mecha-
nism has been put forward to explain the muscle-restricted phenotype 
of GNE myopathy (MIM 603824)30, a disorder caused by recessive 
mutations in the GNE gene encoding UDP-N-acetylglucosamine 
2-epimerase and ManNAc kinase activities in the sialic acid synthe-
sis pathway (Fig. 4). Third, some tissues may be able to rescue and 
recycle sialic acid derived from the lysosomal breakdown of sialylated 
macromolecules (Fig. 4). A fourth possibility, not mutually exclusive 
with the others, is that nutrition-derived sialic acids may be entered 
into biosynthetic pathways and that this may occur in some tissues, 
such as the liver, but not or to a lesser extent in brain or cartilage. 
The observation of normal levels of free sialic acid in the urine of 
our NANS-deficient patients also indicates that there is no systemic 
depletion of sialic acid.
The role of nutrition-derived sialic acid raises the question of a pos-
sible treatment with oral sialic acid in NANS-deficient individuals, in 
analogy to other glycosylation and sialylation defects, such as CDG1B 
(MIM 602579) and GNE myopathy31, which have been amenable to 
treatment by oral administration of specific sugars. Some of our data 
may point in this direction. When added to patient-derived cells in 
culture, the sialic acid analog NeuNPoc (used because of its detecta-
bility) but not the upstream metabolite ManNPoc was able to bypass 
the enzymatic block and be incorporated into macromolecules. In 
zebrafish embryos, exogenously added sialic acid was able to partially 
recue the developmental phenotype caused by nansa knockdown. 
It is possible that dietary supplementation with sialic acid could 
be beneficial for NANS-deficient patients. There is evidence that 
free sialic acid can be taken up and metabolized by cultured cells32; 
this could occur through pinocytosis and release to the cytoplasm 
by the lysosomal sialic acid exporter (SLC17A5; Fig. 4). In young 
mice and rats, sialic acid injected in the peritoneum is incorporated 
into macromolecules33, and orally administered free sialic acid is 
found in plasma and, subsequently, in the liver and the brain29,33. 
N-glycolylneuraminic acid, a sialic acid analog that is widespread 
in mammals and apes but absent in man because of an evolutionary 
mutation, is found in human tissues as the result of dietary uptake 
from meat products34,35. Altogether, there is evidence suggesting that 
alimentary sialic acids could potentially be taken up and incorporated 
into biosynthetic pathways in human. The relative contributions of 
endogenously synthesized, nutritionally derived, and rescued sialic 
acid in different tissues and at different developmental stages in man 
remain to be investigated and may explain how the consequences of 
NANS deficiency are restricted to the developing brain and cartilage. 
In particular, if the brain pathology in NANS deficiency occurs in the 
first months of life (and perhaps even prenatally), this might be an 
obstacle to efficient treatment. Extensive studies in cell culture and 
in vivo are needed before envisaging any treatment possibility for 
NANS-deficient individuals. Such studies would also have the poten-
tial of clarifying the role of nutritional sialic acid in human.
Human milk contains a high concentration of free oligosaccha-
rides, most of which are sialylated27,28,36,37, as well as free sialic acid. 
These oligosaccharides, which are notably absent from cow’s milk and 
infant formulas, have been attributed numerous functions, includ-
ing stimulating brain development and cognition in infants27,28,37,38. 
Because oral administration of sialic acid in humans is considered 
safe and is well tolerated, nutritional supplementation with sialic acid 
in infancy, gestation, and advanced age has been proposed27–29,37. 
In view of the role of sialic acid and its potential use in nutrition, 
exploring the pathogenesis of brain dysfunction and skeletal dyspla-
sia induced by NANS deficiency is worthwhile, not only because of 
the goal of elaborating therapeutic approaches for NANS-deficient 
individuals but also to shed light on sialic acid metabolism with its 
implications for human health.
URLs. Exome Aggregation Consortium (ExAC) database (accessed 
January 2016), http://exac.broadinstitute.org/; Wellderly database at 
the Scripps Wellderly Genome Resource, Scripps Wellderly Study (La 
Jolla, California) (accessed January 2016), https://genomics.scripps.
edu/browser/files/wellderly/vcf/; PolyPhen-2 software for mutation 
assessment, http://genetics.bwh.harvard.edu/pph2/; Provean software 
for mutation assessment, http://provean.jcvi.org/index.php; Ensembl 
database, http://www.ensembl.org/; Novoalign software, http://www.
novocraft.com/; Gaslini Cell Repository and Biobank, http://dppm.
gaslini.org/biobank/; Leenaards Foundation in Lausanne, http://www.
leenaards.ch/; Treatable Intellectual Disability Endeavor in British 
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org/; Rare Diseases Models and Mechanisms Network, http://www. 
rare-diseases-catalyst-network.ca/index.php; Genome Analysis 
Toolkit (http://www.broadinstitute.org/gatk/); Enzyme Commission 
(EC) database, http://enzyme.expasy.org/.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
ACKNOWLEDGMENTS
We thank M. Filocamo at the Gaslini Biobank (Genoa, Italy) for a fibroblast 
line for patient 1. We thank A. Reymond (CIG, FBM, Université de Lausanne) 
and his laboratory for lymphocyte immortalization. We thank C. Chiesa for 
Sanger sequencing and sample handling and shipment; S. de Boer for excellent 
technical assistance; B. Toh at the University of British Columbia for metabolic 
sample handling; X. Han for Sanger sequencing; B. Sayson for consenting and 
data management; M. Higginson for DNA extraction and sample handling; and 
A. Ghani for administrative assistance. We also thank R. Houben for skillfully 
preparing Figure 4 and A. Bandi for all other figures. We are grateful to our clinical 
colleagues in Dolo, Genoa, Lausanne, Manchester, Paris, Reggio Emilia, Tokyo, 
Treviso, and Vancouver for patient management. A.S.-F. dedicates this paper to 
the memory of Paolo Durand who pointed out the relationship between sialic 
acid metabolism and IDD to him in 1980. Finally, we wish to thank the patients 
reported here as well as their parents for the enthusiasm they showed for our 
research efforts, for their patience, which was challenged by the studies lasting 
many years, and for their repeated donation of biological samples. They have been 
the source of continuous motivation for us.
This work has been supported by funding from the Leenaards Foundation in 
Lausanne, Switzerland; the Faculty of Biology and Medicine of the University of 
Lausanne; the BC Children’s Hospital Foundation (Treatable Intellectual Disability 
Endeavour in British Columbia: First Collaborative Area of Innovation); Genome 
BC (grant SOF-195); the Rare Diseases Foundation; the Rare Diseases Models 
and Mechanisms Network; the Canadian Institutes of Health Research (grant 
301221); and the Dutch Organization for Scientific Research, ZONMW (Medium 
Investment Grant 40-00506-98-9001 and VIDI Grant 91713359 to D.J.L.). The 
zebrafish studies were supported by funding to X.-Y.W. from the Canadian Rare 
Disease Models and Mechanisms Network, the Brain Canada Foundation, the 
Natural Sciences and Engineering Research Council of Canada (NSERC), and 
the Canada Foundation for Innovation (CFI). The informatics infrastructures 
were supported by Genome BC and Genome Canada (ABC4DE Project) as well 
as by the Vital-IT Project of the Swiss Institute of Bioinformatics (SIB; Lausanne, 
Switzerland). C.J.R. is funded by a Canadian Institutes of Health Research New 
Investigator Award. C.D.M.v.K. is a recipient of the Michael Smith Foundation for 
Health Research Scholar Award (Vancouver, Canada). E.G. is supported by a Marie 
Skłodowska-Curie fellowship (MSCA-IF-661491).
AUTHOR CONTRIBUTIONS
C.D.M.v.K., L.B., S. Unger, R.A.W., and A.S.-F. conceived the study and coordinated 
and supervised the different teams. A.S.-F., L.B., C.D.M.v.K., T.D., A.C., M.I.V.A., 
C.J.R., J.H., L.G., L.T., V.C., D.H., D.D., C.B., I.M., and S. Uchikawa recruited the 
patients, reviewed the clinical and radiographic features, and obtained biological 
np
g
© 
20
1
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
np
g
© 
20
1
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
	  	   94	   	  
784 VOLUME 48 | NUMBER 7 | JULY 2016 NATURE GENETICS
15. Link, V., Shevchenko, A. & Heisenberg, C.P. Proteomics of early zebrafish embryos. 
BMC Dev. Biol. 6, 1 (2006).
16. Eisen, J.S. & Smith, J.C. Controlling morpholino experiments: don’t stop making 
antisense. Development 135, 1735–1743 (2008).
17. Javidan, Y. & Schilling, T.F. Development of cartilage and bone. Methods Cell Biol. 
76, 415–436 (2004).
18. Wang, B. & Brand-Miller, J. The role and potential of sialic acid in human nutrition. 
Eur. J. Clin. Nutr. 57, 1351–1369 (2003).
19. Simpson, M.A. et al. Infantile-onset symptomatic epilepsy syndrome caused by a 
homozygous loss-of-function mutation of GM3 synthase. Nat. Genet. 36, 
1225–1229 (2004).
20. Hu, H. et al. ST3GAL3 mutations impair the development of higher cognitive 
functions. Am. J. Hum. Genet. 89, 407–414 (2011).
21. Fragaki, K. et al. Refractory epilepsy and mitochondrial dysfunction due to GM3 
synthase deficiency. Eur. J. Hum. Genet. 21, 528–534 (2013).
22. Boccuto, L. et al. A mutation in a ganglioside biosynthetic enzyme, ST3GAL5, 
results in salt & pepper syndrome, a neurocutaneous disorder with altered glycolipid 
and glycoprotein glycosylation. Hum. Mol. Genet. 23, 418–433 (2014).
23. Mohamed, M. et al. Intellectual disability and bleeding diathesis due to deficient 
CMP–sialic acid transport. Neurology 81, 681–687 (2013).
24. Roughley, P.J., White, R.J. & Santer, V. Comparison of proteoglycans extracted from 
high and low weight–bearing human articular cartilage, with particular reference to 
sialic acid content. J. Biol. Chem. 256, 12699–12704 (1981).
25. Vincent, K. & Durrant, M.C. A structural and functional model for human bone 
sialoprotein. J. Mol. Graph. Model. 39, 108–117 (2013).
26. Sodek, J., Ganss, B. & McKee, M.D. Osteopontin. Crit. Rev. Oral Biol. Med. 11, 
279–303 (2000).
27. Wang, B. Sialic acid is an essential nutrient for brain development and cognition. 
Annu. Rev. Nutr. 29, 177–222 (2009).
28. Wang, B. Molecular mechanism underlying sialic acid as an essential nutrient for 
brain development and cognition. Adv. Nutr. 3, 465S–472S (2012).
29. Sprenger, N. & Duncan, P.I. Sialic acid utilization. Adv. Nutr. 3, 392S–397S 
(2012).
30. Salama, I. et al. No overall hyposialylation in hereditary inclusion body myopathy 
myoblasts carrying the homozygous M712T GNE mutation. Biochem. Biophys. Res. 
Commun. 328, 221–226 (2005).
31. Malicdan, M.C., Noguchi, S., Hayashi, Y.K., Nonaka, I. & Nishino, I. Prophylactic 
treatment with sialic acid metabolites precludes the development of the myopathic 
phenotype in the DMRV-hIBM mouse model. Nat. Med. 15, 690–695  
(2009).
32. Oetke, C. et al. Evidence for efficient uptake and incorporation of sialic acid by 
eukaryotic cells. Eur. J. Biochem 268, 4553–4561 (2001).
33. Nöhle, U. & Schauer, R. Uptake, metabolism and excretion of orally and intravenously 
administered, 14C- and 3H-labeled N-acetylneuraminic acid mixture in the mouse 
and rat. Hoppe-Seyler’s Z. Physiol. Chem. 362, 1495–1506 (1981).
34. Tangvoranuntakul, P. et al. Human uptake and incorporation of an immunogenic 
nonhuman dietary sialic acid. Proc. Natl. Acad. Sci. USA 100, 12045–12050 
(2003).
35. Samraj, A.N. et al. A red meat–derived glycan promotes inflammation and cancer 
progression. Proc. Natl. Acad. Sci. USA 112, 542–547 (2015).
36. Bode, L. Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology 
22, 1147–1162 (2012).
37. Fuhrer, A. et al. Milk sialyllactose influences colitis in mice through selective 
intestinal bacterial colonization. J. Exp. Med. 207, 2843–2854 (2010).
38. Röhrig, C.H., Choi, S.S. & Baldwin, N. The nutritional role of free sialic acid, a 
human milk monosaccharide, and its application as a functional food ingredient. 
Crit. Rev. Food Sci. Nutr. doi:10.1080/10408398.2015.1040113 (2016).
materials from patients. A.S.-F., S. Unger, and G.N. reviewed the radiographic 
data. J.R. performed the bone marrow studies. Andrea Rossi reviewed the cerebral 
imaging. K. Harshman, B.J.S., B.C.-X., S.B., B.R.-B., H.R., C.R., M.T.-G., W.W.W., 
and A.d.B. were responsible for exome sequencing, haplotype reconstruction, 
Sanger sequencing, database studies, and mRNA–cDNA studies. R.A.W., L.A.J.K., 
E.v.d.H., and U.F.E. performed the metabolomics studies. Antonio Rossi studied 
ManNAc incorporation in fibroblasts. T. Hennet performed the lectin binding 
studies. A.A., K. Huijben, F.Z., and D.J.L. performed the NANS enzyme assays. 
D.J.L., A.A., T. Heisse, and T.B. studied the incorporation of sialic acid precursors 
in lymphocytes and fibroblasts. E.G. and G.S.-F. obtained the NANS three-
dimensional model and mapped the affected amino acid residues. X.-Y.W. and 
K.B.-A. generated and phenotyped the zebrafish model. C.D.M.v.K. and A.S.-F. 
prepared the manuscript with contributions from all co-authors. All co-authors 
edited and reviewed the final manuscript. 
COMPETING FINANCIAL INTERESTS
The authors declare no competing financial interests.
Reprints and permissions information is available online at http://www.nature.com/
reprints/index.html.
1. Salvador-Carulla, L. et al. Intellectual developmental disorders: towards a new name, 
definition and framework for “mental retardation/intellectual disability” in ICD-11. 
World Psychiatry 10, 175–180 (2011).
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental 
Disorders 5th edn (American Psychiatric Publishing, 2013).
3. de Ligt, J. et al. Diagnostic exome sequencing in persons with severe intellectual 
disability. N. Engl. J. Med. 367, 1921–1929 (2012).
4. Gilissen, C. et al. Genome sequencing identifies major causes of severe intellectual 
disability. Nature 511, 344–347 (2014).
5. van Karnebeek, C.D.M. & Stockler, S. Treatable inborn errors of metabolism causing 
intellectual disability: a systematic literature review. Mol. Genet. Metab. 105, 
368–381 (2012). 
6. Bonafé, L. et al. Nosology and classification of genetic skeletal disorders: 2015 
revision. Am. J. Med. Genet. 167, 2869–2892 (2015).
7. Superti-Furga, A., Bonafé, L. & Rimoin, D.L. Molecular-pathogenetic classification 
of genetic disorders of the skeleton. Am. J. Med. Genet. 106, 282–293 (2001).
8. Camera, G., Camera, A., Di Rocco, M. & Gatti, R. Sponastrime dysplasia: report 
on two siblings with metal retardation. Pediatr. Radiol. 23, 611–614 (1993).
9. Geneviève, D. et al. Exclusion of the dymeclin and PAPSS2 genes in a novel form 
of spondyloepimetaphyseal dysplasia and mental retardation. Eur. J. Hum. Genet. 
13, 541–546 (2005).
10. Tarailo-Graovac, M. et al. Exome sequencing and the management of neurometabolic 
disorders. N. Engl. J. Med. (in the press).
11. Cotton, T.R., Joseph, D.D., Jiao, W. & Parker, E.J. Probing the determinants of 
phosphorylated sugar-substrate binding for human sialic acid synthase. Biochim. 
Biophys. Acta 1844, 2257–2264 (2014).
12. Galuska, S.P. et al. Quantification of nucleotide-activated sialic acids by a combination 
of reduction and fluorescent labeling. Anal. Chem. 82, 4591–4598 (2010).
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ONLINE METHODS
Ethics. The studies were approved by the ethics boards of the following insti-
tutions: BC Children’s and Women’s Hospital, University of British Columbia 
(12-00067) and the Ethics Board of the Lausanne University Hospital. Research 
was performed according to the countries’ ethics code of conduct. Parents or 
guardians provided written informed consent for the biochemical and genetic 
analysis and the publication of photographs and clinical data.
Identification of mutations in NANS. For patients 1–4, fragmented genomic 
DNA was purified with AMPure XP beads, and its quality was assessed with an 
Agilent Bioanalyzer. Preparation of the exome-enriched, barcoded sequencing 
libraries was performed using the SureSelect Human All Exon v4 kit (Agilent 
Technologies). The final libraries were quantified with a Qubit Fluorometer 
(Life Technologies), and the correct size distribution was validated on an 
Agilent Bioanalyzer. Libraries were then sequenced on a HiSeq 2000 machine 
(Illumina), generating 100-bp paired-end reads. Raw reads were aligned onto 
the hg19 reference genome using Novoalign software. Data cleanup and vari-
ant calling were performed according to GATK Best-Practices recommenda-
tions39. Variant filtering was performed with ANNOVAR40 and with in-house 
Perl and Bash scripts, available upon request. For patient 9, who was genotyped 
in the Vancouver laboratory, similar procedures were used. To investigate 
the presence of a possible ancestral haplotype carrying the NANS indel in 
patients 1–4, we extracted all SNP alleles that were present in the region sur-
rounding NANS and that were listed in the dbSNP database. Local genotypes 
were then scored, and likely haplotypes were constructed. In patients 5–8, 
all individual exons of NANS were amplified from genomic DNA (primer 
sequences available upon request) and sequenced directly in both directions 
using the Sanger method. For patient 9, exome sequencing was performed 
as part of the TIDEX gene discovery project using the Agilent SureSelect kit 
and an Illumina HiSeq 2000 instrument. The sequencing reads were aligned 
to human reference genome version hg19 (35× coverage), and rare variants 
were identified and assessed for their potential to disrupt protein function. 
In total, we identified 19 candidate genes affected by two rare heterozygous 
variants. Of these, NANS stood out as the most interesting functional candi-
date because of the preexisting next-generation metabolomics data. Sanger 
sequencing in the patient and his parents confirmed the mutations and their 
segregation with disease.
Construction of a three-dimensional protein model for NANS and map-
ping of the predicted mutations. A molecular model for dimeric full-length 
human NANS protein was generated with I-TASSER41, using as templates 
the N. meningitidis homolog42 and the human AFPL domain43 structures. 
The model illustrations were generated with the PyMol Molecular Graphics 
System, version 1.7.4 (Schrödinger).
mRNA studies. Lymphoblastoid cell lines were cultured in suspension 
under 5% CO2 in T25 flasks with RPMI-1640 medium supplemented with 
GlutaMAX-I (Gibco) containing 10% FBS (Gibco, 10270-106) and 1% peni-
cillin-streptomycin (Gibco), whereas fibroblasts were cultured in DMEM 
(1×) with 1 g/L d-glucose l-glutamine (Gibco), supplemented with 10% FBS 
and 1% penicillin-streptomycin. To test for NMD, treatment with cyclohex-
imide (Sigma-Aldrich) was performed in parallel with controls by incubating 
10 million cells for 4 h in the presence of medium supplemented with 28 Mg/ml 
of this chemical, according to published protocols44. Total RNA was isolated 
from both cycloheximide-treated and untreated fibroblast and lymphoblast 
cultures using the Direct-zol RNA MiniPrep kit (Zymo Research) accord-
ing to the manufacturer’s instructions. cDNA was prepared following the 
retrotranscription of 500 ng of RNA, using the PrimerScript RT–PCR kit 
(Clontech) and random hexamers; 10 ng of the produced cDNA was then 
used as template for downstream experiments. A specific primer pair spanning 
the exon–exon junctions for exons 1 and 2 and exons 5 and 6 (for sequences, 
see Supplementary Table 5) was designed to amplify the regions of the NANS 
cDNA containing all mutations studied. RT–PCR was performed in triplicate 
in a final reaction volume of 20 Ml containing 5× Green GoTaq reaction buffer 
(Promega), 100 MM dNTP mix, 200 nM of each primer, and 0.1 U of GoTaq 
G2 DNA Polymerase (Promega). Reactions were incubated at 94 °C for 1 min 
followed by 35 cycles at 93 °C for 20 s, 64.1 °C for 30 s, and 72 °C for 1 min. 
The obtained products were resolved by capillary electrophoresis with the 
eGene HDA-GT12 Multi-Channel Genetic Analyzer, quantified, and finally 
ligated into the pCRII-TOPO TA vector (Invitrogen). Ligation mixes were 
used to transform chemically competent TOP-10 Escherichia coli (Invitrogen), 
and individual clones (at least 30 clones per electrophoresed sample) were 
sequenced by direct Sanger sequencing using BigDye terminator v1.1 (Applied 
Biosystems) with insert-specific primers. Sequencing data were analyzed using 
CLC Bio software (Qiagen) and compared with the corresponding human 
reference sequence (build hg19).
Next-generation metabolomics analysis. High-resolution untargeted 
metabolomics analysis of body fluids was performed using UHPLC–QTOF 
mass spectrometry. CSF and heparinized plasma samples were deprotein-
ated in methanol:ethanol solution (50:50; 100 Ml of each sample plus 400 Ml 
of methanol:ethanol solution). Samples were analyzed in duplicate. A 2-Ml 
sample was applied to an Acquity HSS T3 reverse-phase column (100 
× 2.1 mm; 100 Å, 1.8 Mm), and an Agilent 6540 UHD accurate mass 
UHPLC–QTOF mass spectrometer with acquisition in positive and negative 
modes was used. The buffers in positive mode consisted of buffer A (0.1 for-
mic acid in water) and buffer B (0.1 formic acid in water:methanol solution 
(1:99)); in negative mode, the buffers consisted of buffer A (10 mM acetic 
acid) and buffer B (10 mM acetic acid in water:methanol solution (1:99)). 
After analysis and XCMS alignment, bioinformatics software developed in 
house showed the features (exact m/z, retention time, and intensity) deriv-
ing from metabolites that were significantly different in intensity in the 
patient sample as compared to age- and sex-matched controls. The Human 
Metabolome Database 3.0 was used to putatively annotate significantly dif-
ferent features45. This technique, also referred to as ‘next-generation meta-
bolic screening’, was clinically validated using body fluids from patients for 
25 known inborn errors of metabolism and introduced in the Nijmegen 
patient care research setting.
Proton (1H) NMR spectroscopy of body fluids, fibroblast homogenates, and 
model compounds of N-acetylated sugars was performed on a 500-MHz NMR 
spectrometer with minor modifications46. The NMR spectrum for fibroblasts 
was recorded on a homogenate obtained after sonicating 7.5 × 106 cells in 
2H2O (D2O). The homogenate was deproteinated over a 10 kDa filter and 
trimethylsilyl-2,2,3,3-tetradeutero propionic (TSP) acid was used as a chemi-
cal shift reagent in the NMR spectrum. The model compounds ManNAc, 
N-acetylgalactosamine, and N-acetylglucosamine were purchased from Sigma 
Chemicals, and ManNAc-6-phosphate was purchased from Carbosynth 
(disodium salt).
Lectin staining on cultured fibroblasts. Fibroblasts were cultured for 48 h in 
DMEM supplemented with 10% FCS and 0, 1, or 10 mM ManNAc. After incu-
bation, fibroblasts were trypsinized, washed twice in Hank’s buffered saline 
solution (HBSS) containing 1% FCS, and resuspended at 1 × 106 cells/ml. 
Aliquots of 1 × 105 cells (in 100 Ml) were incubated with 1 mM FITC-labeled 
S. nigra lectin (Vector Labs) in HBSS for 20 min on ice, washed twice in HBSS 
containing 1% FCS, and analyzed by flow cytometry using a FACSCanto II 
cytometer (BD Biosciences).
N-acetylmannosamine incorporation in fibroblast culture. Skin fibroblasts 
were cultured and expanded in DMEM supplemented with 10% FCS at 37 °C in 
5% CO2 and were then cultured for 24 h in the absence of FCS. For the incorpo-
ration experiment, mycoplasma-negative cells were incubated in DMEM, with-
out serum and antibiotics, with or without 10 mM ManNAc, at 37 °C in 5% CO2 
for 48 h. After incubation, the medium was removed, and cells were harvested 
in PBS and collected by low-speed centrifugation. The cell pellet was sonicated 
in buffer containing 20 mM Tris-HCl, pH 8.0, 5 mM EDTA, 150 mM NaCl, 1 Mg 
aprotinin, and 1 mM PMSF, and the lysate was ultracentrifuged at 30,000g for 
1 h at 4 °C to pellet the membrane fraction. In the clear supernatant, protein 
content was determined with the BCA protein assay (Pierce), and aliquots of 
the supernatant were ultrafiltered with an Amicon Ultra-0.5 Centrifugal Filter 
Unit with a cutoff of 3 kDa to separate sialic acid from soluble protein. The 
dried filtrate was used for sialic acid analysis. The CMP–sialic acid content 
was discriminated from free sialic acid by reduction: labeling with the fluoro-
phore 1,2-diamino-4,5-methylenedioxybenzene (DMB) requires free keto as 
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well as carboxyl groups on the sialic acid molecule, and reduction of the keto 
group before the labeling process precludes the labeling of non-activated sialic 
acid12. Each lyophilized sample was split in two aliquots. To reduce free, non-
activated monosaccharides, the dried samples were dissolved in 0.2 M sodium 
borate buffer, pH 8.0, containing 0.2 M sodium borohydride, incubated at 0 °C 
overnight, and dried in a SpeedVac concentrator. For fluorescent labeling of 
sialic acid, samples were hydrolyzed in 0.2 N trifluoroacetic acid (TFA) for 
4 h at 80 °C, dried, redissolved twice in methanol, and dried again. To label 
sialic acids with DMB, hydrolysates were dissolved in 80 Ml of 0.64 mg/ml 
DMB in 500 mM 2-mercaptoethanol, 9 mM sodium hydrosulfite, and 20 mM 
TFA and incubated for 2 h at 56 °C. Reactions were stopped by adding 
10 Ml of 0.2 M NaOH. The derivatized sialic acids were quantified by HPLC 
on a binary pump system (1525 Binary HPLC Pump, Waters) coupled to a 
fluorescence detector (2475 Multy L Fluorescence Detector, Waters) set at 
an excitation wavelength of 372 nm and an emission wavelength of 456 nm. 
Chromatography was carried out at room temperature with a LichroCART 
250-4 Superspher 100 RP18 (250 × 4 mm) column (Merck) and LiChrospher 
100 RP18 (25 × 4 mm) (Merck) as a pre-column. Mobile phases were metha-
nol:acetonitrile:water:TFA (4:4:92:0.1) and methanol:acetonitrile:water:TFA 
(45:45:10:0.1), and the flow rate was 0.3 ml/min12.
Measurement of the N-acetylneuraminic acid content in fibroblasts. 
Fibroblasts (~2.5 million cells) in 250 Ml of 50 mM Tris-HCl, pH 7.5, were 
sonicated on ice (3 × 8 s) and then centrifuged (10,000g for 10 min at 4 °C). To 
100 Ml of the supernatant (lysate) was added [3-13C]NeuNAc (o23 MM) as an 
internal standard, and the solution was applied to a 30-kDa filter cup (Amicon 
Ultra) with 10 Ml of 2% formic acid in the collection tube for deproteination. 
After centrifugation at 13,000g for 30 min at 4 °C, the flow-through was used 
for quantification of NeuNAc by mass spectrometry according to published 
methods47,48. Assays were performed in duplicate, and NeuNAc levels were 
normalized to protein levels in the lysates.
Determination on NANS activity in fibroblast cultures. Skin fibroblasts were 
obtained from affected individuals and healthy controls and cultured at 37 °C 
under 5% CO2 in culture medium E199, supplemented with 10% FCS and 1% 
penicillin-streptomycin. All cultures were tested for mycoplasma infection before 
growth in culture. We developed an assay for NANS activity as follows: fibroblasts 
(~7.5 million cells) in 300 Ml of 50 mM Tris-HCl, pH 7.5, were sonicated on ice 
(3 × 8 s) and then centrifuged (10,000g for 10 min at 4 °C). The supernatant 
(lysate) was used for the determination of protein concentration (BCA assay) 
and for enzyme activity assays. Incubation of ManNAc-6-phosphate disodium 
salt (Carbosynth; 2 mM) and 20 Ml of lysate was carried out at 37 °C in duplicate 
in a total reaction volume of 100 Ml. The reaction buffer consisted of 50 mM 
Tris-HCl, pH 7.5, 3 mM PEP (Roche), and 1 mM MgCl2. Control incubations 
without ManNAc-6-phosphate were subtracted as a blank from the incubations. 
The reactions were allowed to proceed for 2.5, 5, and 24 h and then stopped by 
freezing (–20 °C). Samples (100 Ml) were deproteinated by the addition of 50 Ml 
of [3-13C]NeuNAc (o23 MM) as an internal standard and centrifuged at 13,000g 
for 30 min at 4 °C on a 30-kDa filter cup (Amicon Ultra); the flow-through was 
collected in 10 Ml of 2% formic acid. NeuNAc levels were quantified by mass 
spectrometry as described47,48 and normalized for protein level in the lysates.
Metabolic labeling of sialic acids and glycoproteins in fibroblast cultures. 
Skin-derived fibroblasts were cultured in M199 medium (PAN biotech) sup-
plemented with 10% FBS (PAA), non-essential amino acids (NEAA; Gibco), 
and 100 U/ml penicillin-streptomycin (Gibco) and tested for mycoplasma 
contamination. Eighty percent confluent cells were further grown for 5 d in 
medium containing 15 MM Ac5NeuNAc, Ac4ManNPoc, or Ac5NeuNPoc. 
Cells were collected in PBS by scraping and lysed in 150 mM NaCl, 50 mM 
Tris-HCl, pH 7.5, 5 mM EDTA, 0.1% SDS, 1% Triton X-100, and 1× Complete 
protease inhibitor cocktail (Roche). To biotinylate propargyloxycarbonyl- 
containing glycoproteins, cell lysates were resolved on 10% SDS gels, blotted 
onto PVDF membrane. Unoccupied membrane sites were blocked with 5% 
dry milk in PBS, and the membrane was incubated with 500 MM CuSO4, 250 
MM l-histidine, 100 MM azide-PEG3-biotin, and 500 MM sodium ascorbate 
in PBS for 1 h at 37 °C. Biotinylated sialoglycoproteins were visualized by 
incubation with horseradish peroxidase (HRP)-conjugated streptavidin (GE 
Healthcare), followed by signal development with SuperSignal West Femto 
Maximum-Sensitivity Substrate (Thermo Fisher Scientific). As a loading 
control, immunostaining was performed with antibody to GAPDH (Abcam, 
ab8245) on the same membranes. On the basis of this protocol, we found that 
NeuNPoc at 15 MM concentration would readily label cellular sialoglycans after 
5 d of incubation. For ManNPoc at the same concentration of 15 MM, longer 
incubation times were required to obtain strong labeling of glycoconjugates 
in fibroblasts from healthy donors (Fig. 5).
Determination of glycosylation of plasma proteins. Analysis of plasma trans-
ferrin N-glycosylation was carried out by isoelectric focusing49 as well as by 
nanochip QTOF mass spectrometry50. The mucin-type O-linked glycosylation 
of plasma apolipoprotein C-III was analyzed by isoelectric focusing49.
Zebrafish studies. Zebrafish were maintained at 28.5 °C on a 10-h dark/14-h 
light cycle. Protocols for experimental procedures were approved by the 
Research Ethics Board of St. Michael’s Hospital (Toronto) (protocol ACC660). 
To knock down gene expression, we used splicing-blocking MOs for nansa 
and nansb knockdown plus a standard control MO (for sequences, see 
Supplementary Table 5). The zebrafish nansa gene has six exons, with the 
translation start codon in exon 1 (ENSDART00000067086; chromosome 1). 
We designed a splicing-blocking MO nansa-e3i3 that could block the splic-
ing donor of exon 3, resulting in intron 3 retention and a truncated protein 
in translation (data not shown). nansb also has six exons, with the transla-
tion start codon in exon 1 (ENSDART00000169540; chromosome 25), and 
we designed an MO nansb-e1i1 to block the splicing donor site of exon 1 
of nansb, resulting in intron 1 retention and a truncated Nansb protein 
(data not shown). MOs were synthesized by Gene Tools (for sequences, 
see Supplementary Table 5) and microinjected individually or in combi-
nation into zebrafish embryos at the one-cell stage. We injected embryos 
individually with nansa-e3i3 (4 ng/nl) and nansb-e1i1 (4 ng/nl) MOs, and 
also coinjected embryos with nansa-e3i3 (4 ng/nl) and nansb-e1i1 (4 ng/nl). 
Each injection was repeated at least three times. Knockdown of nansa and 
nansb was assessed by RT–PCR to confirm splicing defect and retention 
of the intron (data not shown). For control MO, embryos were injected 
at the one-cell stage with 4 ng/nl. At least 30 embryos were injected per 
condition and included in the analysis. At 24 h.p.f., embryos were manually 
dechorionated. Total RNA was extracted from embryos at 48 h.p.f. using 
TRIzol reagent (Invitrogen). The RNA concentration of each sample was 
determined using a NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies). RNA integrity was verified by 1% agarose gel electrophoresis. 
The RNA template was converted into cDNA using Superscript II reverse 
transcriptase (Invitrogen) and used to amplify a nansa-specific cDNA (for 
primer sequences, see Supplementary Table 5).
To visualize the cartilaginous structures, Alcian blue (Sigma) was dissolved in 
70% ethanol and 1% hydrochloric acid. Zebrafish embryos (6 d.p.f.) were fixed 
in 4% paraformaldehyde overnight at 4 °C and maintained in 100% methanol at 
−20 °C until processing. The embryos were washed with PBS containing 0.1% 
Tween-20 (PBST). The embryos were bleached in 30% hydrogen peroxide for 
2 h, washed with PBST, and transferred into Alcian blue solution. Embryos were 
stained overnight at room temperature. The embryos were rinsed four times 
with acidified ethanol (HCl-EtOH); 5% hydrochloric acid and 70% ethanol. 
Embryos were rinsed for 20 min in HCl-EtOH and rehydrated by washing 10 
min in an HCl-EtOH/H2Od series (75%, 25%, 50%, 50%, 25%, and 75%) and 
100% H2Od. Embryos were stored in 1 ml of glycerol-KOH.
39. Van der Auwera, G.A. et al. From FastQ data to high confidence variant calls: the 
Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinformatics 43, 
1–33 (2013).
40. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic 
variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 
(2010).
41. Yang, J. et al. The I-TASSER Suite: protein structure and function prediction. Nat. 
Methods 12, 7–8 (2015).
42. Gunawan, J. et al. Structural and mechanistic analysis of sialic acid synthase NeuB 
from Neisseria meningitidis in complex with Mn2+, phosphoenolpyruvate, and 
N-acetylmannosaminitol. J. Biol. Chem. 280, 3555–3563 (2005).
43. Hamada, T. et al. Solution structure of the antifreeze-like domain of human sialic 
acid synthase. Protein Sci. 15, 1010–1016 (2006).
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Peripheral Osteolysis in Adults Linked to ASAH1 (Acid Ceramidase) Mutations:
A New Presentation of Farber’s Disease
Luisa Bonaf!e,1 Ariana Kariminejad,2 Jia Li,3 Beryl Royer-Bertrand,3 Virginie Garcia,4 Shokouholsadat Mahdavi,5
Bita Bozorgmehr,2 Ralph L. Lachman,6 Laur!eane Mittaz-Crettol,1 Belinda Campos-Xavier,1 Sheela Nampoothiri,7
Sheila Unger,1 Carlo Rivolta,3 Thierry Levade,4 and Andrea Superti-Furga1
Objective. To establish a diagnosis and provide
counseling and treatment for 3 adult patients from one
family presenting with peripheral osteolysis.
Methods. Following clinical and radiographic
assessment, exome sequencing, targeted gene rese-
quencing, and determination of enzyme activity in cul-
tured fibroblasts were performed.
Results. The proband (age 40 years) had a history
of episodic fever and pain in childhood that subsided
around puberty. He and 2 of his older sisters (ages 58 and
60 years, respectively) showed adult-onset progressive
shortening of fingers and toes with redundancy of the over-
lying skin. Radiographs showed severe osteolysis of the
distal radius and ulna, carpal bones, metacarpal bones,
and phalanges. Sequencing of the known genes for reces-
sively inherited osteolysis, MMP2 and MMP14, failed
to show pathogenic mutations. Exome sequencing re-
vealed compound heterozygosity for mutations c.505T>C
(p.Trp169Arg) and c.760A>G (p.Arg254Gly) in ASAH1,
the gene coding for acid ceramidase. Sanger sequencing
confirmed correct segregation in the family, and enzyme
activity in fibroblast cultures from the patients was
reduced to ~8% of that in controls, confirming a diagno-
sis of Farber’s disease.
Conclusion. Our findings indicate that hypomor-
phic mutations in ASAH1 may result in an osteoarticular
phenotype with a juvenile phase resembling rheumatoid
arthritis that evolves to osteolysis as the final stage in the
absence of neurologic signs. This observation delineates
a novel type of recessively inherited peripheral osteolysis
and illustrates the long-term skeletal manifestations of
acid ceramidase deficiency (Farber’s disease) in what
appear to be the oldest affected individuals known so far.
While resorption of bone and cartilage structures
is a frequent finding in inflammatory conditions, there
are at least 3 forms of osteolysis that are genetically
determined (1). The more common, dominant form,
multicentric carpotarsal osteolysis with or without
nephropathy (MIM ID #166300), is caused by heterozy-
gous mutations in the MAFB gene; its pathogenesis
remains unclear. In addition, there are recessively inher-
ited forms that have considerable phenotypic overlap
and are known by different names, including Torg syn-
drome or Winchester syndrome (MIM ID #277950) and
nodulosis arthropathy osteolysis syndrome or multicen-
tric osteolysis nodulosis arthropathy syndrome (MONA;
MIM ID #259600). Two genes,MMP2 andMMP14 (the
genes encoding matrix metalloproteinase 2 (MMP-2)
and MMP-14, respectively), are responsible for the
recessive forms (1). The pathogenesis is unclear but may
involve activation and presentation of transforming
growth factor by matrix components.
PATIENTS AND METHODS
Characteristics of the patients. We observed a family
in which 3 of 8 siblings were ascertained to have severe periph-
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eral osteolysis as adults. Negative results of mutation analysis
of the MMP2 and MMP14 genes prompted exome sequencing,
leading to the discovery of compound heterozygous mutations
in ASAH1, the gene coding for acid ceramidase. Deficient
activity of acid ceramidase is associated with Farber’s disease, a
lysosomal storage disorder with accumulation of the neutral
lipid ceramide. The findings in this family illustrate the presen-
tation of Farber’s disease as peripheral osteolysis in adults.
The proband in this Iranian family came to the atten-
tion of one of the authors (AK) at age 40 years. He was aware
of a condition that affected him and 2 of his older sisters, and
asked for genetic counseling since he planned to have children.
His parents were not related. According to his mother’s report,
he had had episodes of fever and pain beginning at the age of
3 years. The episodes would last ;10–15 days, during which
time he could not walk because of the pain. A small number of
subcutaneous nodules developed, first on the ears, then over
the wrist, elbows, and knee joints. Hoarseness developed at the
same time and progressed over the years. Subsequently, the
episodes subsided, and he remembers having joint pain from
the age of ;12 years. At age 40 years, he has limitation of
movement in the knee joint and limited flexion of all toes. His
hands and toes have progressively shortened, and the skin over
the hands is redundant (Figure 1). There is hyperextensibility
in the fingers and thumbs. He has a few inconspicuous and
indolent subcutaneous nodules on the ears, wrists (Figure 1),
elbows, and ankles. His neurologic and developmental pheno-
type is normal, and he is professionally active as a telephone
operator.
A radiographic study revealed severe osteolysis of the
distal radius and ulna, metacarpal bones, and phalanges (Fig-
ure 2). The feet were similarly affected. The hips and knees
showed signs of arthritis but no erosions, and the spine was
unremarkable.
Two of the proband’s older sisters were seen as adults
(ages 58 years and 60 years, respectively). They had a similar
clinical phenotype with short hands and redundant skin (Fig-
ure 1). Disease onset and progression were generally similar to
those in the proband, with onset in childhood of episodes of
pain and fever and appearance of nodules on the ears. The pro-
gression of the disease was similar to that in the proband, with
shortening of the fingers, joint pain, and the appearance of dis-
crete nodules on the elbows and knees. Hoarseness was present
but milder than in the proband. There were no neurologic signs
or history thereof. There was no history of frequent pulmonary
infections in the proband or in his affected sisters.
Genetic analysis. Genomic DNA was obtained from
the proband, from 2 affected siblings and 5 unaffected siblings,
and from their mother. Their father was no longer alive.
Informed consent was obtained from all family members. The
molecular studies were performed with the approval of the
ethics board of Lausanne University Hospital. Sanger sequenc-
ing of polymerase chain reaction amplicons of the MMP2,
MMP14, and ASAH1 exons was carried out using standard
methods. Exome sequencing on genomic DNA from the 3
affected individuals in the pedigree was performed essentially
as previously described (2). Genomic DNA was amplified using
a SureSelect Human All Exon kit version 4 (Agilent) on a
Figure 1. Pedigree and clinical features in the proband and his sisters. A, Pedigree showing the proband (arrow) and his 2 affected sisters (solid
symbols). Other family members were clinically unaffected (open symbols). ASAH1 genotypes are shown below the symbols. WT5wild-type. B,
Photograph of the arms and hands of the older sister, showing shortened forearms, swollen wrists, and shortened fingers with redundant skin. C
and D, Photographs of the proband, showing shortened forearms and fingers and redundant skin. Arrows indicate a subcutaneous nodule over
the distal radius. E and F, Photographs of the arms and hands of the second sister, showing similar findings. Ulnar deviation at the wrist and
phalangeal subluxations is evident. G, Photograph of the left foot of the proband, showing shortening of the midfoot and toes.
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HiSeq 2000 machine (Illumina), and reads were aligned onto
the hg19 reference genome using NovoAlign (http://www.novo-
craft.com). Data quality control and variant calling were per-
formed according to GATK Best Practices recommendations.
Variant filtering was performed using Annovar and perl and
bash scripts developed in-house (available from the corre-
sponding author upon request) (2). Acid ceramidase activity in
fibroblasts was determined as previously described (3).
RESULTS
No pathogenic variant could be identified in the
exon sequences of the MMP2 and MMP14 genes of the
proband. Whole-exome sequencing of the 3 affected indi-
viduals revealed the presence of 2 mutations in the
ASAH1 gene, c.505T.C (p.Trp169Arg) and c.760A.G
(p.Arg254Gly). Details of the filtering process are pre-
sented in Supplementary Table 1, available on the Arthritis
& Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.39659/abstract. Sanger sequencing of the
other members of the family showed the expected segre-
gation (Figure 1A). Acid ceramidase activity was deter-
mined in fibroblast cultures of the proband and one of
his affected sisters; in both, activity was found to be
;7–8% of average control values.
DISCUSSION
The clinical presentation of our proband in adult-
hood with shortening of the hand bones, redundant skin,
and subcutaneous nodules was highly suggestive of an
osteolysis syndrome from the Winchester-Torg-MONA
spectrum (see above), and radiographic studies con-
firmed that impression. Sequencing of the known genes
for recessive osteolysis showed negative results. In the
Figure 2. Radiographic features in the acid ceramidase–deficient individuals as well as in other individuals with osteolysis. A and B, Radiographs
of the hands of the proband (A) and of his sister (B), showing severe osteolysis of the distal radius and ulna, and of the carpal elements. The
metacarpal bones have a diaphyseal constriction and their distal extremities are pointed. The proximal phalanges show a peculiar “cupping”
around the distal end of the metacarpal bones. The changes at the proximal interphalangeal joints are more severe, but slightly reminiscent of
those seen in longstanding psoriatic arthritis. C, Radiographs of the feet of the proband, showing severe osteolysis of the distal metatarsal bones
and phalanges. D, Radiographs of the hand of an Indian woman with severe osteolysis. Her clinical and radiographic features were similar to
those seen in the family described here. It seems plausible that she also had acid ceramidase deficiency, but this could not be determined since a
blood sample was not available. E and F, Radiographs of the hands of adults with MMP2 mutations. The radiographic pattern is different from
that seen in the family described here. The metacarpal bones and phalanges resemble “sucked sugar candy,” they do not show a diaphyseal con-
striction, and the proximal phalanges do not show cupping on the distal end of the metacarpal bones.
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absence of another obvious candidate gene, an exome
study was done, and this revealed the presence of com-
pound heterozygous mutations in the gene coding for
acid ceramidase, ASAH1, that were found to segregate
in the family according to a recessive model. Functional
relevance of the mutations was confirmed by the demon-
stration of strongly reduced acid ceramidase activity in
cultured cells. These mutations in ASAH1 were unex-
pected; thus, the diagnosis of acid ceramidase deficiency
came as a surprise. The 3 affected siblings illustrate a
markedly protracted course of Farber’s disease with an
inflammatory phase in childhood followed by a quiescent
phase resulting in progressive peripheral osteolysis, a
few subcutaneous (and possibly laryngeal) nodules, and
no neurologic signs.
The ASAH1 mutations identified in this family
have previously been observed in individuals with Farber’s
disease, but they have not been seen in combination with
each other. The c.505T.C (p.Trp169Arg) mutation has
been observed in 2 patients with “classic” Farber’s dis-
ease (Levade T: unpublished observations). The
c.760A.G (p.Arg254Gly) mutation has been reported
at homozygosity in a young patient presenting in the first
year of life with a clinical picture mimicking severe juve-
nile idiopathic arthritis (JIA) (4). Genotype–phenotype
correlations are not easily recognized in Farber’s disease,
but the protracted clinical course associated with
compound heterozygosity for these mutations is surpris-
ing and calls for further studies at the cellular and bio-
chemical level.
While the classic “Farber’s triad” consists of
hoarseness, subcutaneous nodules, and joint pain, it is rec-
ognized today that the primary clinical manifestations of
Farber’s disease are neurologic (for review, see refs. 5 and
6); indeed, ASAH1 mutations may manifest as a purely
neurologic disorder, spinal muscular atrophy with pro-
gressive myoclonic epilepsy (MIM ID #159950) (7,8).
Babies with the classic, infantile form of Farber’s disease
present with symptoms within the first months of life and
rarely survive beyond age 2–3 years. In infants, Farber’s
disease may present as an acute inflammatory condition
mimicking JIA (4,9). Hand radiographs of a boy described
by Kostik et al (4) showed thinning of the diaphysis and
osteopenia, and it is likely that skeletal involvement in
that boy may have progressed to look like the osteolysis in
our patients. Children with the so-called intermediate or
mild forms may lack neurologic involvement but have
severe articular and systemic involvement (particularly of
the airways) and may have longer survival times. Some
individuals with milder forms of Farber’s disease have
been known to reach early adulthood. Our proband was
40 years old at the time we first saw him; his affected
sisters were 58 and 60 years old, respectively). A litera-
ture review and an examination of the database of the
Toulouse laboratory (Centre Hospitalier Universitaire de
Toulouse) suggest that these may be the oldest individu-
als with acid ceramidase deficiency known so far, illus-
trating the longest clinical course of Farber’s disease.
From the perspective of the radiographic find-
ings, this observation delineates a novel phenotype of
peripheral osteolysis that is recessively inherited and
caused by loss-of-function mutations in ASAH1 and that
should be considered in the differential diagnosis of
peripheral osteolysis with nodules in adults. A skeletal
presentation of acid ceramidase deficiency has not been
described, and in contrast to many other lysosomal disor-
ders, the condition has not been included in the nosology
of genetic skeletal disorders so far (1). Comparison of
the radiographs of the affected individuals in this family
with those of individuals with MMP2 and MMP14 muta-
tions revealed some radiographic signs (Figure 2) that
may allow this condition to be distinguished from
MMP-2 and MMP-14 osteolyses. The mechanisms by
which acid ceramidase deficiency results in osteolysis
remain unclear; in the patients in this family, the process
seemed to be progressive in the absence of pain, swell-
ing, or other clinical signs of inflammation.
Genetic counseling regarding recessive inheri-
tance was given to our proband, a recommendation for
laryngoscopy was formulated (to ascertain the presence
of laryngeal nodules), and contacts are being made to
explore the possibility of experimental acid ceramidase
replacement therapy.
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Clinical Images: Symphalangism
The patient, a 34-year-old man with a history of noggin gene (NOG) mutation resulting in proximal symphalangism, presented to our
primary care practice to establish care. He had chronic pain in the affected joints; the symptoms started during childhood and have
progressively worsened since. His mother and brother have a similar condition. On physical examination it was noted that the typical
skin folds over the proximal interphalangeal (PIP) joints of the fingers were absent bilaterally (A) (arrows) and there was minimal to
no movement at the PIP joints. Plain radiography of the hands revealed bilateral osseous coalition/ankyloses of the PIP joints of the
fingers (B) (arrows). Ankle range of motion was decreased bilaterally. Plain radiography of the feet confirmed osseous coalition/
ankyloses at the talonavicular, lateral cuneiform-cuboid, and second tarsometatarsal joints. Symphalangism due to NOG mutation is
a rare inherited condition with an autosomal-dominant pattern. The 2 commonly recognized types are proximal or Cushing’s sym-
phalangism (SYM1), which affects the PIP joints, wrists, and ankles as was the case in our patient, and distal symphalangism
(SYM2), which mainly affects the distal interphalangeal (DIP) joints. Of note, patients with SYM1 may also have conductive deaf-
ness due to fusion of ossicles, which was absent in our patient. Currently, symptomatic care is the only treatment option in adults with
symphalangism; however, surgical procedures have been attempted with some success in children (1).
1. Baek GH, Lee HJ. Classification and surgical treatment of sym-
phalangism in interphalangeal joints of the hand. Clin Orthop
Surg 2012;4:58–65.
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We report two unrelated patients with a multisystem disease
involving liver, eye, immune system, connective tissue, and bone,
caused by biallelic mutations in the neuroblastoma amplified
sequence (NBAS) gene. Both presented as infants with recurrent
episodes triggered by fever with vomiting, dehydration, and
elevated transaminases. They had frequent infections, hypogam-
maglobulinemia, reduced natural killer cells, and the Pelger–
Huët anomaly of their granulocytes. Their facial features were
similar with a pointed chin and proptosis; loose skin and reduced
subcutaneous fat gave them a progeroid appearance. Skeletal
features included short stature, slender bones, epiphyseal dyspla-
sia with multiple phalangeal pseudo-epiphyses, and small C1-C2
vertebrae causing cervical instability and myelopathy. Retinal
dystrophy and optic atrophywere present in one patient. NBAS is
a component of the synthaxin-18 complex and is involved in
nonsense-mediated mRNA decay control. Putative loss-of-func-
tion mutations in NBAS are already known to cause disease in
humans. A specific founder mutation has been associated with
short stature, optic nerve atrophy and Pelger–Huët anomaly of
granulocytes (SOPH) in the Siberian Yakut population. A more
recent report associates NBAS mutations with recurrent acute
liver failure in infancy in a group of patients of European descent.
Our observations indicate that the phenotypic spectrumofNBAS
deficiency is wider than previously known and includes skeletal,
hepatic, metabolic, and immunologic aspects. Early recognition
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of the skeletal phenotype is important for preventive manage-
ment of cervical instability. ! 2015 Wiley Periodicals, Inc.
Key words: NBAS; liver disease; transaminase; fatty acid
oxidation; skeletal dysplasia; retinal dystrophy; optic atrophy;
immunodeficiency; Pelger–Huët anomaly; cervical instability
INTRODUCTION
Mutations in NBAS (neuroblastoma amplified sequence; MIM
608025) were first observed byMaksimova et al. [2010] as the cause
of short stature, optic nerve atrophy, and Pelger–Huët anomaly of
granulocytes (SOPH syndrome, MIM 614800). This syndrome was
observed in 31 Yakut families, an isolated population of east Russia,
and associated with a biallelic recessive founder mutation in NBAS
(c.5741G>A, which predicts p.Arg1914His). Clinical features in-
cludedpostnatal growth retardation, senile face, reduced skin turgor
and elasticity, osteoporosis, optic atrophy with loss of visual acuity
and color vision, underlobulated neutrophils, and normal intelli-
gence. Recently, Haack et al. [2015] reported biallelic mutations in
NBAS as the causeof recurrent acute infantile liver failure in a cohort
of 11 individuals from ten German families. Here, we describe the
clinical phenotype of two unrelated children with NBASmutations
that were ascertained for recurrent liver failure, short stature, loose
skin, and abnormal skeletal radiographs.
CLINICAL REPORTS
Patient 1 was a 12-year-old boy born to healthy Swiss parents after
uneventful pregnancy and delivery (Table I). Birth weight and
length were 2,360 g (3rd–5th centile) and 46 cm (3rd–5th centile),
respectively. He presented at 4.5 months of life with fever, vomit-
ing, dehydration, and elevated transaminases (up to 2,500U/L),
which normalized within 48 hr following glucose infusion. He
presented several similar episodes in the first year of life, always
triggered by fever. He had hypoglycemia on two occasions (plasma
glucose 2.1 and 2.7mmol/L respectively, normal>3.0), but neither
cholestasis nor significant coagulopathy were observed;
factor V was normal (125%, normal: 70–140%) during crises.
Serology tests for a large panel of viruses did not identify an
infection. At 6 months of life, hepatomegaly was noted; a liver
biopsy was performed at age 8 months, showing normal histology
and ruling out an inflammatory or autoimmune hepatitis; there
were no signs of metabolic derangement, such as steatosis or other
storage material. His hepatomegaly normalized by the age of
3 years, despite recurrent acute liver disease episodes with elevated
transaminases that persisted till the age of 8 years. Early suppression
of fever by mefenamic acid seemed to help in preventing hepatic
crises in some instances. Blood cell count was always normal but
blood smears, reviewed retrospectively, showed the Pelger–Huët
anomaly of granulocytes (Fig. S1). Metabolic evaluations showed
mild hyperammonemia (70mmol/L, normal <50), normal lactate
and blood gases, and urinary ketosis (beta-hydroxybutyrate
118–258mmol/mol creatinine, normal <91.8mmol/mol creati-
nine in morning urine [Boulat et al., 2003]) but inappropriately
low in respect to prolonged vomiting and fasting; dicarboxylic
aciduria was noted at urinary organic acids: adipate 38–119mmol/
mol creatinine (normal <11), suberate 18–26mmol/mol creati-
nine (normal <6.4), 3-hydroxyadipate 23–55mmol/mol creati-
nine (normal <16), 3-hydroxysebacate 93–148mmol/mol
creatinine (normal <2.7), as well as unusual presence of 3-
epoxy-acid excretion (not quantified). Organic acids normalized
when hewas not acutely ill. Amino acid and acylcarnitine profiles in
plasma and total and free carnitine were normal during and
between crises. Isoelectric focusing of serum transferrin was nor-
mal. Causes of exogenous intoxication were extensively searched
for and excluded. An intravenous fructose challenge excluded
fructose intolerance. Very long-chain fatty acids in plasma were
normal. A skin biopsy was performed and fatty acid oxidation
(FAO) enzymes quantified: 3-hydroxyacyl-CoA dehydrogenase
(SCHAD) activity was significantly reduced (25.2 nmol/min/mg
protein; reference range 40–200) and nomutation was found in the
HADH gene (MIM 601609) (data not shown). Similarly, no
mutation was found in any of the FAO genes (ACSL3, MIM
602371; ACSL6, MIM 604443; ACSL5, MIM 605677; ACSL4,
MIM 300157; ACSBG1, MIM 614362; ACSBG2, MIM 614363;
SLC27A2, MIM 603247; ACSL1, MIM 152425; ECHS1, MIM
602292; EHHADH, MIM 607037; HSD17B10, MIM 300256;
HADHB, MIM 143450; SCP2, MIM 184755; ACAA2, MIM
604770; ACAA1, MIM 604054). Because of the recurrent hypo-
ketosis with dicarboxylic and 3-hydroxydicarboxylic aciduria dur-
ing crises, and the rapid reversal of liver disease with glucose
infusion, a secondary disturbance of fatty acid oxidation was
suspected; fasting was limited to a maximum of 10 hr, frequent
meals with slow carbohydrates were recommended and supple-
ments of maltodextrins administered regularly, with improvement
of physical endurance. With this management, the child could
participate in all physical activities in social settings and at school.
His learning abilities were apparently normal.
From infancy, his growth curve was slightly below the 3rd centile
for weight and length; at 4.5 months his weight was 5 kg (<3rd
centile), length 60.5 cm (<3rd centile), OFC 42 cm (10th–25th
centile). He had a “progeroid” appearance due to redundant
abdominal skin and pseudo-exophthalmos caused by reduced
peri-orbital fat. During childhood, the skeletal and connective
tissue phenotype became more evident, with persistent propor-
tionate short stature (stature at 6 years was 105 cm, !2 SD), short
neck, dorsal kyphosis, slender habitus with reduced subcutaneous
fat at the trunk, and redundant skin (Fig. 1). Facial features (Fig. 1)
included triangular face, pointed chin, proptosis, and narrow
forehead. Neurologic examination was normal and psychomotor
development was apparently normal. Skeletal survey (Figs. 2–4)
showed long bones with mild diaphyseal stenosis but flared meta-
physes, and mild epiphyseal dysplasia. At 8.5 years, there was
delayed epiphyseal ossification and discordance between hand
bone age (7 years) and cubital bone age (5 years) and the presence
of distal pseudoepiphyses at the proximal and middle phalanges.
The bones were gracile and osteopenic, despite no history of
fracture. Parathyroid hormone, osteocalcin, procollagen-1-N-pro-
peptides (P1NP), thyroid function, growth hormone and insulin
secretion tests were normal. At the age of 9 years, after a fall, he
presented with acute paresthesia and transient paralysis of all four
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limbs; X-rays andCT scan of the cervical spine showed small C1-C2
and cervical instability (Fig. 5) with compression of the cervical
spinal cord, confirmed by pathologic brainstem evoked potentials.
Stabilization surgery was performed with complete reversal of
symptoms.
Eye examination at 5 years of age showed optic atrophy (Fig. S2)
with retinal dystrophy at electroretinogram; he became symptom-
atic (photophobia, loss of visual acuity, and color vision) at the age
of 8 years, therefore reading aids were provided.
At age 3 years, he was hospitalized for bacterial pneumonia,
requiring intravenous antibiotics. He had five to eight episodes of
middle ear infection per year from age 3 to 11 years, necessitating
oral antibiotics. Since the age of 5 years he had recurrent labial
herpes simplex virus (HSV) infection, with almost no free interval,
associated with diffuse palpable lymphadenopathy. At 5 years of
age, he was hospitalized for a chickenpox infection with prolonged
fever, necessitating several weeks to recover; transaminases in
plasma were as high as 15,000U/L (reference values <45U/L for
AST and<38U/L for ALT) during this infection. At age 7 years, he
had a reactivation of varicella-zoster virus (VZV) infection in the
thoracic regionwith ophthalmic involvement. A second recurrence
of cutaneous and ophthalmic VZV occurred at age 11.5 years.
Immunologic workup showed hypogammaglobulinemia (Table I),
absent response to vaccinations, and reduced natural killer (NK)
cell count (Table I). Subcutaneous weekly injections of immuno-
globulins were started at age 11.5 years, restored normal IgG levels
and substantially reduced both the upper airway infections and the
labial HSV reactivations, with improvement of general well-being
TABLE I. Clinical Features of Patients With NBAS Deficiency
Clinical features and laboratory abnormalities Patient 1 Patient 2
Age 12 5
Nationality Swiss American
Consanguinity – –
Stature (P) !3 SD !3.5 SD
Redundant skin, reduced subcutaneous fat þ þ
Skeletal dysplasia þ þ
Cervical instability (small C1-C2) þ þ
Fractures – þa
Max. level of AST / ALT 15,000/9,300 >7,500/9,700
Normal (U/L): <45/38 (12 years); <46/52 (5 years)
Hepatomegaly in infancy þ þ
Acute liver failure (low PT, PTT, Factor V) – þ
Pelger-Huët anomaly of granulocytes þ þ
Hypogammaglobulinemia: normal values [Jolliff et al., 1982] þ !
IgG (g/L): 6.39–13.49 (12 years); 4.63–12.36 (4–5years) IgG 4.9–5.2 IgG 7.39
IgA (g/L): 0.7–3.12 (12 years); 0.25–1.54 (4–5 y) IgA 0.07–0.18 IgA 1.07
IgM (g/L): 0.56–352 (12 years); 0.43–1.96 (4–5 years) IgM 0.43–0.56 IgM 1.61
Response to vaccinations – n.d.
Reduced natural killer (NK) cells þ þ
Absolute NK cell count 43 40
Normal (cells/ml): 70–480 (12 years); 130–720 (5 years)
Frequent infections þ þ
Chronic/recurrent viral infections þ (VZV) þ (EBV)
Optic atrophy þ –
Retinal dystrophy þ –
Recurrent vomiting (crises) þ þ
Metabolic abnormalities during crises þb !
Neurological abnormalities – –
Cardiomyopathyc – –
Acute renal failurec – –
Erythema nodosumc – –
Inflammatory bowel diseasec – –
Epilepsyc – –
Celiac diseasec – –
n.d., not done/not tested.
VZV, Varicella Zoster Virus; EBV, Epstein Barr Virus.
a1 skull and 1 left femur fracture.
bHypoketosis, dicarboxylic aciduria, and epoxy-acid excretion during crises.
cAdditional clinical features reported by Haack et al. [2015].
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FIG. 1. Phenotype of patients with NBAS deficiency. A) and B) facial features of patient 1 (A) and 2 (B): triangular face, pointed chin,
prominent eyes, narrow forehead. C) and D) Patient 1 at age 8 years: reduced subcutaneous fat with prominent musculature, skin folds
(arrow), and prominent scapula. E) Patient 2 at age 3 years: pectus excavatum and prominent abdomen.
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of the patient. He has not had any further acute liver crisis after
8 years of age. At the most recent evaluation (12 years), his weight
was 24.7 kg (3 kg <3rd centile), stature was 131 cm (5 cm <3rd
centile; !3 SD) and OFC was 54 cm (50th centile).
Patient 2, a 5-year-old girl, was born to Caucasian parents at
37 weeks of gestation with a birth weight of 2.52 kg (50th centile)
(Table I). She required one week of neonatal intensive care due to
transient tachypnea of the newborn. At discharge, she was able to
feed normally. However, she had feeding difficulties and delayed
milestones by 6 months of age. She presented at 23 months of age
with fever, recurrent episodes of non-bloody, non-bilious vomit-
ing, and elevated transaminases. Transaminases were significantly
FIG. 2. Radiographic features of long bones in patients with NBAS deficiency. Panels A, C, E, G: patient 1 at age 1 year (humerus, radius, and
ulna, femur, tibia, and fibula, respectively). Panels B, D, F, H: patient 2 at age 2 years (humerus, radius, and ulna, femur, tibia, and fibula,
respectively). Note mild osteopenia, slender bones with stenotic diaphyseal shafts (particularly in panels B, E, and G), flared metaphyses.
Knee epiphyses are mildly flattened.
FIG. 3. Hand radiographs in patients with NBAS deficiency: A) Patient 1 at age 7 years; B) Patient 1 at age 8.5 years; C) Patient 2 at age
2 years. Note presence of pseudo-epiphyses at the distal phalanges (arrows). In panel B, note the dissociation of bone age: carpal bone and
hand epiphyses are compatible with a bone age of 7 years; the delayed ossification of distal cubital epiphysis is compatible with a bone age
of 5 years. In panel C, note delayed carpal bone age (<6 months) compared to epiphyseal bone age (1.5 years).
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elevated (AST>7,500U/L, normal: 16–46; ALT 9,070; normal: 33–
52) which decreased during the initial crisis, but remained elevated
upon discharge from the hospital. Coagulation studies were ab-
normal (PT 24.4 sec, normal: 11.4–15.1; PTT 39 sec, normal: 22.4–
37.5, INR 2.3) and ferritin was increased (977mg/L, normal: 10–
95). She presentedwith hepatomegaly during the initial crisis. Liver
biopsy was performed during the second crisis at 26 months of age
and showed EBV nucleic acids and erythrophagocytosis suggestive
of Epstein-Barr virus (EBV)-related hepatitis. Her hepatomegaly
resolved after age 3 years. A metabolic evaluation during one of the
crises including plasma lactate and ammonia, urine organic acids,
plasma amino acids, acylcarnitine profile, succinylacetone, isoelec-
tric focusing of transferrin, and alpha-1-antitrypsinwas reported to
be normal. The CSF cell counts, neurotransmitters, amino acids,
and lactate were all normal. Sweat chloride testing was normal.
Initial white blood cell count was low; however, all other blood
counts were normal. Extensive serology for hepatotropic viruses
was negative, except for chronic EBV infection. A blood smear was
performed during the second acute crisis when she was 26 months
and showed an absolute monocytosis. Repeat blood smear per-
formed at 4 years showed Pelger–Huët anomaly in approximately
5% of neutrophils. An immunologic evaluation showed normal
IgG and low NK cell count (Table I). In the first 2 years of life, she
was hospitalized three times for acute liver failure. All crises began
with fever and vomiting. Her transaminases normalized about
2months after the prior acute crisis. Her facial phenotype included
triangular face, pointed chin, down-turned corners of the mouth,
and proptosis (Fig. 1). Her growth parameters were small for age;
she had abundant skin and reduced subcutaneous fat (Fig. 1).
During the hospitalization at 23 months of age, skeletal survey
(Fig. 5) showed a J-shaped sella and small C1-C2. Cervical insta-
bility was diagnosed and fixation surgery performed. This study
also showed a bone dysplasia similar to patient 1 (Figs 2–4). She has
a history of two fractures (skull at 11 months and left femur at 4
years) that were the result of accidental falls. Her motor and speech
development were delayed at age 3 years, but improved and motor
development normalized. She still requires speech therapy formild
delays due to poor articulation. At last evaluation she was diag-
FIG. 4. Radiographs of the pelvis and chest in patients with NBAS deficiency. A) Pelvis of patient 1 at age 7 years and 10 months: the capital
femoral epiphyses are mildly flattened; there are metaphyseal irregularities at the proximal femur, bilaterally. B) Pelvis of patient 2 at age
2 years; note small capital femoral epiphyses. C) Chest radiograph of patient 1 at age 7 years; note thin ribs and normal vertebral bodies. D)
Chest radiograph of patient 2 at age 2 years; note short twelfth rib.
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nosed with systemic HSV infection and her growth parameters at
that time (5 years) were as follows: weight 12.3 kg (1st centile),
stature 91 cm (!3.5 SD) and OFC 48.5 cm (5th centile). Eye
examination at 4 years did not identify optic atrophy or retinopa-
thy, however she did have nearsightedness with astigmatism.
Exome Sequencing (ES)
The study was conducted within the frame of a Swiss National
Science Foundation-funded research project on skeletal dysplasias
for which ethical approval was obtained from the State Ethic
Committee (Canton Vaud). DNA was extracted according to
standard protocols from leucocytes from the two probands and
their parents and siblings who consented to the study. We per-
formed ES in the DNA of patients 1 and 2 as described [Shi et al.,
2011]. The results were analyzed with an informatic pipeline
excluding variants present at significant frequency in public data-
bases, and variants frequently observed in the in-house database.
Results were further prioritized in terms of data quality and
assuming recessive inheritance in the two probands. Candidate
mutations were screened using known annotations for gene func-
tion and associated phenotypes. Sanger sequencing was used to
validate the presence and status of suspected pathogenic mutations
in the two probands and to confirm segregation in the parents.
Measurement of Matrix Gamma-
Carboxyglutamate (Gla) Protein (MGP) Activity
Circulating MGP levels were measured in plasma from patient 1.
For this study, peripheral blood was drawn in EDTA, immediately
centrifuged and frozen. TheMGPwasmeasured by ELISAmethods
as described [Cranenburg et al., 2011].
RESULTS
ES Data
Upon inspection of the filtered ES data, biallelic mutations were
found in 14 genes in commonbetween the two unrelated probands;
among them, four mutations in NBAS met the criteria of correct
FIG. 5. Cervical instability in patients with NBAS deficiency. Panel A, B, and C: radiographs of the cervical spine of patient 1 at age 10 years
(B in extension; C after fixation surgery). Panel D and E: MRI and CT scan of the cervical spine of patient 1 at 10 years. Panel F: radiograph of
cervical spine of patient 2 at age 3 years. Note J-shaped sella in both patients (panels C and F) and the small C1 and C2 (all panels) with
reduced space around the myelon (panel D).
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segregation and low frequency in control datasets: patient 1 was
compound heterozygous for c.284C>T, p.Ala95Val (exon 4) and
c.850A>T, p.Lys284Ter (exon 10) and patient 2 was compound
heterozygous for c.409C>T, p.Arg137Trp (exon 7) and
c.1186T>A, p.Trp396Arg (exon 14) (according to ENSEMBL
Accession Number ENST00000281513). Three of these mutations
were absent in variant databases but the missense mutation
c.409C>T, p.Arg137Trp (exon 7) was listed twice in Exome
Aggregation Consortium (ExAC) with a heterozygous frequency
of 0.00001648 and once in Exome Variant Server (EVS). The four
mutations were not found in our in-house database (>400 ES).
Sanger sequencing showed the four variants were each heterozy-
gous in one of the parents.
The PROVEAN software (Protein Variation Effect Analyzer)
predicted a deleterious impact on the biological function of protein
for p.Ala95Val (score !2.837; deleterious effect < !2.5), p.
Arg137Trp (score !4.762) and p.Trp396Arg (score !12.671). The
Polyphen-2programv2.2.2r398predicted the p.Ala95Val as probably
damaging (score 0.982 with sensitivity 0.75 and specificity 0.96).
Figure 6 summarizes all NBAS mutations with software pre-
dictions, conservation, and population frequencies for mutations
described herein.
Circulating MGP measurement in plasma of patient 1 showed
normal concentration of uncarboxylated MGP: 120 pmol/L (ref-
erence values 71–756) [Cranenburg et al., 2011].
DISCUSSION
These patients presented with hepatic, metabolic, skeletal, retinal,
and immunologic abnormalities that were undiagnosed until ES
identified mutations in NBAS, in both. Upon review of their
manifestations and other patients reported with NBASmutations,
we concluded that these variants were causative.
NBASisacomponentof the syntaxin18complex involved inGolgi-
to-endoplasmic reticulum (ER) retrograde transport of vesicles,
allowing the distribution of proteins from the ER to the Golgi
compartments [Aoki et al., 2009] necessary for balanced macromole-
cule intracellular trafficking. NBAS interacts with p31 of the syntaxin
18 complex in both HeLa cells [Aoki et al., 2009] and human
fibroblasts [Haack et al., 2015]. A disturbance of retrograde Golgi-
to-ER transport may result in ER stress, as suggested by expression
profiling in NBAS-mutant fibroblasts [Haack et al., 2015].
NBAS is also important in nonsense-mediated mRNA decay
(NMD) control. It forms an autoregulatory, conserved NMD
circuit that regulates endogenous RNA targets [Longman et al.,
2013]. Knockdown of NBAS causes up-regulation of genes in-
volved in ER-stress, NMD factors, genes involved in response to
wounding and nutrients, and in regulation of inflammatory re-
sponse [Longman et al., 2013].
These functions suggest a pleiotropic role of this gene, poten-
tially explaining the diversity of the phenotypic features of the
patients.
Metabolic Aspects
The multisystem involvement observed in these patients resembles
that of congenital disorders of glycosylation (CDG), in which
defective glycosylation in the ER or Golgi affects the function of
diverse proteins. However, isoelectric focusing of serum transferrin
was normal in both children, thus excluding CDG type I or II and
confirming the findings of Haack et al. [2015], who also found no
glycosylation defect in their series.
The metabolic disturbances found in patient 1 were significant,
although present exclusively during crises. The inappropriate
hypoketosis and dicarboxylic aciduria during crises and the
good response to glucose infusion suggested FAO dysfunction;
the reduced activity of SCHAD enzyme in fibroblasts in the
absence of any mutation in the HADH gene implicated a second-
arily reduced HADH expression. Experiments to test this are
underway. A generalized mitochondrial dysfunction as cause of
the metabolic derangement in patient 1 seems unlikely because
plasma lactate and urinary Krebs cycle intermediates were not
elevated. Interestingly, 3-epoxy-acids were recurrently elevated in
urine during crises, suggesting a peroxisomal disturbance. The
NBAS protein contains a leucine zipper motif, three putative
transmembrane helices, an ER signal sequence, and two peroxi-
somal targeting signals [Scott et al., 2003]. Our findings suggest a
possible role of NBAS in regulating peroxisomal metabolism and/
or protein trafficking in this organelle; further experiments are
necessary to test this hypothesis.
Hepatic and Immunologic Aspects
Acute liver disease was triggered by fever in these patients and in
those ofHaack et al. [2015]. It has been proposed that the sensitivity
to fever in these patients may be due to thermal susceptibility of the
syntaxin complex 18 [Haack et al., 2015]. However, the evidence of
immunodeficiency in the present patients and specific NBAS
transcriptional targets identified by Longman et al. [2013] in
HeLa cells suggest a link between immune dysregulation and
recurrent liver inflammation. Knockdown of NBAS in HeLa cells
caused upregulation of CCL20 and IL6R. CCL20 is a chemokine
known to be upregulated in alcoholic hepatitis; it is a biomarker
and a mediator of lipopolysaccharide-induced liver inflammation
[Affo et al., 2014]. Its upregulation in NBAS deficiency may
therefore facilitate liver inflammation and cytolysis upon stress
factors. IL6 is a multifunctional cytokine involved in induction of
immunoglobulin production from activated B-cells, in T lympho-
cyte proliferation, survival and differentiation, and in regulation of
acute phase proteins in the liver [Zohlnhofer et al., 1992]. IL6R is
expressed predominantly by hepatocytes, neutrophils, monocytes/
macrophages, and some lymphocytes [Wang et al., 2013]. IL6
down-regulates IL6R via endocytosis (by internalization) and
lysosomal degradation. The reappearance of the receptor at the
cell surface is cycloheximide-sensitive. Degradation is likely to be
protective for the cell against overstimulation [Zohlnhofer et al.,
1992]. NBAS deficiency is associated with reduced degradation of
IL6RmRNA inHeLa cells [Longman et al., 2013]. Thismay explain
the hypersensitivity of liver cells to inflammatory cytokines and
may provide a link between the immunologic and hepatic abnor-
malities in NBAS deficiency. Soluble IL6R (sIL6R) plays a role in
systemic inflammatory response and its expression is induced by
viral infection via the cyclo-oxygenase 2 (COX-2) pathway and
inhibits viral replication [Wang et al., 2013]. This model may
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provide a rationale for the use of non-steroidal anti-inflammatory
drugs at the onset of febrile illnesses to reduce liver inflammation in
patients with NBAS deficiency.
The immunodeficiency in NBAS deficiency is subtle and possi-
bly not consistent; patient 1 had a derangement of both humoral
and cellular immune responses, and patient 2 only derangement of
cellular immune response at last evaluation. Immunoglobulin
replacement should be considered in affected patients to reduce
frequency of infection and at the same time to avoid triggers of liver
failure. Reduced NK cells may predispose to chronic viral infection
and be a risk factor for tumorigenesis [Artis and Spits, 2015], for
which patients should be monitored longitudinally.
Skeletal Aspects
Postnatal short stature was evident from early infancy and is a
feature of the SOPH syndrome in the Yakuts [Maksimova et al.,
2010]. No details on growth were provided by Haack et al.
[2015], however those patients may not have been investigated
because of the prominence of the hepatic involvement. Maksi-
mova et al. [2010] suggested primary skeletal involvement in
their patients, however those radiographic studies were done at
adult age when dysplastic changes are usually less evident. They
highlighted osteoporosis, delayed bone age, and late ossification
of vertebral apophysis in one patient [Maksimova et al., 2010].
The skeletal dysplasia in the patients reported here showed thin,
gracile bones, with stenotic diaphyses and flared metaphyses, and
mild generalized epiphyseal dysplasia, suggesting a disturbance in
bone mineralization rather than in skeletal patterning.
In theNBAS knockdown model of Longman et al. [2013],MGP
was upregulated. MGP is a negative regulator of bone formation
and deficiency causes Keutel syndrome, with abnormal calcifica-
tion of cardiac valves, ear pinnae, and bronchial arches [Munroe
et al., 1999]. Increased expression of MGP would be compatible
with the bone phenotype observed in the present patients, with
delayed maturation of epiphyses, thin bones, and underossified
vertebrae.Wemeasured circulatingMGP in patient 1, whichwas in
the reference range for adult controls, in contrast to upregulation
FIG. 6. The exon structure of the NBAS gene and a schematic representation of the NBAS protein with its domains are shown. At the top are
the mutations described by Maksimova et al. [2010] and by Haack et al. [2015]. Between the gene cartoon and the protein cartoon are the
four mutations identified in this paper. Below the protein cartoon are screenshots from the UniProt website showing that all four mutated
amino acids are completely conserved in all species available. Finally, at the bottom are the results of pathogenicity predictions (PolyPhen-2
and PROVEAN) as well as allelic frequencies in the ExAC and EVS databases.
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found in HeLa cells [Longman et al., 2013]. Our results, although
limited to one patient, do not support a role for this protein in the
skeletal phenotype of NBAS deficiency.
Independent from the pathogenetic mechanism, the under-
ossification of the cervical spine observed in these patients indicates
a serious risk of neurological complications and should be assessed
in patients with NBAS deficiency.
Ophthalmologic Aspects
Finally, we confirm that eye involvement includes optic atrophy
and retinal dystrophy, as reported by Maksimova et al. [2010] and
is not limited to the Yakut population. While optic atrophy is a
frequent feature in disturbances of energy metabolism, retinal
dystrophy may be linked to disturbed Golgi-to-cilium vesicle
transport [Evans et al., 2010]. Therefore, NBAS is likely to play
an important role in retinal homeostasis and patients should be
monitored accordingly. Patient 1 had signs of atypical cone-rod
dystrophy from age 5, but became symptomatic at age 8. Patient 2
did not have evidence of retinal dystrophy but her last eye exami-
nation was done at age 4. No details are available about the visual
function of patients reported by Haack et al. [2015].
Our observations highlight the heterogeneous and pleiotropic
clinicalmanifestations ofNBASdeficiency. This report should raise
awareness on the syndrome; we have expanded the syndrome,
highlighting some clinical issues, which could be important to
recognize early, such as cervical instability and immunodeficiency.
Our observations also suggest possible molecular and pathogenetic
mechanisms to be investigated in future research to understand
and treat this disorder.
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REPORT
Mutations in CEP78 Cause Cone-Rod Dystrophy
and Hearing Loss Associated with Primary-Cilia Defects
Konstantinos Nikopoulos,1,12 Pietro Farinelli,1,12 Basilio Giangreco,2 Chrysanthi Tsika,3
Beryl Royer-Bertrand,1,4 Martial K. Mbefo,5 Nicola Bedoni,1 Ulrika Kjellstro¨m,6 Ikram El Zaoui,1
Silvio Alessandro Di Gioia,1 Sara Balzano,1 Katarina Cisarova,1 Andrea Messina,7 Sarah Decembrini,5
Sotiris Plainis,3 Styliani V. Blazaki,3 Muhammad Imran Khan,8 Shazia Micheal,8 Karsten Boldt,9
Marius Ueffing,9 Alexandre P. Moulin,10 Frans P.M. Cremers,8,11 Ronald Roepman,8 Yvan Arsenijevic,5
Miltiadis K. Tsilimbaris,3 Sten Andre´asson,6 and Carlo Rivolta1,*
Cone-rod degeneration (CRD) belongs to the disease spectrum of retinal degenerations, a group of hereditary disorders characterized by
an extreme clinical and genetic heterogeneity. It mainly differentiates from other retinal dystrophies, and in particular from the more
frequent disease retinitis pigmentosa, because cone photoreceptors degenerate at a higher rate than rod photoreceptors, causing severe
deficiency of central vision. After exome analysis of a cohort of individuals with CRD, we identified biallelic mutations in the orphan
gene CEP78 in three subjects from two families: one fromGreece and another from Sweden. The Greek subject, from the island of Crete,
was homozygous for the c.499þ1G>T (IVS3þ1G>T) mutation in intron 3. The Swedish subjects, two siblings, were compound hetero-
zygotes for the nearby mutation c.499þ5G>A (IVS3þ5G>A) and for the frameshift-causing variant c.633delC (p.Trp212Glyfs*18). In
addition to CRD, these three individuals had hearing loss or hearing deficit. Immunostaining highlighted the presence of CEP78 in
the inner segments of retinal photoreceptors, predominantly of cones, and at the base of the primary cilium of fibroblasts. Interaction
studies also showed that CEP78 binds to FAM161A, another ciliary protein associated with retinal degeneration. Finally, analysis of skin
fibroblasts derived from affected individuals revealed abnormal ciliary morphology, as compared to that of control cells. Altogether, our
data strongly suggest thatmutations inCEP78 cause a previously undescribed clinical entity of a ciliary nature characterized by blindness
and deafness but clearly distinct from Usher syndrome, a condition for which visual impairment is due to retinitis pigmentosa.
Cone-rod degeneration (CRD [MIM: 120970]) represents
an extremely rare class of hereditary diseases that affect
the light-sensing neurons of the retina, the cone and rod
photoreceptors.1 Cones are involved in daytime vision,
providing the brain with color information and central,
precise visual input. Conversely, rods are active in very
dim light conditions, are more abundant in the retinal pe-
riphery, and produce achromatic information, typical for
instance of the visual stimulation provided by a landscape
on a moonless night. Individuals with CRD experience
initial loss of visual acuity (central vision) and aberrant
color vision as a result of the prominent loss of cones,
whereas rod functions remain relatively preserved.2 As
the disease progresses, both cone and rod functions deteri-
orate and central vision is severely impaired or lost, but
peripheral islands of the retina might retain some residual
activity.3 On the basis of these clinical parameters, CRD
can be distinguished from retinitis pigmentosa (RP [MIM:
26800], also called rod-cone degeneration), the most com-
mon form of hereditary retinal degeneration. In retinitis
pigmentosa, rods are more severely affected than cones;
initial symptoms include night blindness due to loss of
rod function, and central vision (cone function) is often
preserved until the very late stages of the disease.4 CRD is
almost invariantly inherited as a Mendelian trait, predom-
inantly according to a recessive pattern of transmission,
and is characterized by an elevated genetic and allelic het-
erogeneity.5 Although as many as 33 CRD-associated genes
have been identified to date (RetNet; see Web Resources),
they are found to be mutated in only ~25% of clinical
cases, implying that a substantial percentage of affected
people might carry mutations in yet-to-be-identified
genes.6
According to this rationale, we performed whole-exome
sequencing (WES) in 34 unrelated individuals with
CRD (29 from Greece and five from Sweden). Genomic
DNA was extracted from peripheral blood leukocytes
according to standard procedures, and then exomic li-
braries (SureSelect V5 kit, Agilent) were sequenced on an
Illumina HiSeq 2000. Raw sequence files were assessed,
trimmed, and finally mapped back to the human genome
reference sequence (build hg19); DNA variants were called
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8Department of Human Genetics and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525GA Nijmegen, The
Netherlands; 9Medical Proteome Center, Institute for Ophthalmic Research, University of Tuebingen, 72074 Tuebingen, Germany; 10Department of
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and scored according to a specific in silico pipeline,
described previously.7 Aggregate data analysis and variant
filtering procedures (Tables S1 and S2 in the Supple-
mental Data available online) revealed biallelic mutations
in two probands, one from Greece and another from Swe-
den, in CEP78 (centrosomal protein 78, composed of 16
exons for its longest coding isoform [GenBank: NM_
001098802.1]). Both had classical signs and symptoms of
CRD, clearly distinct from retinitis pigmentosa, as detailed
below. Written informed consent was obtained from all in-
dividuals enrolled in this study, and approval for research
on human subjects was obtained from the institutional re-
view boards of all participating Institutions.
The Greek subject (KN10, individual II-1 on the left pedi-
gree in Figure 1) was a 59-year-old male from the island of
Crete and the eldest of two siblings of a non-consanguin-
eous family. His sister was unaffected, and the family re-
ported no history of retinal degeneration. Clinical history
indicated hemarelopia since early adulthood (18–20 years
of age); the condition progressed to severe central vision
loss at the age of 35–40 years and evolved into severe visual
impairment, nystagmus, and photophobia. Dyschroma-
topsia was also reported. Fundus examination at first visit
showed normal color and normal vessels but a small atro-
phic foveal area with subjacent ring-like glistening in one
eye and bull’s-eye maculopathy in the other eye. A few
atrophic lesions were present in the inferior periphery in
one eye (Figure 2). The 30! static automated perimetry re-
vealed a diffuse suppression of the visual field in both
eyes and a relative conservation of the peripapillary and su-
perior periphery. Full-field electroretinography (ERG)
showed flat cone responses but still some residual rod-
mediated signals in the left eye. This person also com-
plained about minor hearing problems, and his audiogram
exhibited relatively mild deficit; nonetheless, such deficit
was clearly distinct and more severe than natural age-
related hearing loss (presbycusis)9 (Figure 2). KN10 carried
a homozygous substitution in the first invariant base of
intron 3 splice donor site c.499þ1G>T (IVS3þ1G>T)
(Figure 1). This variant was located within a very small
stretch of homozygosity that was not statistically signifi-
cant for autozygosity, possibly indicating a mutational
founder effect of geographic origin (not shown). The
only relative who could be tested was his paternal uncle
(individual I-1, left pedigree), who carried this DNA change
heterozygously (Figure 1).
The Swedish proband (2716s15, individual II-2 on the
right pedigree in Figure 1), now deceased, was last exam-
ined at 69 years of age. He was born from unaffected
parents andwas the first child of a kindred of two. His sister
(2702r34, individual II-3, right pedigree), examined at age
65, also had retinal degeneration. Both had visual prob-
lems, including loss of color sensitivity and central vision,
since childhood. Both also reported a hearing deficit since
they were young, and both had hearing aids. Audiogram
of the living Swedish subject at age 66 years revealed
substantial sensorineural hearing loss, which did not
seem to progress substantially over the following 11 years
(Figure 2). Hospital records containing information on
the hearing status of her deceased brother were destroyed
upon his death. Fundus examination showed degenerative
changes for both siblings in the macular region and some
spicular pigment in the mid-periphery but fewer changes
in the periphery (Figure 2). Progressive deterioration of
the visual field was reported and documented as ex-
panding from the center to the periphery. At last exami-
nations, both siblings retained some residual vision at
the periphery of the visual field, especially in dim-light
conditions. Similar to the situation for the Greek subject,
full-field ERG of both individuals highlighted almost no
residual cone activity but still revealed some rod-mediated
responses, even at these late ages. These siblings were
compound heterozygotes for two CEP78 mutations: a
frameshift-causing single-nucleotide deletion (c.633delC;
p.Trp212Glyfs*18) in exon 5 and an intronic base substi-
tution (c.499þ5G>A; IVS3þ5G>A) in the vicinity of the
donor site for intron 3, just four nucleotides away from
the mutation identified in the Greek subject. Genetic
examination of the proband’s son (individual III-1, right
pedigree) uncovered the presence of this latter mutation
in heterozygosis, confirming the biallelic nature of the
changes detected in his father and his aunt (Figure 1).
Sanger sequencing of the entire reading frame of CEP78
in a cohort of 99 unrelated CRD-affected individuals of
Swedish, Swiss, Dutch, and Pakistani ethnic background
failed to identify any additional causative variants. The
three mutations present in our two families were not
detected in the genome of an internal control cohort
of 350 unrelated individuals or in any other public
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Figure 1. CEP78 Mutations
Pedigrees and electropherograms of the identified DNA changes.
Asterisks indicate the site of mutations. Abbreviations are as fol-
lows: Mx, mutant alleles; wt, wild-type allele.
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database, including the 1000 Genomes Project, the
Exome Variant Server (EVS), and the Exome Aggregation
Consortium (ExAC) Browser, which reports sequencing
data from more than 61,000 unrelated individuals. In
addition, in silico assessment of the c.499þ1G>T and
c.499þ5G>A mutations via two distinct web-based plat-
forms, NNSPLICE 0.910 and Human Splicing Finder,11 pre-
dicted for both variants the abolishment of the donor
splicing site for intron 3.
To analyze the functional consequences of the three mu-
tations, we obtained fresh blood samples and skin biopsies
from the Greek proband and the living Swedish subject
and performed the following experiments. We first retro-
transcribed total RNA from immortalized lymphoblasts
(GoScript Reverse Transcriptase, Promega). Then, after per-
forming saturating RT-PCR of the region spanning all mu-
tations (primers: 50-TTTTGCAGAAGTCGTGTTCCT-30 and
50-TTCAAGGGCCTCTAGCAAAG-30), we cloned the ampli-
fied products in E. coli (Zero Blunt PCR Cloning Kits,
Invitrogen) and performed colony PCRs and capillary elec-
trophoresis on 96 clones (48 clones per affected individ-
ual). Representative samples were Sanger sequenced, and
relative numbers of splicing events were assessed and
quantified. The c.499þ1G>T mutation resulted invari-
antly in the skipping of exon 3, leading to the production
of an aberrant isoform, never reported in genomic data-
bases, for which exons 2 and 4 were joined together.
This event ablated 24 codons and altered the reading
frame of CEP78, leading to the formation of a premature
termination codon at nucleotides 16–18 of exon 4. There-
fore, this non-canonical transcript was predicted to trigger
nonsense-mediated mRNA decay (NMD)12 and result in no
viable mRNA. The same exon-skipping occurrence was
observed for the other, nearby mutation, c.499þ5G>A,
that was present in the Swedish subjects. Finally, the
frameshift mutation c.633delC resulted in reduced
mRNA amounts, as deduced by the low number of E. coli
colonies carrying this cDNA clone (4 out of 48), again,
probably as a result of the action of NMD. Immunoblot
analysis in fibroblasts’ extracts (antibodies: A301-799A,
Bethyl Laboratories, epitope between residues 550 and
600 and A2066, Sigma, for beta actin) revealed the pres-
ence of CEP78 in very reduced amounts in the Greek sub-
ject and the absence of any detectable band in the Swedish
subject, in agreement with the mRNA findings described
above (Figure 3). More specifically, the homozygous
c.499þ1G>T mutation probably resulted in a few canoni-
cal mRNA forms not detected by our cloning experiments,
in turn producing small amounts of CEP78. Concerning
the Swedish subject, it is likely that both the c.633delC
and the c.499þ5G>A alleles produced mostly non-viable
mRNA and minimal quantities of wild-type mRNA and
protein. In fact, overexposed films showed a faint band
corresponding to CEP78, indicating that the protein was
present in trace amounts (not shown).
To gain insights into the relationship between vision
andCEP78, we analyzed its expression in a panel of human
tissues of cadaveric origin (Human Total RNAMaster Panel
II, Takara, primers 50-GTTTCCCATTAATCAAAACACG-30
and 50-TCAACTTCAGAGGATGAAGGACT-30 for CEP78
and 50-AGAGTGGTGCTGAGGATTGG-30 and 50-CCCTC
ATGCTCTAGCGTGTC-30 for the housekeeping gene
GUSB). Although the number of CEP78 transcripts in the
retina was higher than in many other tissues and organs,
retinal CEP78 mRNA did not display the highest expres-
sion level (Figure 4). A time-course experiment on eyes of
developing and postnatal mice (primers 50-CTTCAGA
AAGTGTCCAGGAAGC-30 and 50-GATCACTCTCTCCTCC
TTCAGC-30 for Cep78 and 50-CCTAAGATGAGCGCAAGTT
GAA-30 and 50-CCACAGGACTAGAACACCTGCTAA-30 for
the housekeeping gene Hprt1) revealed high expression at
embryonic stages, followed by a progressive decrease at
perinatal stages and by a plateau at adulthood (Figure 4).
This pattern is reminiscent of the expression of other
genes involved in retinal degenerations and in early
biogenesis and homeostasis of the centriole, notably
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Figure 2. Clinical Features of the
Analyzed Subjects
(A) Individual KN10. Fundus pictures (at
age 53 years) reveal macular coalescent
hypochromatic lesions in the right eye
and minor macular changes in the left
eye. Pure tone audiograms at age 57 years
(black lines) and 59 years (red lines) show
mild hearing impairment at higher fre-
quencies compared to the normal range
for gender and age, indicated by the
shaded area.8
(B) Individual 2702r34. Fundus examina-
tion at age 65 years highlights attenuated
vessels and degenerative changes in the
posterior pole. Audiograms at age 66 years
(black lines) and 77 years (red lines) show
clear hearing loss at most frequencies.
Abbreviations are as follows: OD, right
eye; OS, left eye; RE, right ear; and LE,
left ear.
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CEP76, CEP110, CEP164 (MIM: 614848), RAB8A (MIM:
165040), BBS4 (MIM: 600374), and RPGR (MIM:
312610).13 Although we could not obtain primary data
on CEP78 expression in human cochlea, we assessed its
RNaseq values from the only comprehensive transcrip-
tome repository currently available for the inner ear.14
CEP78 displayed a FPKM (fragments per kilobase of exon
per million reads mapped) value of 4.53 (average from
three human cochleae), indicating moderate expression
in this structure. Importantly, this FPKM value for CEP78
appeared to be higher than that of most genes already
known to be associated with hereditary deafness (40 out
of 70, or 57%), as assessed in the same organs and in the
same conditions (Table S3).
Little is known about the function of CEP78. Identified
as a component of the centrosome by two independent
proteomic screenings,15,16 CEP78 is composed of five
leucine-rich repeats located at the N-terminal half of the
protein, as well as a coiled-coil domain at the C terminus.
An important study using Planaria as the main experi-
mental model revealed that miRNA-based knockdown of
CEP78 resulted in defective primary cilia assembly in flat-
worms and human RPE1 cells.17 Intriguingly, CEP78 was
also found upregulated more than 5-fold by noise stress
in rat cochlea.18 The function and impact of CEP78 in hu-
man physiology, however, remain largely elusive.
The reportedcentrosomal localizationofCEP78prompted
us to investigate a possible role in relationship to the photo-
receptor primary cilium. Immunofluorescence of human
retinal sections with anti-CEP78 antibody (IHC-00364,
Bethyl Laboratories, epitope between residues 550 and 600)
and anti-cone arrestin (SC-54355, Santa Cruz) showed that
CEP78 is present in dot-shaped foci in the inner segments,
probably at the base of the primary cilium in retinal photo-
receptors, predominantly cones (Figure 5 and Figure S1).
This observation was confirmed when CEP78 was labeled
together with acetylated tubulin, staining the primary
cilium of human skin fibroblasts (Figure 5). Interestingly,
positive staining was observed in fibroblasts from KN10
and 2702r34 as well, confirming that CEP78 was in fact
expressed at the protein level in these individuals, as inferred
(Figure 5). The mild differences between these experiments
and the protein-expression observations might be due to
different sensitivities of the two analytical tools and the use
of distinct antibodies (A301-799A for immunoblot and
IHC-00364for immunofluorescence).Nospecificdifferences
concerning CEP78 subcellular localization were observed in
cells from affected individuals versus cells from controls.
Presence at the base of the connecting cilium is a charac-
teristic that is shared by other proteins associated with
retinal degeneration, and in particular by FAM161A, the
deficiency of which causes the RP28 form of retinitis pig-
mentosa (MIM: 606068).19–21 Indeed, tandem-affinity pu-
rification analysis performed with full-length FAM161A
showed a positive interaction with CEP78,22 and co-immu-
noprecipitation with an anti-CEP78 antibody (A301-800A,
Bethyl Laboratories, epitope between residues 639 and
0
2
4
6
8
10
12
Bo
ne
 m
ar
ro
w
Br
ai
n
Ce
re
be
llu
m
Co
lo
n
He
ar
t
Ki
dn
ey
Liv
er
L u
n g
M
us
cle
Pl
a c
en
t a
Pr
o s
ta
t e
Re
na
Sm
a l
l i
nt
e s
ne
Sp
in
al
 co
rd
S p
le
en
S t
om
a c
h
Te
s
s
Th
ym
us
Ut
er
us
0
0.5
1
1.5
2
2.5
E1
3 P0 P7 P2
1
P6
5
P9
0
P1
20
ce
p7
8 
ex
pr
es
si
on
 (a
rb
itr
ay
 u
ni
ts
, r
el
at
iv
e 
to
 P
0)
C
EP
78
 e
xp
re
ss
io
n 
(a
rb
itr
ay
 u
ni
ts
, r
el
at
iv
e 
to
 re
tin
a)
A B
Figure 4. CEP78 mRNA Expression in Various Human Tissues and Organs and in the Developing Murine Eye
Data are from real-time PCR relative expression analysis, for which GUSB and Hprt1 were used as normalizing genes for (A) and (B),
respectively.
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Figure 3. Immunoblot Analysis of Endogenous CEP78 in Fibro-
blasts from Affected Individuals
Numbers on the left refer to molecular-size markers. Control indi-
cates human fibroblasts from a control individual; HEK293T indi-
cates HEK293 cells containing SV40 large T antigen as a control for
specificity of the anti-CEP78 antibody.
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689) in HEK293T cells transfected with full-length FLAG-
FAM161A revealed direct binding between these two
ciliary proteins (Figure 5).
On the basis of these findings, we speculated that CRD
due to mutations in CEP78 could be a consequence of
hindered ciliary function, similar to what occurs in many
other retinal degenerations.23 To test this hypothesis, we
analyzed the morphology of primary cilia in fibroblasts
derived from KN10 and 2702r34, with respect to four con-
trols, after serum starvation. Unsupervised counting of at
least 82 events per sample (207 events in affected individ-
uals and 430 in controls) revealed that induced cilia in
fibroblasts from KN10 and 2702r34 were significantly
longer than those from control cells (Figure 6 and
Figure S2), a phenomenon that has been previously associ-
ated with impaired function of this organelle. For instance,
mutations in murine orthologs of BBS4, ICK, and TSC1,
linked with ciliopathies such as Bardet-Biedl syndrome,
endocrine-cerebro-osteodysplasia, and tuberous sclerosis,
respectively, display kidney cells with elongated primary
cilia.24–26
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Figure 5. CEP78 in Human Cells and Its
Interaction with FAM161A
(A) Immunostaining of CEP78 (red dots)
and of cone arrestin (green) in a section
of human retina. Margins of a cone photo-
receptor are highlighted by a dotted line.
The scale bar represents 10 mm.
(B). Co-immunoprecipitation of endoge-
nous CEP78 and FLAG-tagged FAM161A
in HEK293Tcells. FLAG-SOX4 is a negative
control. Abbreviations are as follows: IP:x,
protein targeted by the antibody used in
immunoprecipitation; and WB:x, protein
or peptide targeted by the antibody used
in immunoblots. The single and double as-
terisks indicate the expected molecular
sizes for CEP78 (78 kDa) and the FLAG-
FAM161A construct (90 kDa), respectively.
(C) Staining of CEP78 (red) and acetylated
tubulin (green) in fibroblasts from a
control individual, KN10, and 2702r34.
CEP78 localizes at the centrioles and at
the base of the induced primary cilium.
The scale bars represent 5 and 1 mm for reg-
ular and magnification panels,
respectively.
In recent years, a significant num-
ber of hereditary conditions have
been recognized to be the conse-
quence of abnormalities of the
cellular cilium. These diseases, collec-
tively called ciliopathies, form a
genetically heterogeneous spectrum
of disorders affecting various tissues
and organs, for instance kidney, co-
chlea, brain, and retina.23,27 Classical
examples of ciliopathies involving
retina and other tissues are Usher
syndrome (MIM: 276900, blindness and deafness) and
Bardet-Biedl syndrome (BBS [MIM: 209900], blindness
and multi-organ defects) for both of which vision loss is
due to retinitis pigmentosa.28 In addition, syndromic cilio-
pathies such as Senior–Løken syndrome (SLS [MIM:
266900]), Joubert syndrome (JBTS [MIM: 213300]), and
Jeune syndrome (JATD [MIM: 616300]) can occasionally
be accompanied by retinal dystrophy and, in particular,
retinitis pigmentosa and/or Leber congenital amaurosis
(LCA [MIM: 204000]).29–32 Another multi-organ ciliopathy
is Alstro¨m syndrome (ALMS [MIM: 203800]),33 caused by
null mutations in the gene ALMS1 (MIM: 606844). This
disease is characterized by cone-rod degeneration, dilated
cardiomyopathy, obesity, type 2 diabetes, and short stat-
ure, which can be accompanied by hepatosteatosis and de-
fects in the lungs, kidney, and bladder.33,34 Most cases also
display progressive sensorineural hearing loss.35 Of inter-
est, mutations in ALMS1 have recently been suggested as
being causative of non-syndromic CRD.36
In this study, we show that mutations in CEP78 result
in cone-rod degeneration associated with hearing loss,
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another hallmark of ciliopathy, but no other syndromic
features. Interestingly, the two Swedish affected indi-
viduals had declared hearing loss, and the Greek subject
had borderline hearing impairment. An intriguing possi-
bility involves the presence of a genotype-phenotype
correlation between CEP78 alleles and hearing (but not
vision), as it is the case for instance for mutations in
USH2A and ALMS1.36–38 Taken together, our data indicate
that genetic defects in CEP78 define a newly recognized
ciliopathy, distinct from Usher and Alstro¨m syndromes,
affecting both the visual and the hearing systems.
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Abstract
Hereditary retinal degenerations encompass a group of genetic diseases characterized by extreme clinical variability.
Following next-generation sequencing and autozygome-based screening of patients presenting with a peculiar, recessive
form of cone-dominated retinopathy, we identified five homozygous variants [p.(Asp594fs), p.(Gln117*), p.(Met712fs),
p.(Ile756Phe), and p.(Glu543Lys)] in the polyglutamylase-encoding gene TTLL5, in eight patients from six families. The two
male patients carrying truncating TTLL5 variants also displayed a substantial reduction in spermmotility and infertility,
whereas those carrying missense changes were fertile. Defects in this polyglutamylase in humans have recently been associ-
ated with cone photoreceptor dystrophy, while mouse models carrying truncating mutations in the same gene also display
reduced fertility in male animals. We examined the expression levels of TTLL5 in various human tissues and determined that
this gene has multiple viable isoforms, being highly expressed in testis and retina. In addition, antibodies against TTLL5
stained the basal body of photoreceptor cells in rat and the centrosome of the spermatozoon flagellum in humans, suggesting
a commonmechanism of action in these two cell types. Taken together, our data indicate that mutations in TTLL5 delineate a
novel, allele-specific syndrome causing defects in two as yet pathogenically unrelated functions, reproduction and vision.
Introduction
Cone dystrophies (CDs) and cone-rod dystrophies (CRDs) are
rare heterogeneous retinal disorders with an estimated preva-
lence of "1:40,000 (1). They lead to severe visual impairment,
primarily or exclusively due to the degeneration of cone photo-
receptors. Patients experience progressive loss of visual acuity,
defective colour vision, photophobia, and have central scoto-
mas. Only later, as the disease progresses, in some cases loss of
peripheral vision may also occur (2,3).
The progressive degeneration of retinal photoreceptors in
CDs and CRDs is mostly nonsyndromic and has been associated
with multiple genetic causes, with at least 20 associated disease
genes (RetNet; http://www.sph.uth.tmc.edu/RetNet/; date last
accessed July 8, 2016). However, more than 75% of cases pre-
senting with dominant or recessive forms of these conditions
are genetically unsolved (4). Recent discoveries in CD molecular
genetics include the identification of pathogenic variants in the
tubulin polyglutamylase TTLL5 (Tubulin Tyrosine Ligase-Like
Protein 5) gene, found to cause retinal dystrophy in four British
families (5). This gene, like the 12 other members of the TTLL
superfamily, is involved in post-translational modifications of
a- and b-tubulin, which are components of the axonemes of
both cilia and flagella.
Interestingly, male mice with a defective TTLL5 display dra-
matically reduced fertility associated with defects in sperm mo-
tility (6). Most sperm tails of mutant mice were found to have
disrupted axonemes with loss of tubulin doublets and a signifi-
cantly decreased polyglutamylation in the upper and lower seg-
ments. No abnormal phenotype of retinal photoreceptors or of
cochlear cells was initially observed, based on histologic exami-
nation (6). A second study with a more thorough characterization
of the ocular phenotype in the same mouse model showed a de-
cline of electroretinographic (ERG) amplitudes for both rods and
cones in aged mice (20-22mo). However, no microtubule defects
were found after examination of electronmicrographs (7).
Ciliopathies represent a class of hereditary disorders involv-
ing deficiencies in ciliary and cilia-associated proteins, often af-
fecting a variety of tissues and organs (8). Due to the presence of
an immotile cilium in both rods and cones photoreceptors,
many ciliopathies display a retinal phenotype, either as part of
a syndromic condition (associated with hearing defects, renal
nephronophtisis, liver fibrosis, bone and/or brain anomalies) or
as the sole pathological sign (9–11).
Following the investigation of a cohort of patients displaying
CD or CRD, we identified mutations in TTLL5 that are associated
with both retinal degeneration and reduced sperm motility in
humans, possibly defining a novel syndromic ciliopathy.
Results
Clinical and molecular findings
Our research started with the molecular characterization of a
Swiss male patient (P1), aged 75 years, presenting with a late-
onset cone dystrophy (CD). He was the eldest of three brothers
and his parents were first cousins (Fig. 1, F1), without any his-
tory of ocular problems. The patient was first seen at the age of
33 years, when he first noticed blurred vision. His best corrected
Snellen visual acuity (BCVA) at that time was 0.6 in the right eye
and 0.8 in his left eye. Seven years later, his BCVA was still sta-
ble, but worsened when he was 53 years old, dropping dramati-
cally to 0.05 in the right eye and 0.08 in the left eye. He was also
complaining of a reduced dark adaptation. Twenty-two years
later his vision remained stable, with the patient using more of
his peripheral vision.
The clinical examination was typical of a cone dystrophy:
the fundus examination showed central foveal atrophy with
peripapillary hyperpigmentation and atrophy, while the periph-
eral retina was within normal limits (Fig. 2). The first ERGs (per-
formed when the patient was 56 years old) showed normal
scotopic responses, whereas photopic responses had severely
reduced amplitude. The following ERG testing, when the patient
was 70 years old, showed some rod involvement, with reduced
rod-specific b-wave. The 30-Hz flicker was undetectable.
Autofluorescent (AF) images at age 66 years (Fig. 2) showed cen-
tral hypofluorescence corresponding to atrophy, surrounded by
a large hyperfluorescent ring. AF imaging at age 72 indicated
that the ring mildly increased in diameter, and so did the area
of hypofluorescence (Fig. 2). Kinetic visual field tested at this
later age showed mild constriction and central scotoma in both
eyes.
The DNA of the patient was first screened for mutations in
known disease genes. Following the negative output of a panel-
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based Next-Generation Sequencing screening [the IROme (12)],
we performed whole-genome sequencing (WGS) of the patient’s
DNA. This latter procedure resulted in more than 4 million DNA
variants with respect to the human reference genome (Build
hg19). These were evaluated by the use of an internal in-silico
pipeline assessing their frequency in the general population,
quality, etc. (Supplementary Material, Table S1), as well as their
presence within autozygous regions (Supplementary Material,
Fig. S1). At the end of this process, we were left with 19 variants
(7 in autozygous regions), including c.1782delT in TTLL5 (Fig. 3),
a gene known to be involved in microtubule posttranslational
modifications and associated with ciliary microtubule stabiliza-
tion (13). The variant was in exon 20 and consisted of a 1-bp de-
letion causing a frameshift starting from codon 594 and
terminating with the creation of a premature stop triplet 29 co-
dons downstream [p.(Asp594Glufs*29)]. It was also not detected
in the genome of 400 healthy controls from the same geo-
graphic region of Switzerland [data from the CoLaus study (14)],
and from publicly available databases [ExAC (15), dbSNP (16)].
Importantly, this DNA change localized to a region of chromo-
some 14 (75,986,579-80,875,911, Build hg19) showing clear auto-
zygosity (Supplementary Material, Fig. S1) in P1’s genome.
Because of the possible involvement of TTLL5 in extra-
ocular ciliary functions, the patient underwent more detailed
clinical examinations. To assess the presence of additional sub-
tle abnormalities in organs known to be affected by ciliopathies,
he was evaluated for both renal and otorhinolaryngological
functions. He did not display the classical clinical features of re-
nal ciliopathy (no polyuria/polydipsia), but chronic renal insuffi-
ciency without proteinuria (stage G3aA1) (17) was identified,
associated with low-grade chronic anemia. By ultrasound, the
size of the kidneys appeared to be preserved, but a small asym-
metry was noted (9.6 cm on the left vs. 10.7 cm on the right
side), without significant renal artery stenosis. No cysts were
visible and no biopsy was performed. Altogether, the renal fea-
tures were consistent with age-related decreased renal func-
tion, but low-grade and late appearance nephronophtisis
cannot be fully excluded. The observed minor sensorineural
hearing loss, and loss of some high frequencies, was compatible
with the natural course of hearing about a person of the age of
the subject (Supplementary Material, Fig. S2). The clinical exam-
ination and patient’s history did not reveal any upper airway
pathology necessitating further investigations for impaired
mucocillary function in the sinus or the bronchi. The patient re-
ported a history of infertility due to reduced sperm motility, di-
agnosed when he was in his late 20’s. He could not have
offspring and adopted two children. Following our findings, a
new semen analysis was performed at age 75, revealing azoo-
spermia, a sign that nonetheless could simply be related to the
difficulty in obtaining an ejaculate at his current age.
Based on these findings, we extended our analyses to a num-
ber of additional cohorts of 365 patients with CD and CRD from
Switzerland, Sweden, Greece, The Netherlands, and Britain. In a
Swedish male patient of Iraqi descent (P2), we identified the ho-
mozygous nonsense variant c.349C>T;p.(Gln117*) by targeted
Sanger sequencing of TTLL5 (Figs. 1, F2; 3). Again, this variant
was absent from controls and publicly available databases.
Although the patient did not report any history of consanguin-
ity, the occurrence of this extremely rare variant in a homozy-
gous state suggests the presence of residual consanguinity or of
a geographical founder effect, which was not tested at the ge-
nome level. The patient, aged 46 years, reported no family his-
tory of similar visual impairment. Fundus examination revealed
degenerative changes, especially in the posterior pole, but more
normal features in the periphery. Visual field analysis by
Goldmann perimetry showed residual fields in the periphery,
but a large central scotoma. Full-field ERG demonstrated resid-
ual cone and rod response, consistent with a diagnosis of cone-
rod degeneration. In addition to these signs and symptoms typi-
cal of CRD, the patient had high myopia (Table 1). This subject
was also infertile, but had been able to have a child by in vitro
fertilization. His semen analysis revealed a normal spermatozoa
count but, similar to P1, reduced sperm motility. He also had
morphologically normal spermatozoa for 5% of the count, over
three independent assays.
Following autozygome-based analysis (Supplementary
Material, Fig. S1), we identified homozygous mutations in three
additional patients from the Netherlands (Fig. 1, F3–5). All of
them were diagnosed with CD, with full-field ERGs showing re-
duction of cone function but preserved rod responses (Table 1).
Similar to the cases described above, the female patient P3 had
a TTLL5 truncating mutation, c.2132_2133insGATA;p.
(Met712IleAspfs*15), resulting in a premature termination co-
don. The other two patients (P4, and P5) were males and
both carried homozygous missense mutations, namely c.
1627G>A;p.(Glu543Lys) and c.2266A>T;p.(Ile756Phe),
Figure 1. Pedigrees from families with pathogenic TTLL5 variants. The probands are: subject P1 [II:3, family F1; c.1782del;p.(Asp594Glufs*29)], subject P2 [II:4, family F2;
c.349C>T;p.(Gln117*)], subject P3 [II:3, family F3; c.2132_2133insGATA;p.(Met712IleAspfs*15)], subject P4 [II:4, family F4; c.1627G>A;p.(Glu543Lys)], subject P5 [II:4, fam-
ily F5; c.2266A>T;p.(Ile756Phe)], and subject P6 [IV:14, family F6; c.1627G>A;p.(Glu543Lys)].
3Human Molecular Genetics, 2016, Vol. xx, No. xx |
 at Universite and EPFL Lausanne on September 27, 2016
http://hmg.oxfordjournals.org/
Downloaded from 
	  	   128	   	  
respectively (Fig. 3). Following colour vision testing, substantial
mistakes were made in all three colour axes. All patients had a
myopic refractive error, but none of them showed any addi-
tional extraocular symptoms. In particular, they did not report
any fertility problems, and both male patients had offspring.
Finally, a male patient (P6) of Pakistani origin was screened
by whole-exome sequencing (WES). He was a member of a con-
sanguineous pedigree that included six additional individuals
with high myopia and an acquired CD or CRD with loss of cor-
rected visual acuity from the second decade onwards (Fig. 1, F6).
In this case as well, a homozygous mutation in TTLL5 was iden-
tified within an autozygous region in chromosome 14
(Supplementary Material, Fig. S1). It was the same missense de-
tected above [c.1627G>A;p.(Glu543Lys), Fig. 3], which perfectly
co-segregated with the disease in the three affected and two un-
affected individuals for which DNA samples were available.
Figure 2. Fundi of index patient P1. Autofluorescence imaging of the right (A) and left (B) eye at age 66 years, showing a distinctive pattern of abnormalities, including a
hyperfluorescent ring and hyperfluorescent area at the fovea surrounded by patchy hypofluorescence in both eyes. Hypofluorescence around the optic nerve was also
present. The same images, obtained 6 years later (C,D), showed an increase of hypofluorescent areas within the ring and a mild enlargement of the hyperfluorescent
ring in both eyes. Composite pictures of the fundi at age 72, showing atrophic areas around the fovea and around the optic nerve (E,F). Peripheral retina was within nor-
mal limits.
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Of note, in addition to retinal dystrophy, all patients from this
pedigree reported high to very-high myopia (-5 to -22 diopters)
(Table 1). None of the patients reported fertility problems, and
indeed patient P6 had five children.
TTLL5 RNA isoforms and expression in different tissues
According to publicly-available databases, TTLL5 produces six
protein-coding and alternatively spliced isoforms (transcripts
001, 002, 003, 016, 017, 018 of the Ensembl database GRCh37, re-
lease 84), presenting a rather widespread expression throughout
different tissues and organs (UniGene). To gain insights into
this topic, we investigated the composition and abundance
of TTLL5 transcripts in a panel of cadaveric organs and tissues
(Fig. 4).
Our data confirmed that TTLL5 has an extremely variable ex-
pression pattern, both in terms of isoforms and of presence in
various tissues. However, qualitative and quantitative assess-
ment of all transcripts revealed that expression of the canonical
isoform 001 was overwhelmingly more abundant (more than
40-fold higher than the average of the remainder) and that ex-
pression in the retina and testis represented !64% of TTLL5
presence across all tissues and organs examined (31 and 33% in
testis and retina, respectively; Fig. 4). Interestingly, all muta-
tions identified in our cohort of patients affected isoform 001,
and individuals with inactivating mutations showed reduced
fertility (Table 1).
TTLL5 mRNA level in the index patient P1
Since mutations leading to premature termination codons trig-
ger nonsense-mediated mRNA decay (NMD) and result in no or
in short-lived transcripts (18), we analysed expression of TTLL5
in skin fibroblasts from patient P1, displaying retinal degenera-
tion and infertility. Quantitative real time PCR (q-PCR) resulted
in a dramatically reduced detection of the transcript of interest
as compared to a healthy control fibroblast mRNA (!10%; Fig. 4).
TTLL5 protein in ciliated fibroblasts,
retina, and spermatozoa
To better understand the role of TTLL5 with respect to the cellu-
lar cilium, we analysed control fibroblasts following serum
starvation, a procedure that induces ciliogenesis.
Immunofluorescence analysis revealed the clear localization of
TTLL5 at both centrioles (Fig. 5, panels A–D).
Subsequently, we performed immunofluorescence analyses
in the retina and sperm cells from rat and human, respectively
(Fig. 5, panels E-G). In agreement with previous results in mouse
and human (5), the anti-TTLL5 antibody decorated the inner
segment of photoreceptors in proximity of the basal body and
the connecting cilium, suggesting that TTLL5 may in fact play
its functions at the base of the photoreceptor primary cilium.
Staining of mature human spermatozoa also indicated for
the first time a clear centrosomal localization of TTLL5, with no
overlap with the polyglutamylated a- and b-tubulin of the
flagellum.
Discussion
Both primary (or immotile) and motile cilia play crucial roles in
the normal function of most tissues of the human body. These
tiny hair-like organelles participate in a wide range of cellular
functions during development, tissue morphogenesis and ho-
meostasis. It is therefore not surprising that mutations in ciliary
genes are often associated with a broad range of conditions,
classified as ciliopathies, either involving single organs or caus-
ing syndromic phenotypes (8). Some examples of diseases af-
fecting primary cilia are polycystic kidney disease, Usher
syndrome, retinitis pigmentosa, Bardet-Biedl and Joubert syn-
dromes (19–22). On the other hand, motile cilia defects have
been shown to be causative for Kartagener syndrome and allied
diseases, collectively grouped under the disease spectrum of
primary ciliary dyskinesias.
Cilia and flagella, highly conserved in their core structure,
are ancestral organelles composed of more than 650 proteins
(10,23). The building units of both ciliary and flagellar
A
B
C
D
Figure 3.Mutation diagram of the TTLL5 protein (A), and corresponding cDNA. Red and green dots indicate truncating and missense mutations, respectively. Exons are
numbered and drawn to scale (B) with respect to the protein sequence. The TTL domain responsible for polyglutamylation activity is indicated. Chromatograms of the
mutations identified (C), compared to their relevant wild type sequences (D).
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microtubules, a- and b-tubulin, are subject to post-translational
modifications, accomplished by enzymes catalyzing different
reactions such as the generation of D2-tubulin, acetylation (24),
tyrosination (25), polyglutamylation (26) and polyglycilation
(27,28). Among members of the TTLL superfamily there are glu-
tamylases and glycilases (29–31). TTLL5 initiates the formation
of side chains within the C-terminal tail of a- and b-tubulin,
with a preference for a-tubulin (32), and current models indicate
that the role of polyglutamylation is to provide the necessary
conditions for proper MT-MAPs (microtubule and microtubule-
associated proteins) interactions. Studies have shown that poly-
glutamylation exerts differential regulation by selectively re-
cruiting different MAPs: MAP1B, MAP2, tau, and neuronal
kinesins have higher affinity for tubulins with 1-3 glutamyl
units, whereas MAP1A has higher affinity for longer side chains
(25,26,28). Moreover, it has been shown that masking polygluta-
mylated sites with a specific anti-polyglutamylated tubulin an-
tibody (GT335) affects the amplitude of flagellar beating in sea
urchin sperm axonemes, suggesting a key role of polyglutamy-
lated sites for interaction with ciliary dyneins (33). Centriole sta-
bility was also shown to be influenced by the degree of
polyglutamylation, and GT335 antibody-loaded HeLa cells
showed a complete transient disappearance of the centriole
pair (13). Finally, members of the TTLL family, Ttll3 and Ttll6,
play a role in cilia structure and motility in zebrafish (34). All
TTLL proteins have a preference for either a- or b-tubulin and
participate to either initiation or elongation of the polyglutamyl
side chain. TTLL5, together with TTLL4 and TTLL7, initiates
polyglutamylation, while other members function in the elon-
gation of the polyglutamyl side chain or in the initiation or the
elongation of polyglycylation.
Specific patterns of modifications on microtubules might be
responsible for various functions. In the case of polyglutamyla-
tion, the side chains are built within the carboxy-terminal tail
of tubulin, where the binding sites of motor and MT-associated
proteins (MAPs) are also found. Thus, it is plausible that the in-
teraction of MTs with such proteins might depend on specific
patterns of modifications (35). Additional studies highlighted
the importance of polyglutamylation for the proper beating of
airway cilia (36), as well as for providing a molecular traffic sign
required by motor proteins in order to maintain continuous
synaptic transmission (37). Major evidence of the implication of
polyglutamylation in photoreceptor ciliary function was re-
cently reported (7), showing that Ttll5-/- mice developed a simi-
lar retinal phenotype to Rpgr-/- mice, a known mouse model for
retinitis pigmentosa. In addition, Ttll5-/- mice display strongly
reduced glutamylation of RPGRORF15, a retina-specific variant of
RPGR (38). Altogether, current evidence strongly supports the
notion that the presence and length of polyglutamyl side
chains, not only on tubulin but also on other substrates, is cru-
cial for proper functioning of both motile and immotile cilia.
In our work we show that mutations in a gene involved in
the polyglutamylation of a-tubulin is associated with defects in
the retina and spermatozoa. Clinically, these molecular pheno-
types translate into cone-first CRD and reduced sperm motility,
likely due to the functional impairment of the primary cilium
and the flagellum, respectively. Our assumption is supported by
immunofluorescence data, demonstrating that TTLL5 localizes
at the basal body of the cilia in photoreceptors, as well as at the
base of the spermatozoal axoneme and in ciliated skin fibro-
blasts. Moreover, we reveal that the highest levels of expression
of the major TTLL5 protein-coding isoform is in the retina
and testis. It is also very interesting to note that, in terms of fer-
tility and TTLL5 pathogenic variants, there is an apparentT
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genotype/phenotype correlation, which seems to be irrelevant
for retinal degeneration. In other words, the phenotype elicited
by TTLL5 pathogenic changes appears to depend on mutation
classes. Missense variants are seemingly associated with a non-
syndromic phenotype that is limited to the retina, whereas
inactivating mutations appear to disrupt the functions of both
photoreceptors and spermatozoa, thus defining a novel allele-
specific syndrome. Yet, three male patients with truncating
TTLL5 mutations were previously reported having offspring (5),
raising the possibility of variable expressivity or reduced pene-
trance of this class of mutations. In support of the latter hypoth-
esis, Ttll5 knockout mice display extremely reduced but
not completely abolished fertility (6). Alternatively, this geno-
type/phenotype correlation in our cohort could also be coinci-
dental. The association of TTLL5 mutations with severe
myopia is another intriguing hypothesis that warrants addi-
tional investigation in a larger cohort of patients, especially
given the complex pattern of inheritance of nearsightedness in
humans.
In conclusion, we show that mutations in TTLL5 are associ-
ated with a newly-defined syndrome affecting vision and the
male reproductive system. Despite the fact that cilia and flagella
have different morphologies and functions, they may share
similar physiological mechanisms, and the enzymatic reaction
of polyglutamylation performed by TTLL5 may be one of these
common elements.
Materials and Methods
Patients and controls
Patient P1 was recruited from the Jules Gonin Ophthalmic
Hospital (Lausanne, Switzerland); and patient P2 from the
Department of Ophthalmology of Lund University Hospital
(Lund, Sweden). Patients P3, P4 and P5 were recruited from the
Radboud University Medical Center (Nijmegen, The
Netherlands) and the Erasmus University Medical Center
(Rotterdam, The Netherlands). Patients P6-8 were sampled by
author MMK, an ophthalmologist based at St James’s University
Hospital (Leeds, England), while on a field trip to Pakistan. DNA
of all subjects was extracted from peripheral blood leukocytes.
A control sperm sample was provided by a healthy donor. Our
research has been conducted in accordance with the tenets of
the Declaration of Helsinki and was approved by the
Institutional Review Boards of our respective Organizations.
A B C
Figure 4. Relative expression of TTLL5 isoforms and their expression. TTLL5 has six known alternative transcripts (001, 002, 003, 016, 017, and 018), resulting from the
splicing of the exons indicated here in dark grey (A). Their expression within seven different human tissues, measured by quantitative real time PCR, is indicated by
both numerical values and shades of grey (B). Although all isoforms seem to be widely expressed, isoform 001 is the most prominent one, among all tissues considered
(‘Total’ column). Asterisks show the position of the mutations identified in this work. TTLL5 isoform 001 expression in fibroblasts of the index patient P1 vs. a control,
by quantitative PCR (C). TTLL5mRNA amounts were normalized with respect to the housekeeping gene HPRT1.
Figure 5. Immunofluorescence staining of ciliated control human skin fibroblasts (A-D). TTLL5 co-localizes with acetylated tubulin at the centrioles, as indicated by ar-
rowheads (C,D). Immunofluorescence in rat retina sections (E, and magnified cilium in F) and in control human spermatozoon (G). TTLL5 decorates the basal body in
photoreceptors and the centrioles in spermatozoa. Scale bars: A-E, 5 mm; F, 1 mm; G, 20 mm.
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Clinical evaluation
For patients P1-5, ophthalmologic examination included assess-
ment of BCVA, slit-lamp examination, funduscopy, fundus pho-
tography, and optical coherence tomography. Full-field ERGs
were also recorded, as prescribed by the International Society
for Clinical Electrophysiology of Vision (ISCEV).
For patients P6-8, ophthalmologic assessment was limited to
slit-lamp examination and fundus inspection using direct and
indirect ophthalmoscopy through dilated pupils. Owing to the
non-hospital setting, electrodiagnostic and other testing was
not available. Visual acuity was recorded together with a history
of nyctalopia or photoaversion.
Semen analysis was carried out for patients P1 and P2 by
standard procedures of andrology laboratories, and according to
WHO guidelines (39). For P1 patient, two Leja chambers (Leja)
filled with 6 ml of semen were entirely scanned under phase
contrast microscopy to confirm the absence of spermatozoa.
Additional clinical features were assessed only for patient P1,
due to substantial problems in getting back to the other pro-
bands. These tests included a thorough otorhinolaryngologic
examination assessing structure and function of the nasopha-
ryngeal mucosa, the ear canal and the hearing (by pure-tone au-
diometry), as well as a full renal examination, including a
complete checkup of renal function, urine and blood analysis,
assessment of blood pressure, and ultrasonography. Analyses
involving other tissues and organs known to be involved in
other ciliopathies were not performed due to a negative clinical
history: normal body mass index, no respiratory complains, no
metabolic disturbance and no skeletal abnormalities.
Whole-genome and whole-exome sequencing
WGS in the Swiss index patient P1 was performed using 4 mg of
DNA. Sequencing was performed by Complete Genomics Inc.
(Mountain View, CA, USA), as described previously (40). Genetic
variants were identified using v2.0 of the Complete Genomics
pipeline (41). WES was performed for proband P6 using 3 mg of
DNA. Protein-coding regions were captured using the SureSelect
All Exon v4 kit (Agilent) and paired-end sequencing was per-
formed using the Illumina HiSeq 2500 platform. Single nucleo-
tide variants and small insertions or deletions were detected
using the Genome Analysis Tool Kit (GATK v2.4.7) software
package, using the Best Practice Guidelines identified by the de-
velopers (42). The pathogenicity of genetic variants detected
through WGS and WES were assessed after functional annota-
tion through ANNOVAR (43).
Homozygosity mapping
Genomic regions with high homozygosity were determined us-
ing the free web-based tool HomozygosityMapper (44).
Mutation screening
Primer pairs for TTLL5 exons and flanking intron boundaries
were designed using the CLCbio Genomics Workbench (Qiagen,
Supplementary Material, Table S2). PCR amplification was per-
formed in a 20 ll total volume containing 10ng genomic DNA,
1x GoTaq buffer, 0.1mM dNTPs, 10 lM of each primer, and 5U/ll
of GoTag polymerase (Promega). PCR products were purified
(ExoSAP-IT, USB) and a sequencing reaction was performed in a
total volume of 5 ll using 1 ll primer 3.3 mM, 0.5 ll BigDye
Terminator v1.1, and 1 ll of the provided Buffer (Applied
Biosystems).
Antibodies
Commercial goat polyclonal anti-TTLL5 antibody (Santa Cruz
Biotechnology Inc), raised against a peptide mapping near the
C-terminus of TTLL5 human origin, was used at a 1:100 dilution.
Mouse monoclonal anti-centrin clone 20H5 antibody was
purchased from Millipore and used at a dilution of 1:1000. Anti-
polyglutamylated tubulin GT335 and monoclonal anti-
acetylated tubulin antibodies were provided by Dr C. Janke
(Institut Curie, Orsay, France) and purchased from Sigma-
Aldrich, respectively. Secondary donkey anti-goat antibodies
conjugated with Alexa Fluor 488 were purchased from
Invitrogen and secondary goat anti-mouse antibodies (Life
Technologies) were conjugated with Alexa Fluor 594 (1:1000).
Fibroblast immortalization and culture
Primary skin fibroblasts were immortalized with exogenous
hTERT by the use of pLOX-TERT-iresTK (45) and grown in
DMEM(1x)þ 1g/L D-glucose L-Glutamine Pyruvate (Gibco), sup-
plemented with 10% FBS, 1% penicillin-streptomycin, and 1%
fungizone, adapted from previously published protocols (46).
Immunofluorescence
Immunofluorescence was performed for TTLL5 localization in
human control spermatozoa and rat retinal sections. The sperm
staining procedure used was adapted from a previously pub-
lished protocol (47). After washing five times with PBS 1X in a
15ml Falcon tube and centrifugation steps of 5’ at 800g, all at
room temperature (RT), the semen pellet was resuspended and
fixed with 4% (v/w) PFA in PBS, and incubated for 30min on ice.
The sample was then washed three times with PBS and stored
at 4 "C for future use. The immunostaining procedure used 20 ml
aliquots of fixed sperm cells, transferred to a 1.5 ml Eppendorf
tube. Blocking was done for 30min at RT in 100 ml PBS contain-
ing 3% (w/v) BSA (PBSA). Primary antibody incubation was per-
formed with specified dilutions in 100 ml PBSA, overnight at 4 "C.
Samples were washed three times with PBS containing 0.1%
(v/v) TX100 (PBST). Secondary antibody incubation for 30min
was carried out at RT in 100 ml PBSAT [PBST containing 3% (w/v)
BSA and 0.1% (v/v) TX100]. After three washes with PBST and
two washes with PBS the final pellet was resuspended in PBS
and 5 ml were placed on a slide. 5 ml DAPI vectashield were added
to the sample, which was then coverslipped and fixed with nail
polish.
Unfixed Sprague-Dawley rat eyes and C57BL/6J mouse eyes
were isolated and soaked for 3h in PBS containing 30% sucrose.
Eyes were embedded in Yazulla medium (30% egg albumen and
3% gelatin in water) and cryosectioned (12 mm) onto Superfrost
Plus slides (Thermo Scientific). Sections were washed three
times with PBS and a stepwise procedure was followed similar
to that described for sperm immunostaining, the only differ-
ence being that this was carried out on the slide and with lower
volumes.
Quantitative real time PCR
Primer pairs used for q-PCR are listed in Supplementary
Material, Table S3. The q-PCR product was visualized on 1%
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agarose gel to verify the primer’s specificity. A standard curve
using a control cDNA template prepared from human normal
tissues total RNA (BioChain) was used to test the efficiency of
each primer pair. HPRT1 was used as a normalization control, as
described (48). Amplification was performed using the SYBR
Green PCR Master Mix (Applied Biosystems).
Supplementary Material
Supplementary Material is available at HMG online.
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